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Burgeoning genetic research is enabling the personalization of medical 
treatments based on patients’ individual genetic profile. One potential application that 
is likely to make significant impact in transforming patient care in the near future is 
pharmacogenetics, where patients’ genetic traits can predict their responses to 
drugs, and appropriate treatment that maximizes effectiveness and minimizes side 
effects can be selected based on genetic testing results. The pharmacogenetics of 
several life-threatening adverse drug reactions have been well established, however, 
the adoption of pharmacogenetic testing in clinical care has been slow. The main 
reason being that the clinical utility, adverse consequences and economic value of 
genetic testing are unclear. In many cases, the decision of technology adoption often 
involves tradeoffs between the above factors, which is difficult without a systematic 
evaluation of various factors all together and a commonly accepted standard.  
The objective of the thesis is to conduct health economic evaluations to 
generate evidence to inform clinical and regulatory decision making on whether 
pharmacogenetic testing should be routinely conducted in order to reduce the risk of 
a life-threatening adverse drug reaction named Stevens-Johnson syndrome (SJS) 
and Toxic Epidermal Necrolysis (TEN) in the context of Singapore. To assess the 
value of pharmacogenetic testing in Singapore, two health economics evaluation 
methods are employed: cost-effectiveness analysis (CEA) and discrete choice 
experiment (DCE).  
Cost-effectiveness analysis adopts a health system perspective to estimate 
the long-term cost and effectiveness related to pharmacogenetic testing in the 
population, with consideration of test accuracy, predictive power of test results, 
population risk allele prevalence, efficacy of various drugs, side effects of various 
drugs and their sequelae, patients’ quality of life, survival, and treatment costs. Cost-
effectiveness evaluates the incremental effectiveness and incremental costs 
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 associated with genetic testing relative to the status quo treatment strategy to reveal 
the incremental value of genetic testing. A threshold of cost-effectiveness that 
reflects the societal willingness-to-pay can then be applied to judge whether genetic 
testing is cost-effective in the health system. Cost-effectiveness analysis favors 
technologies that achieve high effectiveness at low costs at the health system level, 
and is useful for policy makers to make resource allocation between various 
healthcare needs, and make efficient use of public healthcare resources. However, 
cost-effectiveness does not speak to what individuals would do or should do. To 
understand individual level decision making, discrete choice experiment can be used 
to elicit patients’ preferences and willingness-to-pay for genetic test to reduce risk of 
adverse drug reactions.   
The thesis consists of six chapters. Chapter 1 lays the general background of 
the thesis.  It outlines the advancement and challenges in the adoption of 
pharmacogenetic testing in clinical practice, and describes how health economics 
evaluations can inform the genetic testing decision making. Chapter 2 assesses the 
cost-effectiveness of HLA-B*1502 testing prior to carbamazepine treatment for 
epilepsy patients from a health system perspective to inform clinical and regulatory 
policy making in Singapore.  Results suggest that compared with the status quo 
strategy of providing carbamazepine to all patients without genotyping, genotyping 
and targeted treatment is highly cost-effective for Chinese and Malays, but not 
Indians in Singapore. The study, together with other related studies, has led to a 
regulatory recommendation of HLA-B*1502 testing prior to carbamazepine initiation 
among epilepsy patients, and subsequent adoption in clinical practice. These 
changes as well as intended outcomes and unintended consequences are briefly 
reviewed at the end of Chapter 2. Chapter 3 assesses the cost-effectiveness of HLA-
B*5801 testing, and other risk-mitigation strategies for allopurinol among chronic gout 
patients. Results suggest that HLA-B*5801 testing-guided treatment selection, in 
which allopurinol is avoided in test positive patients, is not cost-effective at the 
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 population level, as the limited choice of alternative drugs to allopurinol will result in 
poorer serum urate control and worse gout treatment outcomes in some patients. On 
the other hand, a combination of genetic testing and a safety monitoring program is 
favored from the cost-effectiveness perspective under certain circumstances. 
Chapter 4 adopts a different perspective to review the literature on patients’ 
preferences for pharmacogenetic testing, and motivate the study in Chapter 5. 
Chapter 5 describes a discrete choice experiment to quantitatively measure patients’ 
preferences for genetic testing prior to initiating allopurinol in chronic gout treatment. 
Empirical data suggest that there is significant heterogeneity in patients’ preferences. 
A group of patients are risk averse, and have high willingness-to-pay for genetic 
testing even though the test is not perfectly predictive and treatment costs are 
significant higher. On the contrary, other patients are cost conscious, and consider 
cost containment to be more important than risk reduction. The preferences of both 
groups of patients are quantified in Chapter 5. In addition, this study also revealed 
the strong impact of doctor’s recommendation and herd effect on patients’ decision 
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 Chapter 1 . Challenges in adoption of Pharmacogenetic 
testing and the role of health economics analyses 
1.1 Chapter summary 
This chapter is an introduction to the general background of the thesis. It 
outlines the advancement of pharmacogenetics, particularly the application of 
pharmacogenetics in preventing severe adverse drug reactions. Then the current 
status of adoption and challenges are discussed, followed by an introduction of two 
health economics evaluation methods that can facilitate the decision of genetic testing 
adoption. 
1.2 Trend in personalized medicine and pharmacogenetics  
Burgeoning genetic research has started to transform medicine and enable the 
personalization of medical treatment based on patients’ individual genetic traits. 
Genetic testing is the process of identifying individual genetic variability, for a broad 
spectrum of medical applications using various testing methods.1 Diagnostic genetic 
testing can be used to confirm suspected diagnosis. Predictive genetic testing can be 
used to screen for genetic markers to predict susceptibility to a future disease.  
Pharmacogenetic testing, which can be used as companion diagnostic, 
predicts patient responses to a particular treatment. Among various applications, 
pharmacogenetic testing has direct and clear guidance on prescribing behavior, and is 
likely to have a more immediate impact in transforming clinical practice.2  
Pharmacogenetics study how genetic differences influence the variability in 
patients' responses to drugs, including individual variability in drug dose requirement, 
efficacy and risk of adverse reactions.3  Pharmacogenetic information may help to 
identify the patients who are most likely to respond to a certain drug, and/or to have 
adverse reactions, and therefore facilitate drug selection and optimize drug dosing to 
achieve better efficacy and lower risk of side effects.4 
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 Large amount of pharmacogenomic information is available. Of 1200 drugs 
reviewed by the United States Food and Drug Administration (US FDA) between 1945 
and 2005, 10% have pharmacogenomic information in their drug label.4,5 A drug 
utilization review based on the prescription claims database of a large pharmacy 
benefits manager in the US showed that a quarter of all outpatients received at least 
one drug with pharmacogenomic information on the label.5 Applying pharmacogenetic 
information is therefore promising to have significant impact on medication usage and 
treatment outcomes.  
One success of pharmacogenetic testing in influencing clinical practice is the 
targeted treatment of cancers.6-9 Breast tumors that overexpress human epidermal 
growth factor receptor type 2 (HER2) have better response to the drug trastuzumab. 
HER2 gene-amplification test and HER2 protein immunochemistry tests are now used 
to identify patients whose tumor cells overexpress HER2 and are therefore more likely 
to benefit from trasuzumab treatment.6,8 The American Society of Clinical Oncology 
recommends KRAS mutation testing for all patients with metastic colorectal carcinoma 
before anti-EGFR antibody therapy, and states that those with mutations in codon 12 
or 13 should not receive anti-EGFR antibody therapy.9 Immunochemistry tests for two 
other proteins: EGFR and c-kit are also approved as “companion diagnostics” for the 
colorectal cancer drug Erbitux and the gastrointestinal stromal tumor drug Gleevec, 
respectively.6 
1.3  ADRs and pharmacogenetics 
Another area of pharmacogenetics with potential is to reduce the risk of 
adverse drug reactions (ADRs) and improve drug safety. ADRs incur significant health 
care burden and cost to the health system. It was estimated that in the US in 1994, 
overall 2216000 hospitalized patients had serious ADRs, among which 106,000 had 
fatal ADRs.10 5%-7% of hospital admissions in US and Europe are due to ADRs each 
year, which ranks among the top six causes of inpatient death.10,11 Other than the 
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 threats to the quality of care and medical cost, ADRs have also resulted in the 
withdrawals of many effective drugs. Between 1999 and 2012, 43 drugs were 
withdrawn from the market due to ADRs,12 with an even larger number of drugs 
experiencing decreased usage after severe ADRs were reported. ADRs therefore have 
significant adverse impact on availability of drugs and the appropriate use of effective 
drugs at the health system level, in addition to the direct medical consequences.   
In Singapore, 3155 cases of ADRs are voluntarily reported each year to the 
Health Sciences Authority (HSA), with 49% being classified as severe ADRs, and 
22.4% being skin-related disorders.13 A review of admission causes in a general 
hospital in Singapore revealed that 0.42% of inpatients had drug allergy, with 
cutaneous eruptions being the most clinical presentation (95.7%).14 Serious cutaneous 
ADRs occurred in 5.2% of patients who had drug allergy.14 Cutaneous ADRs are 
therefore among the most concerned ADRs in Singapore.  
The most severe forms of cutaneous ADRs are Stevens-Johnson syndrome 
(SJS), and Toxic Epidermal Necrolysis (TEN). SJS and TEN are life-threatening 
hypersensitivity reactions, characterized by erosions of the mucous membranes, and 
extensive detachment of the epidermis.15,16 SJS is the milder form, where less than 
10% of body surface area has skin detachment, with an average mortality of 5%. TEN 
is the severe form, with skin detachment in more than 30% of body surface area, and a 
mortality of up to 40%.15,17 SJS-TEN overlap is a transition between SJS and TEN, 
with average mortality of 15%. Even though the incidence is low, SJS/TEN is a 
significant public health concern due to the high mortality, expensive hospitalization 
and treatment, as well as the fear and reluctance to treatment.18  
Medications are major causes of SJS/TEN.17 Notably, many SJS/TEN-causing 
drugs are commonly used, such as carbamazepine, allopurinol, phenytoin, 
phenobarbital, amoxicillin, coamoxiclav, cotrimoxazole, and non-steroidal anti-
inflammatory drugs (NSAIDs) of the oxicam type.13,18  Data from the multinational 
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 EuroSCAR study revealed that allopurinol, the first line urate-lowering therapy for 
chronic gout management, is the most common cause of SJS in Europe and Israel.19 
In Singapore, among all voluntarily reported SJS cases between 2003 and 2008, 
carbamazepine, a drug commonly indicated for epilepsy, neuropathic pain and bipolar 
disorders, was the leading drug cause of SJS, followed by phenytoin, cortrimoxazole, 
and allopurinol.13 A retrospective study of case records of SJS patients in India 
revealed that carbamazepine was the most common cause of SJS.20 The incidence of 
SJS varies across populations. For instance, the incidence is significantly higher in 
Han Chinese than Caucasians (8 per million person-years vs 1-6 per million person-
years),17,21  presenting more challenges to drug safety in Asian countries.  
The associations between genetic factors and SJS induced by some commonly 
used drugs have been discovered in the past decade. Chung et al first discovered the 
strong association between carbamazepine-induced Stevens–Johnson syndrome and 
the human leukocyte antigen HLA–B*1502 allele among Han Chinese in Taiwan, with 
the odd ratio being 2,504.21 The strong association was subsequently confirmed in 
various other Asian populations, including Han Chinese in Taiwan,22 Hong Kong,23 
southern China,24 central China,25 northern China,26 Thai,27,28 Malaysian,29,30 
Singaporean,31,32 Korean,33 and Indian34 populations. On the other hand, the 
association was not found among Japanese35 or Caucasian36,37 populations. The 
association between allopurinol-induced SJS and the HLA-B*5801 allele was also 
identified in Han Chinese in Taiwan,38 Hong Kong,39 and mainland China,40 
Korean,41,42 and Thai,43 where a moderate percentage of population are carriers of the 
HLA-B*5801 allele (8-20%), as well as Japanese population35,44 even though the 
carrier frequency is low.45 The strong genetic association particularly in Asian 
populations presents promising opportunities to use genetic testing to guide drug 




 1.4 Adoption of Pharmacogenetic Testing and Barriers 
Despite rapid advancement in genetic research, the adoption of 
pharmacogenetic testing in routine clinical practice is still in its early stage. The 
number of genetic tests that are commonly used for routine clinical care is relatively 
small. Of all drug labels with pharmacogenomic information in US and Europe that 
were licensed between 1998 and 2012, only 14 labels direct clinicians to test prior to 
prescribing.46 Often times, the information doesn’t lead to specific actions or changes 
in clinical practice.  
There were several barriers in the adoption of pharmacogenetic testing. Four 
aspects were commonly emphasized when evaluating whether a genetic test should 
be used in clinical decision making: analytical validity, clinical validity, clinical utility and 
ethical, legal and social implications.47,48 Analytical validity and clinical validity requires 
that a test can accurately and reliably detect the genotype, and the association 
between genotype and clinical manifestation is statistically significant. Clinical utility is 
the extent to which the test can improve treatment outcome or reduce ADR risks for 
specific patients. Genetic tests that make non-actionable predictions will have limited 
clinical utility. Testing HLA-B*1502 and HLA-B*5801 allele for drug-induced SJS have 
relatively well-established analytical validity, clinical validity and clinical utility through 
case-control genetic association studies and randomized control trials in general 
patient population. However, three issues remain unclear. Firstly, the current clinical 
studies focus on the immediate outcome of SJS, but often ignore the long-term 
medical consequences. Genetic testing may influence the choice of medications, 
which also influence the long-term treatment efficacy and patients outcomes. Weighing 
different domains of clinical outcomes can be challenging. In an era of rising health 
care cost, the cost impact of genetic testing is important. Genetic test may results in 
higher or lower medical costs. When extra costs are incurred, the value of the service, 
or whether the benefit justify the cost, becomes an important issues. With limited 
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 healthcare budget and resources, spending on the high value or cost-effective services 
will achieve the biggest outcome improvement. It is therefore important to quantify the 
benefit and cost of testing at a societal level to better inform the economic value of 
testing.   
The above barriers to the adoption of HLA-B*1502 and HLA-B*1502 
pharmacogenetic testing for SJS are not pure medical decisions, and involve the 
judgement and tradeoffs between various domains of clinical outcomes, long and 
short-term outcomes, as well as cost consequences, both at population level and 
individual patient level.  
In this dissertation, I employed a series of economic analyses and economic 
criteria to evaluate the value of pharmacogenetic testing for the two leading drug 
causes of SJS/TEN (carbamazepine and allopurinol) in Singapore from a health 
system perspective and an individual patient perspective. First, cost-effectiveness 
analyses were conducted to evaluate the long-term cost and benefit of 
pharmacogenetic testing for these two drugs at the population level. Subsequently, 
patients preferences for allopurinol pharmacogenetic testing, and tradeoffs made 
between various factors are quantified using a discrete choice experiment.  
1.5 Health economic evaluations to inform decision making 
1.5.1 Cost-effectiveness analysis 
Cost-effectiveness analysis is a commonly used decision tool in health 
economics to evaluate new technologies and programs. It systematically compares the 
costs and effectiveness associated with each available alternative strategy to manage 
the same condition. Effectiveness is measured in Quality-adjusted life years (QALYs), 
which unifies various dimensions of clinical outcomes (such as treatment efficacy, side 
effects, mortality, disability, quality of life, disease duration) into one measure. Cost-
effectiveness of a new technology or program is usually calculated in incremental 
terms relative to a status quo strategy, to reveal the incremental value added by the 
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 new treatment. A threshold which reflects the societal willingness-to-pay for one 
quality-adjusted life year is then applied to judge the incremental cost-effectiveness of 
the new technology or program. New technologies or programs that significantly 
improves effectiveness at low costs are considered to have high value. Cost-
effectiveness offers a criteria to allocate scare resources based on efficiency. 
Spending on high value treatment and services will lead to efficient use of healthcare 
resources.  
Cost-effectiveness analysis is increasingly used to facilitate decision making at 
various levels. Clinicians can evaluate the long-term cost and effectiveness of various 
treatment alternatives and choose the most cost-effective treatment. Regulatory 
agencies such the National Institute for Health and Clinical Excellence (NICE) in the 
UK uses a cost-effectiveness threshold in its assessment and guidance.49 Public and 
private payers can rely on cost-effectiveness criteria to determine whether a new 
technology or service will be reimbursed, based on the ground of value and efficiency.  
1.5.2 Discrete choice experiment 
Discrete choice experiment is a stated-preference method to quantify individual 
preferences using a series of choice questions.50-52 When revealed preferences or 
actual market behaviors are not observable, such as when a market does not exist, or 
when a product is not yet available, stated preference method can provide useful 
insights on preferences by offering hypothetical choice sets. Discrete choice experiment 
is also referred to as choice-based conjoint analysis. The name “Conjoint analysis“ 
arose from the key characteristics of this type of study that different features of products 
or services are “CONsidered JOINTly”.53 Each feature is referred to as an attribute. And 
each choice alternative is composed of combinations of levels or each attribute. 
Compared to other stated-preference methods, such as contingency valuation, DCE is 
advantageous in measuring preferences for each attribute level (the marginal value), 
the relative important of various attribute, and the tradeoffs between different 
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 attributes.54 DCE elicit preferences using choice questions, which is a more intuitive and 
realistic way of everyday decision making, compared to other methods such as rating, 
or ranking.53  
First developed in marketing, later adopted by public and environmental 
economists, conjoint analysis and DCE have been increasingly used in health care in 
the recent decade. The preference of patients and other stakeholders regarding medical 
treatments, screening and preventive services, health service delivery, have been used 
to inform clinical practice and priority setting.53,55-59  Recently, DCE has gained popularity 
in informing regulatory decisions. US FDA has published a draft guidance on the use of 
patients’ preference information in 2015.60 The DCE methodology and the applications 
in weighing benefit and risk of drugs and devices were reviewed.   
Common attributes included in DCEs are health care outcome-related attributes 
(such as treatment efficacy, side effects, survival etc), health care process-related 
attributes (such as waiting time, quality of care, mode of service, and type of health care 
professional), cost attributes, and others. DCE allows the explicit quantification of 
tradeoffs individual make between different attributes. The tradeoff between an attribute 
and the cost attribute provides estimates on the monetary value of the attribute level, or 
the willingness-to-pay (WTP). The DCE results have also been used to predict the 
choice probability or the uptake rate of a certain product or service. 
1.6 Objective and structure of this thesis 
The objective of the thesis is to conduct health economic evaluations to 
generate evidence to inform clinical and regulatory decision making on whether 
pharmacogenetic testing should be routinely done in order to reduce the risk of drug-
induced SJS/TEN in the context of Singapore. The two leading causative agents, 
carbamazepine and allopurinol, were the focus of my studies.  
The thesis consists of four research chapters. Chapter 2 assesses the cost-
effectiveness of HLA-B*1502 testing prior to carbamazepine treatment for epilepsy 
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 patients from a health system perspective to inform clinical and regulatory policy 
making in Singapore.  The study, together with other related studies, has led to a 
change in regulatory recommendation, and subsequent changes in clinical practice. 
These changes as well as intended outcomes and unintended consequences were 
briefly reviewed at the end of Chapter 2. Chapter 3 assesses the cost-effectiveness of 
HLA-B*5801 testing for allopurinol among chronic gout patients. Nevertheless, cost-
effectiveness analysis does not speak to what individual patients should do or will do. 
Chapter 4 adopts a different perspective to review the literature on patients’ 
preferences for pharmacogenetic testing, and motivate the study in Chapter 5. Chapter 
5 describes a discrete choice experiment to quantitatively measure patients’ 
preferences for genetic testing prior to initiating allopurinol in chronic gout treatment. 
The thesis is concluded in Chapter 6, with recommendations for future research. 
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 Chapter 2 . Cost-effectiveness of HLA-B*1502 
Genotyping Newly Diagnosed Adult Epilepsy Patients in 
Singapore 
2.1 Abstract  
Objective 
Asians who carry the HLA-B*1502 allele have an elevated risk of developing 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) when 
treated with the antiepileptic drugs (AEDs) carbamazepine (CBZ) and 
phenytoin (PHT). Using data in Singapore, this study evaluates the cost-
effectiveness of HLA-B*1502 genotyping, and identifies circumstances in which 
genotyping and targeted treatment with alternative antiepileptic drugs that do 
not induce SJS/TEN is likely to be more cost-effective. 
Methods 
A decision tree model was developed in TreeAge. The model takes into 
account costs of epilepsy treatments and genotyping, reductions in quality of 
life (QoL) and increased costs resulting from SJS/TEN complications, the 
prevalence of the risk allele, the positive predictive value (PPV) of genotyping, 
life expectancy and other factors.   
Results 
Compared with the status quo strategy of providing CBZ to all patients without 
genotyping, genotyping and targeted treatment results in an incremental cost-
effectiveness ratio of $37,030/QALY for Chinese patients, $7,930/QALY for 
Malays and $136,630/QALY for Indians in Singapore. 
Conclusions 
Due to the different population allele frequencies of HLA-B*1502, genotyping 
for HLA-B*1502 and targeted epilepsy treatment is cost-effective for 
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 Singaporean Chinese and Malays, but not for Singaporean Indians. Based on 




 2.2 Introduction   
The World Health Organization (WHO) estimates the population 
prevalence of active epilepsy to be 4 to 10 per 1,000 worldwide, but higher in 
developing countries.61 Roughly 50 million people worldwide suffer from 
epilepsy, with more than half living in Asia.61,62 The first line treatment for 
epilepsy consists of first generation antiepileptic drugs (AEDs) aimed at 
reducing the frequency of seizures. Due to their effectiveness and low cost, the 
most frequently prescribed drugs are carbamazepine (CBZ) and phenytoin 
(PHT).62,63 However, they are not without side effects, including cutaneous 
hypersensitivity reactions, ranging from mild rash to rare but potentially fatal 
Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and SJS-
TEN overlap.  These conditions are characterized by blistering exanthema of 
purpuric macules, mucosal involvement and skin detachment.16,64 The fatality 
rate is reported to be roughly 5% for SJS, 30% for TEN,17,64 and somewhere in 
between for SJS-TEN overlap.65  
Epidemiologic data reveal that epilepsy patients from certain Asian 
populations have a higher risk of developing SJS or TEN following CBZ 
treatment compared with Caucasians.28,66 In 2004, a strong association 
between the HLA-B*1502 allele and risk for CBZ-induced SJS and TEN was 
discovered among Han Chinese in Taiwan (odds ratio of 2,504, positive 
predicted value of 5.6%, and negative predicted value of 99.9%)66,67. This 
association was later confirmed in various other Asian populations including 
Han Chinese in Hong Kong,23 southern China,24 central China,25 northern 
China,26 Thai,27,28 Malaysian,29,30 Singaporean,31,32 Korean,33 and Indian34 
populations. On the other hand, the association was not found among 
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 Japanese35 or Caucasian36,37 populations. For these groups with established 
genetic associations, the prevalence of the allele ranges between 5.7 % and 
27.5%,68whereas it is virtually absent in Caucasians and Japanese. These 
differences, along with differences in CBZ prescribing patterns, largely explain 
the differences in CBZ induced SJS/TEN across countries.  
Based on the evidence on genetic associations, in 2007, the US Food 
and Drug Administration (FDA) amended the prescribing information for CBZ, 
recommending (but not requiring) genotyping in populations in which HLA-
B*1502 is present before prescribing CBZ. 69 Though it is not yet accepted 
practice in Asia, given the above findings, it might seem appropriate to 
genotype for the HLA-B*1502 risk allele and provide an alternative to CBZ to 
those who are HLA-B*1502 positive. Phenytoin, another anti-epileptic drug, can 
also induce SJS/TEN and has also been associated with the HLA-B*1502 
allele.(Hung 2010) In Singapore, based on a registry of adverse drug reactions 
maintained by the Health Sciences Authority, between 2003 and 2009, 262 
reports of SJS, 35 reports of SJS-TEN overlap and 74 cases of TEN were 
received. CBZ was the leading suspected causative agent in 18% of the 
reports, whereas phenytoin (PHT) was suspected in 9.6% of cases.70 Therefore 
HLA-B*1502 genotyping may be considered prior to CBZ or PHT treatment for 
epilepsy patients in Singapore to reduce risk of SJS/TEN.  
Despite the risk reduction, there are several concerns related to the 
adoption of genotyping, particularly on the higher costs, and the predictive 
power of the genetic test. There are alternatives drugs to CBZ and PHT for 
those suffering from epileptic seizures, including sodium valproate (SVP), 
lamotrigine (LTG), topiramate (TPM), levetiracetam (LEV) and gabapentin 
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 (GPT). These drugs have comparable efficacy to CBZ but lower or no risk of 
SJS/TEN. However, they are substantially more expensive. It is also not clear 
whether genotyping and using these alternative medications for those who test 
positive for the HLA-B*1502 risk allele is cost-effective. The other issue 
concerns the predictive power of the test. The risk allele is present in 5.2% of 
Singaporean Chinese (Singapore Immunology Network) and 15.7% of 
Malays,71 In contrast, the incidence of SJS/TEN is around 0.2% among Han 
Chinese, implying that even among risk allele-carriers, more than 90% will not 
develop SJS/TEN.     
The goal of this analysis is to present a cost-effectiveness model to 
allow for identifying those circumstances in which genetic testing and targeted 
treatment with an alternative medication for those who test positive is likely to 
be more cost-effective that: 1) treatment with CBZ or PHT without genotyping 
and 2) providing alternative drugs with no SJS/TEN risk without genotyping. 
Although the model is populated using cost and SJS or TEN data from 
Singapore, through sensitivity analyses it identifies the threshold conditions in 
which genotyping and targeted therapy would be cost-effective in other 
settings. The model and results will be useful for all countries and health plans 
considering the decision of whether or not to genotype for the risk allele. 
2.3 Methods 
A decision tree model was developed in TreeAge Pro 2011 (TreeAge 
Software, Williamstown, MA) to estimate the cost-effectiveness of HLA-B*1502 
genotyping for newly diagnosed adult epilepsy patients in Singapore for whom 
CBZ or PHT is considered suitable as first-line monotherapy (Figure 1). CBZ 
and PHT are assumed to be perfect substitutes in the model and denoted as 
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 CBZ/PHT, for their similar cost, efficacy and safety profiles.72 A local anti-
epileptic drug usage study revealed that CBZ and PHT was used as first line 
monotherapy in 74% of adult patients with newly diagnosed epilepsy, most of 
whom had partial seizures. 73 The model also assumes VPA to have 
comparable efficacy and safety profile with CBZ/PHT but without SJS/TEN 
risk.74,75 Though the evidence on relative efficacy of various drugs remains 
inconclusive, this assumption is supported by clinical trials and meta-analyses 










   Figure 1. Decision tree model of three treatment strategies for newly diagnosed adult epilepsy patients in Singapore for whom CBZ/PHT is considered 





 Model structure 
Figure 1 shows the different strategies modeled, and the treatment 
pathway and patients outcomes for each treatment strategy. The upper branch 
of the decision tree represents the status quo practice, which is using CBZ/PHT 
as first line treatment without genotyping. The middle branch considers the 
genetic testing strategy, where all newly diagnosed adult epilepsy patients are 
genotyped for HLA-B*1502 allele before treatment initiation. Test positive 
patients will receive VPA as first line drug, and test negative patients receives 
CBZ/PHT due to minimal risk of SJS/TEN. The lower branch examines an 
alternative risk-mitigation strategy that is likely to occur in real clinic settings, 
where CBZ/PHT is avoided and all patients receive VPA as first line therapy 
without genotyping.  
Based on the clinical literature, five treatment outcomes are modeled 
post initial treatment (1) being seizure-free (SF) after treatment and 
continuously taking the same drug for the long term; (2) being non-SF but 
achieving satisfactory seizure control (defined as achieving greater than 50% 
reduction in seizure frequency), and taking the same drug for the long term; (3) 
showing no satisfactory response (defined as < 50% reduction in seizure 
frequency) to the drug and switching to an alternative drug; (4) having 
intolerable side effects (such as rash, fever, fatigue, dizziness, alopecia as 
documented in clinical trials), and switching to an alternative drug; (5) 
development of SJS /TEN and complete recovery, followed by alternative 
epilepsy treatment; (6) death due to SJS/TEN. The first four outcomes are 




 When SJS/TEN occurs, extensive and expensive medical care is 
required, but usually last for only a few days or weeks.65 Patients are assumed 
to either die within 1 month after CBZ/PHT initiation or to fully recover by the 
end of 1 month. For patients requiring second line epilepsy treatments (with 
outcome 3, 4 and 5), we modeled a hypothetical second drug whose cost is a 
weighted average of the commonly used anti-epileptics, and producing an 
efficacy reflecting the average efficacy of different drugs. For patients who fail 
CBZ/PHT treatment, the alternatives include VPA, Lamotrigine (LTG), 
Levetiracetam (LEV) and Topiramate (TPM), whereas for patients who fail with 
VPA treatment and intend to avoid all SJS/TEN-inducing drugs, LEV and TPM 
are the assumed alternatives. The choice of second line drugs and treatment 
pathway in each scenario, drug dosage and usage patterns were advised by 
physicians.  
To mirror clinical practice, we explicitly modeled three distinct treatment 
periods. The first period spans the first month after treatment initiation, after 
which clinicians evaluate the risk of intolerable side effects and life-threatening 
SJS/TEN. One month is chosen as the literature shows most SJS/TEN cases 
develop within 3 weeks.64  The second period encompasses months 2 through 
6, which allows physicians to evaluate short-term drug efficacy. Short-term 
efficacy data are from a clinical trial conducted in the UK.78 Based on treatment 
efficacy in the second period, treatment is adjusted in the third period and 
continues for an additional seven years, which is roughly the median 
cumulative treatment duration. Even though some guidelines and physicians 
support life-time treatment even for those who remain seizure-free, it is not 
common in practice. Beyond the treatment period we assume that treatment is 
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 discontinued and health related quality of life is restored to perfect health and 
lasts for another 30 years. The time horizon of 30 years is chosen as the 
average onset age for adult epilepsy is around 40 and average life expectancy 
for epilepsy patients is 70 (ten years shorter than that of the general 
population).79 The impact of these assumptions on results was evaluated in 
sensitivity analyses. 
Model Inputs 
Table 1 lists all input variables and sensitivity ranges. Several key 




 Table 1. Model Inputs.   





Cost (in 2010 US dollars) 
Average annual cost of CBZ/PHT 
(Daily median dosage = 420mg /300mg) 170 85-340 
Selling prices were from IMS 
HEALTH and median daily dosage 
prescribed by local clinicians 
Average annual cost of VPA  
(Daily median dosage=1050 mg) 470 235-940 
Average annual cost of hypothetical 
therapy for patients who fail CBZ treatment 1,100 550-2,200 
Average annual cost of hypothetical 
therapy for patients who fail VPA treatment 1,860 930-3,720 
Cost of HLA-B*1502 genotyping 270 80-380 
Cost of per case SJS treatment 3,480 1,740-5,220 
 Singapore public hospital 
discharge data 




Cost of per case TEN treatment 17,030 8,510-25,540 
Cost of therapeutic drug monitoring test 15 8-23 
Public hospitals in Singapore  
cost of neurologist consultation (per visit) 80 38-115 
QoL 
SF with tolerable side effects 0.9418 0.8836-1 
80,81 
Non-SF but show >50% reduction in 
seizure frequency 0.907 0.814-1 
No effect 0.8288 0.7576-0.9 
On hypothetical treatment 0.909 0.868-0.95 
Intolerable side effects 0.8 0.7-0.9 
SJS (duration=8.9 days) 0.35 0.175-0.525 
Estimated with reference to QoL of 
burn patients82 SJS-TEN overlap  (duration=9.2days) 0.3 0.15-0.45 
TEN (duration=12.4 days) 0.25 0.125-0.375 
SJS/TEN fatality and incidence 
Fatality for SJS  5% 2.5-7.5% 
 64 Fatality for SJS-TEN overlap 15% 7.5-22.5% 
Fatality for TEN 30% 15-45% 
Percentage of SJS-TEN overlap among 
SJS/TEN overlap and TEN 10% 5-15% 
 
Singapore Health Sciences 
Authority (2003-2009 data)70 
Percentage of TEN among SJS/TEN 20% 10-30%  
HLA-B*1502 genotyping 
Population frequency of HLA-B*1502a 14.87% 11-18.74% 
83 and unpublished data from 
Singapore Genome Variation 
Project and Singapore 
Immunology Network  
Positive predictive value of positive 
genotyping results in CBZ/PHT usersa 5. 96% 4-7.92% 
 84 
Efficacy and safety of CBZ (clinical response at 6 months post treatment initiation among patients with partial 
seizures) 
Non-seizure-free but show >50% reduction 
in seizure frequency and stay on treatment 48% 38-58% 
 78 No effect 8% 2-14% 
Intolerable side effects 25% 5-45% 
Other inputs 
Duration modeled (in years) 30 20-40  79 
Percentage of duration on epilepsy 
treatment 23.3% 25%-41% Clinician’s recommendation 
Annual discount rate 3% 0-5% 
All monetary amounts are presented in US dollars. Data in Singapore dollars were converted to US dollars using 





 Incidence of SJS/TEN  
Calculating the incidence of CBZ/PHT-induced SJS/TEN in Singapore 
is challenging, as the exact number of new CBZ/PHT users are not measured, 
and cases are reported on voluntary basis. A study in Taiwan used the 
national insurance claims database and estimated the incidence of CBZ-
induced SJS to be 0.23%. Taiwan Chinese and Singaporean Chinese have 
similar origin, and genetic profiles. Therefore, the incidence among Singapore 
Chinese is assumed to be the same as that in Taiwan (0.23%).84 To estimate 
the incidence in Singaporean Malays and Indians, we used data from a 
voluntary adverse drug reaction registry maintained by the Singapore Health 
Sciences Authority.70 There may be under-reporting in voluntary registries, we 
therefore assumed the incidence to be the same among Singaporean 
Chinese and Taiwan Chinese, and scaled the estimated incidence for 
Singaporean Malays and Indians assuming equal degree of under-reporting 
for different ethnic groups. The adjusted incidence of CBZ/PHT-induced 
SJS/TEN among Singapore Malays and Indians patients initiating CBZ/PHT 
are 0.61% and 0.14%.  More than 95% of Singapore resident population are 
Chinese, Malays or Indians. 85 Among ethnicity-weighted Singapore CBZ/PHT 
users, the incidence is 0.27%.  
Positive predictive value (PPV) of HLA-B*1502 genotyping 
PPV is defined as the probability of actually developing the condition 
when the test predicts the condition. Based on the sensitivity and specificity 
established in Taiwan Chinese (98.3% and 95.8% respectively),84 PPVs of 
HLA-B*1502 genotyping were estimated as 5.96% for the entire population, 
5.1% for Singapore Chinese, 12.5% for Singapore Malays and 3.2% for 
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 Singapore Indians. In the base case analysis, we considered the ethnicity-
weighted Singapore population. The ethnicity-weighted Singapore population 
was considered for main analysis. The negative predictive value (NPV) is 
close to 100%. 
Costs and Utilization 
Wholesale prices of available anti-epileptic drugs in Singapore in 2010 
were obtained from IMS HEALTH. To approximate the retail prices, the 
obtained wholesale prices were multiplied by 1.2 to account for the markup. 
Average daily costs for each drug was calculated by multiplying the unit price 
by the median dosage for each drug, as commonly prescribed by local 
clinicians (Supplementary Table e1). The costs of hypothetical drugs were 
calculated as a weighted (by utilization) average of the several commonly 
used alternative drugs. SJS and TEN treatment costs were estimated based 
on National University Hospital discharge data for 20 cases. None of these 
cases were fatal, and we assumed the costs for cases that ended in a fatality 
to be double of the base case value due to additional resources required at 
the end of life. We made the assumptions that each patient required one 
therapeutic drug monitoring test immediately after treatment initiation, four 
specialists visits in the first year of treatment and 2 visits per year thereafter 
during treatment period. All costs were converted to US dollars at the 
exchange rate of $1.3 Singapore dollars to $1 US dollar as of October 2010. 
Sensitivity Analyses 
The robustness of the cost-effectiveness results and the impact of 
specific parameters were tested through one-way sensitivity analyses and a 
probabilistic sensitivity analysis (PSA). In one way sensitivity analyses, 
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 variables were varied one at a time, within reasonable sensitivity ranges, and 
the incremental cost-effectiveness ratios were calculated. Several key 
variables of interests were further analyzed using threshold analysis to identify 
the threshold at which the cost-effectiveness results will be altered. Scenario 
analysis and two-way sensitivity analyses were also conducted.  
The probabilistic sensitivity analyses allowed all variables to vary 
simultaneously based on 10,000 repeated draws from assigned distributions. 
All variables except percentage of remaining life expectancy on treatment 
were assumed to follow triangular distributions. The base-case value was 
used as the likeliest value in the triangular distribution, and the lower and 
upper bounds of the sensitivity ranges were used as the min and max (Table 
1). The percentage of remaining life time a patient is on epilepsy treatment is 
approximated using a bimodal distribution, which was constructed as a 
combination of two triangular distributions to account for patient heterogeneity 
in drug responses and epilepsy recurrence. The first triangular distribution 
(min=2 yrs; mode=3.5 yrs; max=5 yrs) represents patients with good 
responses to drugs and no recurrence, whereas the second triangular 
distribution (min=10 yrs; mode=15 yrs; max=20 yrs) corresponds to patients 
who require longer term treatment. We assumed that 60% of patients fall in 
the first distribution and 40% in the second, based on expert opinions. We 
conducted sensitivity analyses to explore the impact of this assumption on the 
cost-effectiveness results (Supplementary Table e2). This study was reviewed 
and granted exemption by the National University of Singapore Institutional 
Review Board (NUS IRB). 
2.4 Results  
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 Base case cost-effectiveness results are shown in Table 2. 
Effectiveness is measured in quality-adjusted life years (QALYs), which is, the 
remaining life years after adjusting for quality of life (Qol) within that time 
period. Qol is a quality weight between 0 and 1, with 0 indicates death and 1 
represents perfect health). Our results show that genotyping and prescribing 
VPA for those who test positive generates a modest improvement in QALYs 
(0.019 QALYs) at a $570 marginal increase in cost relative to the status quo 
practice, resulting in an incremental cost-effectiveness ratio (ICER) of 
$29,750/QALY. The strategy of providing VPA to all patients without 
genotyping is not favorable as it gives the same QALYs as the genotyping 
strategy but at a higher cost. This is referred to as a dominated strategy. If the 
annual cost of VPA drops to within $37 of the cost of CBZ, this strategy would 
become cost-effective.  
 
Table 2. Cost-effectiveness of 3 strategies for newly diagnosed epilepsy 








QALYs Incremental QALYs 
ICER (US 
dollars/QALY) Dominance 
No genotyping and 
CBZ/PHT for all patients 4,110 - 18.846 - - 
Not 
Dominated 
Genotyping and VPA for 
test positive patients 
and CBZ/PHT to test 
negative patients 
4,680 570 18.865 0.019 29,750 Not Dominated 
No genotyping and VPA 
for all patients 6,780 2,100 18.865 0 0 Dominated 
ICER: incremental cost-effectiveness ratio, QALY: quality-adjusted life-years  
 
 
The cost-effectiveness results for Singapore Chinese, Malays and 
Indians are shown separately in Table 3. Relative to the status quo strategy, 
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Table 3. Incremental cost-effectiveness of genotyping versus no genotyping 
strategy for 3 major ethnical populations in Singapore 




QALYs Incremental QALYs 
ICER (US 
dollars/QALY) 
Singapore Chinese 4,650 560 18.865 0.015 37,030 
Singapore Malays - 5,050 610 18.865 0.077 7,930 
Singapore Indians 4,370 360 18.865 0.00263 136,630 
ICER: incremental cost-effectiveness ratio, QALY: quality-adjusted life-years  
 
 
 Sensitivity analyses  
A commonly used cost-effective threshold is $50,000/QALY86. Using 
this threshold to define what signifies cost-effectiveness, the one-way 
sensitivity analyses (Figure 2 Panel A) show that any single variable when 
varied within the assigned sensitivity does not increase the ICER beyond the 




Figure 2. Sensitivity analyses. (A) One-way sensitivity analysis of all uncorrelated 
variables on Incremental cost-effectiveness ratio (ICER) of the genotyping strategy. 
Variables that are correlated with other variable(s) were not shown. The minus sign 
at the left side of the bar indicates ICER decreases when the variable increases. SF: 
seizure free. (B) Two-way sensitivity analysis of the effects of positive predictive 
value (PPV) and population HLA-B*1502 frequency on ICER. (C) Cost-effectiveness 
acceptability curves of 3 treatment strategies from probabilistic sensitivity analysis. 
Red vertical line: the willingness-to-pay at which genotyping is cost-effective for 50% 




 In efforts to generalize the model beyond Singapore, various sensitivity 
analyses were conducted. Two population-specific variables, PPV and 
frequency of HLA-B*1502 allele in the population, were varied within wider 
ranges to identify the threshold values at which the cost-effectiveness results 
would alter. Holding other variables constant at the base case values, a PPV 
below 3.8% will increase the ICER to above $50,000/QALY, as will an HLA-
B*1502 population frequency lower than 6.1%. To show the impact of 
combinations of PPV and allele frequency on the ICER, two-way sensitivity 
analyses are shown in Figure 2B. Genotyping is cost-effective in populations 
with higher test PPV and higher HLA-B*1502 frequency. A higher allele 
frequency could compensate for a lower PPV to make genotyping cost-
effective. However, if the PPV is below 3%, genotyping is likely to be not cost-
effective regardless of allele frequency. This result holds under current 
genotyping costs, however, a lower genotyping cost could compensate for a 
lower PPV.   
Using the base case values of input variables, the probabilistic 
sensitivity analysis (PSA) reveals that, assuming a willingness-to-pay of 
$50,000/QALY, genotyping is cost-effective in 75% of iterations. As long as 
the societal willingness-to-pay is higher than $31,000/QALY, genotyping 
would be preferred in more than 50% of iterations among 10,000 draws in the 
simulation (Figure 2C).  Additionally, the genotyping cost of $270 currently 
represents roughly 6% of the expected epilepsy treatment cost. This 
percentage is likely to decrease in the future due to technological 
advancements and increased availability of genotyping services, which will 
make genotyping even more cost-effective. 
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 2.5 Discussion 
The study estimated the incremental cost-effectiveness of genotyping 
for each ethnic group in Singapore, and revealed the differences in cost-
effectiveness for each ethnic groups. This is due to the differences in 
population characteristics HLA-B*1502 frequency and PPV of genotyping. The 
product of the two determines the likelihood of an average CBZ/PHT user 
developing SJS/TEN. In the base case, it is estimated that the proportion of 
new patients who would develop SJS/TEN after initiating CBZ/PHT is 0.70% 
among Chinese, 3.55% among Malays and 0.12% among Indians. Among 
those who develop SJS/TEN, fatality is expected to be 9.5%. To prevent one 
case of SJS/TEN, 142 Chinese patients, 28 Malay patients, or 833 Indian 
patients would need to be genotyped on average. To avoid one death due to 
CBZ/PHT-induced SJS/TEN, 1,500 Chinese patients, 297 Malays patients 
and 8,770 Indians patients would need to be genotyped prior to initiating 
CBZ/PHT.  
Besides population HLA-B*1502 allele frequency and PPV of HLA-
B*1502 genotyping, two additional factors influential on results are the 
treatment duration and remaining life expectancy (Table e2). Longer 
treatment duration increases the long-term costs of providing expensive 
alternative medications. However, among those expected to live a long life, 
such as young people, death due to SJS/TEN generates a large loss of 
QALYs. The cost-effectiveness results from the tradeoff of these two factors. 
Nevertheless, our model shows that if treatment is life-long, then genotyping 
is not cost-effective regardless of remaining life expectancy. This is because 
when the life expectancy is short, preventing an SJS/TEN-induced death 
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 results in few QALYs saved; whereas for long life expectancies, the increased 
cost of lifetime alternative treatments, drives the ICER beyond the acceptable 
threshold. As a general rule of thumb, as the percentage of remaining life on 
treatment increases, genotyping becomes less cost-effective.  
 The above analysis assumes drug prices to be at the base case 
values.  However, there is substantial variation in medical practices and drug 
prices across countries and across health plans within countries. Higher drug 
prices (due to either higher dosage prescribed or higher prices per unit) would 
reduce the cost-effectiveness of HLA-B*1502 genotyping, all else equal. For 
example, if all drugs cost 5 times that of the base case values, the ICER of 
genotyping would increase to $107,520/QALY, which is no longer cost-
effective. However, locations with high anti-epileptic drug costs are likely to 
also have higher costs of SJS/TEN treatments, which may drive the cost-
effectiveness ratio back to acceptable levels depending on the magnitude of 
the increase. If the costs of a particular drug change differentially from the 
other drugs, such as when patent expires or when the demand changes, 
ICERs will change accordingly. For example, if VPA and CBZ have the same 
price, then providing VPA to all patients as first line therapy would be the 
preferred strategy as it avoids the risk of SJS/TEN without the need to 
genotype. On the other hand, if the prices of all alternative drugs increase 
beyond $1,420 per year while the price of CBZ remains unchanged, 
genotyping be not cost-effective, and using CBZ/PHT without genotyping 
would become the optimal strategy, as the higher long-term costs of epilepsy 
treatment would outweigh the benefit of genotyping.  
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 In the study, it is assumed that health related qualify of life is restored 
to perfect health after anti-epileptic treatment. Actual health related qualify of 
life may be lower due to imperfect responses to drugs, recurrence of epilepsy, 
or other health problems. If true, the QALY gains due to prevention of 
SJS/TEN and related death might be over-estimated. However, scenario 
analysis shows that even assuming that the low QoL during treatment is 
sustained until death, the ICER for genotyping ($27,980) is still below the 
cost-effectiveness threshold. Additional sensitivity analyses reveal that, based 
on our assumptions, as long as the QoL for successful treatment is greater 
than 0.83, genotyping is cost-effective. We also made assumptions on the 
clinical treatment pathways, following clinical guidelines and experts opinions. 
However, in reality, treatment decisions depends on many factors and may 
substantially deviate from our base case assumptions. For instance, when 
selecting anti-epileptics, patients who does not tolerate a single seizure may 
request to switch to the (more expensive) alternative drugs even when they 
have a substantial reduction in seizure frequency. Among those patients, 
genotyping would not be cost-effective as they are more likely to switch to the 
more expensive drugs irrespective of the genotyping results. In addition to the 
above, the model includes several additional assumptions and simplifications. 
The model simplifies the treatment rules for who receives which drugs. In real 
clinic settings, many factors, including seizure type may influence the 
treatment regimens. Besides, treatment options are sometimes more 
complicated than what’s captured in the model, such as when more than two 
lines of treatments and combination therapies using multiple drugs are 
involved. In addition, based on available literature, this study assumes VPA, 
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 CBZ, and PHT to have similar efficacy for the epileptic conditions concerned 
in this study. This assumption is supported by clinical trials and meta-analyses 
for generalized seizures and secondary generalized tonic-clonic seizures76,77. 
For partial seizures, some evidence suggests CBZ is superior to VPA in the 
short term for complex partial seizures75-77. In cases where CBZ is superior to 
VPA, genotyping will be less cost-effective. Moreover, the effectiveness data 
is from clinical trials in Caucasian populations. Though no evidence suggests 
differences on drug response and QoL perception among epilepsy patients 
across different ethnicities, we cannot rule out the possibilities of population 
variations in drug response, cultural differences on QoL values, or different 
clinical practices.  
 A final limitation is that genotyping results are assumed to be 
immediately accessible at the time of diagnosis, which may be challenging in 
clinical practice. While waiting for testing results (several days), it may be 
appropriate to provide an alternative treatment to CBZ/PHT until when the 
genotyping results can be obtained, and then, switch to CBZ/PHT for those 
who test negative.   
 Barring the above limitations, this model provides a template to 
assess the cost-effectiveness of HLA-B*1502 genotyping in other Asian 
countries, though local clinical practice and medical costs should be 
considered. In general, in countries with high HLA-B*1502 frequency and high 
incidence of CBZ/PHT-induced SJS/TEN, genotyping is more likely to be cost-
effective. This includes many Southeast Asian countries (such as Singapore, 
Malaysia, Vietnam, Thailand, Indonesia, and the Philippines) and southern 
eastern regions of Asia (such as Hong Kong, Taiwan and certain southern 
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 provinces of china). The frequency of HLA-B*1502 in these populations is 
generally higher than 5% and even above 20% in some ethnic groups287. 
Contrarily, prevalence is below 2.5% in India (except certain ethnic groups) 
and northern Asian countries including Japan, South Korea, and northern 
regions of China, suggesting that genotyping is unlikely to be cost-effective in 
these regions.  
 
2.6 Changes in HLA-B*1502 genotyping policies and 
practices in Singapore 
Various regulatory actions have been undertaken after the completion 
of this study, and clinical practice has changed as a result of this study and 
other related studies. Through the collaborative effort of multiple sectors to 
implement HLA-B*1502 testing in clinical practice, valuable lessons have 
been learned. 
Before this study 
In March 2009, the Health Sciences Authority (HSA) published a 
Product Safety Alert on serious adverse skin reactions associated with 
carbamazepine based on international studies on the genetic association, 
local ADR reports and US FDA recommendations.88 The package insert of 
Tegretol® (carbamazepine) was updated in Singapore by the manufacturer to 
reflect the association observed between HLA-B*1502 allele and CBZ-
induced SJS, the prevalence of this allele in various Asian population, and a 
recommendation to consider testing for the presence of HLA-B*1502 allele in 
patients with Asian ancestry prior to prescribing Tegretol®. In the package 
insert, it was also stated that the use of carbamazepine should be avoided in 
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 tested patients who are found to be positive for HLA-B*1502 unless the 
benefits clearly outweigh the risks.  
However, as the test was new to Singapore, the service was not readily 
available in hospitals or clinics in Singapore where carbamazepine was 
prescribed. The only accredited lab in Singapore that offers the HLA-B*1502 
test was the HSA’s Tissue Typing Laboratory, which conducted 
comprehensive HLA typing mostly for patients prior to organ transplantation 
and bone marrow transplantation.  
There were several perceived barriers to the uptake of the test. Firstly, 
the test could only be done outside practitioners’ institutions, which adds 
additional administrative workload for physicians and hospital staff to order 
the test, transport samples, and receive hard copy test results. The 
independency of the IT systems between different institutions created 
difficulties to the delivery of test results, the incorporation of results into 
electronic medical record, and the sharing of test results between different 
providers such as the tertiary hospitals and primary care clinics.  Secondly, 
the available test service was not tailored for carbamazepine testing. The 
tissue-typing based procedure has high accuracy, but high cost (S$350) and 
long turnover time (3-7 working days). A cost of S$350 was considered high 
relative to the cost of carbamazepine. In addition, for epilepsy patients who 
require immediate relief, a turnover time of 3-7 days may cause delay in their 
critical treatment. Indeed, a low take-up rate was observed. On the other 
hand, an unpublished analysis of the anti-epileptics sales data from IMS 
HEALTH database and communications with neurologist both suggested a 
drop in the use of carbamazepine. Similar trend was also observed in Hong 
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 Kong.89 With the risk information provided, and barriers to testing, an easy 
alternative solution was to switch away from carbamazepine to alternative 
medicines. Carbamazepine is an old generic drug with long proven clinical 
efficacy and low cost. Switching from carbamazepine to alternative drugs that 
are often branded and more expensive will elevate medical costs.  This is 
considered an unintended consequence of policy. More efforts were needed 
to promote the appropriate use of the risk information.  
After the study 
With stronger evidence on genetic association, clinical utility, and cost-
effectiveness (thanks to our study), in April 2013, Singapore Ministry of Health 
(MOH) made an announcement that HLA-B*1502 genotyping prior to the 
initiation of carbamazepine therapy in new patients of for Asian ancestry was 
the new standard of care. HSA, together with MOH, issued a Dear Healthcare 
Professional Letter to communicate the new recommendations for HLA-
B*1502 genotyping the use of test results.90 Meanwhile the National University 
Hospital (NUH) Molecular Diagnosis Centre (MDC) started to offer the test at 
a cost of S$187 (excluding GST) with a turnover time of 2-4 working days. 
The decrease in price was due to economies of scale and improvements in 
testing methods. To ensure the access to test service by low-income patients, 
75% of the test cost was subsidized for patients from the MOH-funded 
restructured hospitals and institutions. The test later became available in 
several other hospitals, with improvement in IT system and results delivery. 
6 months after the new recommendation was announced, a preliminary 
evaluation was published by HSA in November 2013.91 A total of 307 tests 
were performed, with 9.8% of samples tested positive for HLA-B*1502. 
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 Contrary to a historical average of 15 CBZ-SJS/TEN reports to HSA per year, 





 Chapter 3 . HLA-B*5801 genetic testing and safety 
program when initiating allopurinol therapy for chronic 




Allopurinol is an efficacious urate-lowering therapy (ULT), but on rare occasions, 
patients develop potentially fatal adverse reactions. The risk of reactions such as 
Stevens-Johnson syndrome (SJS) is significantly higher among HLA-B*5801 carriers. 
We assessed the cost-effectiveness of risk-mitigation strategies that use HLA-B*5801 
genetic testing, an enhanced safety program or a combination of both.  
Methods 
The analysis adopted a health systems perspective and considered Singaporean 
patients with chronic gout, over a lifetime horizon, where allopurinol and probenecid are 
appropriate medications. The model incorporated SJS outcomes, long-term gout 
treatment outcomes, HLA-B*5801 allele frequencies, drug prices, and other medical 
costs.  
Results and Conclusions 
Based on a cost-effectiveness threshold of US$50,000/QALY, HLA-B*5801 guided 
ULT selection or enhanced safety program were not cost-effective in the base case 
analysis. Avoidance of ULTs was the least preferred strategy as uncontrolled gout 
leads to lower QALYs and higher costs. Conditions under which genotyping or 
enhanced safety program would become cost-effective were identified. 
 
3.2 Introduction  
Gout is a common rheumatic disease with increasing prevalence worldwide due 
to increased longevity, dietary changes, and greater use of medications with urate 
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 retentive effects such as diuretics and low-dose aspirin.92-94 Gout increases medical 
costs, reduces patients’ quality of life (QoL), 95-97 and is an independent risk factor for 
all-cause and cardiovascular mortality.98  
Pharmacologic management of chronic gout aims to reduce serum uric acid 
(SUA) levels to prevent formation and promote crystal dissolution.97 Allopurinol is 
generally well-tolerated and the most commonly used urate-lowering therapy (ULT).99 
However, Allopurinol was one of the drugs most commonly associated with Stevens-
Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN),17,18,100-103 which are 
rare but serious cutaneous reactions with average fatality at 30% for TEN.64,104  
Strong genetic association between HLA-B*5801 and allopurinol-induced 
SJS/TEN was confirmed in various populations,42,43,102,105-107 suggesting that genotyping 
may mitigate risks of allopurinol-induced SJS/TEN. The test has a negative predictive 
value (NPV) of close to 100% but a positive predictive value (PPV) of only 1.52% for 
SJS/TEN among Han Chinese in Taiwan.43,106 The American College of Rheumatology 
recommends HLA-B*5801 genotyping as a risk management measure for at-risk 
populations;94 however the European Medicines Agency (EMA) Pharmacovigilance 
Working Party cautions against routine HLA-B*5801 genotyping given the lack of 
suitable alternative therapies to allopurinol and the lack of evidence of clinical utility.108 
The Taiwan Food and Drug Administration has issued a notice that HLA-B*5801 should 
be considered prior to allopurinol treatment, but testing is not mandatory.109 Given the 
seriousness of SJS/TEN, but low PPV of the HLA-B*5801 genetic test, it is still unclear 
what role HLA-B*5801 genetic testing should play in clinical practice, especially in Asian 
populations with high prevalence of HLA-B*5801 allele, such as the Han Chinese, 
Southeast Asian, and Korean.110 When available, HLA-B*5801 genetic testing results 
will influence physicians’ choice of ULTs in gout management, which has impact not 
only on rates of adverse drug reactions (ADRs), but also the long-term clinical outcomes 
and treatment costs of chronic gout. These long-term implications of HLA-B*5801 testing 
are not well envisaged, and are often neglected in evaluations of genetic testing. 
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 An alternative risk mitigation strategy is enhanced safety monitoring of SJS/TEN 
symptoms for early drug withdrawal and SJS/TEN management. It has been shown that 
early withdrawal of causative drugs among SJS/TEN patients is associated with lower 
risk of dying.111   
 This study examined the incremental cost-effectiveness of six strategies, 
including those involving genetic testing and safety monitoring program, to mitigate the 
risk of allopurinol-induced SJS/TEN and to identify the conditions in which each strategy 
is incrementally cost-effective over a life time horizon, from the Singapore health system 
perspective. 
3.3 Methods  
A decision tree model was developed for a hypothetical cohort of gout patients 
who were eligible for allopurinol and probenecid, using TreeAge Pro 2013 (TreeAge 
Software, Williamstown) to evaluate incremental cost-effectiveness of five strategies 
over a 30-year time horizon. 30 years roughly represents the remaining life expectancy 
of gout patients, given an average onset age of 50,112 and life expectancy of 80.113 
Treatment strategies  
The strategies modeled were: (a) Standard ULT with allopurinol as first-line drug 
(Standard ULT); (b) Standard ULT with allopurinol as first-line drug coupled to a safety 
program (ULT+SP). The hypothetical 3-month safety program (SP) comprised of one 
nurse-led  patient education session on SJS/TEN, 6 fortnightly phone calls to check for 
early signs of SJS/TEN and a hotline for adverse reaction reporting and triaging for 
medical attention when needed; (c) HLA-B*5801 genetic testing-guided ULT treatment 
(GULT) in which patients received different first-line ULT based on test results 
(probenecid for test positive, allopurinol for test negative); (d) HLA-B*5801 genetic 
testing to enroll test positive patients in SP when initiating allopurinol  (GSP); test 
negative patients would receive allopurinol without SP; (e) HLA-B*5801 genetic test-
guided ULT with the enhanced safety program (GULTSP), in which test positive 
patients are initially given probenecid as in the GULT strategy, but non-responders 
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 are subsequently switched to allopurinol and monitored via the enhanced safety 
program; (f) No ULT and treatment of acute flares only (no ULT) (Table 4).  
 
 
Table 4. Components of six strategies 




ULT Allopurinol No No 
ULT + SP Allopurinol No Yes 
GULT 
Allopurinol (for HLA-B*5801 
negative patients) 
Probenecid (for HLA-B*5801 
positive patients) 
Yes No 
GSP Allopurinol Yes 
Yes (for HLA-B*5801 
positive patients only) 
GULTSP 
Allopurinol (for HLA-B*5801 
negative patients) 
Probenecid (for HLA-B*5801 
positive patients) 
Yes 
Yes (for HLA-B*5801 
positive patients who do not 
respond to probenecid only) 
No ULT Treatment of Acute flares only No No 




Treatment sequence was based on international gout management guidelines 
and local clinical practices.97,99,114 Response to ULT treatment was defined as achieving 
target SUA ≤6 mg/dl (360 µmol/l) and non-response referred to SUA > 6 mg/dl.97 First-
line ULT was assumed to be allopurinol at 300 mg/day.115 As higher doses may be 
necessary to reach SUA target for some patients,116,117 allopurinol up to 600 mg/day was 
modeled as next treatment step for non-responders. Probenecid (up to 2g/day) was 





 The decision tree in Figure 3 describes the treatment pathways. To mirror clinical 
treatment pathway, a titration period and a maintenance period were modeled. In 
titration period, patients on genetic-testing guided ULT strategy (GULT) received 
allopurinol if test negative or probenecid if test positive. Patients on other strategies 
except no ULT, received allopurinol. After 3 months, patients’ response was evaluated 
and next step in the treatment sequence was initiated for non-responders, and those 
with side effects. In maintenance period, appropriate ULT identified in titration period 
was maintained over 20 years. When no appropriate ULT was identified, no ULT was 









Figure 3.  Decision tree model. ULT, urate-lowering therapy; SP, safety program; G, HLA-B*5801 genetic testing; SJS, Stevens-
Johnson syndrome; TEN, Toxic Epidermal Necrolysis. 
 
 
 SJS/TEN may occur shortly after allopurinol exposure.119,120 Most allopurinol-
induced SJS/TEN cases occur within 60 days of allopurinol exposure,119 and the average 
duration for SJS/TEN treatment is within 2 weeks.65 Patients who develop SJS/TEN are 
therefore assumed to succumb within 3 months after allopurinol initiation or to recover after 
treatment. Various complications such as ocular complications may occur among patients 
recovered from SJS/TEN, and have long-term implications on quality of life and medical 
costs.121,122 The common and lasting condition, dry eye syndrome, was modeled to account 
for the impact of SJS complications. 
Model inputs 
Model input variables and the sensitivity ranges are listed in Table 5. 
























Cost, 2012 US$  
  Cost of per case SJS treatment 3,477 1,738 6,962 
123 
 Cost of per case SJS-TEN overlap treatment 10,254 5,123 20,500 
  Cost of per case TEN treatment 17,031 8,515 34,062 
  Cost of HLA-B*5801 genetic testing 270 135 404 
Singapore Health Sciences 
Authority tissue typing lab 
  
Average annual cost of allopurinol (daily dosage=up 
to 300mg) 33 16 66 
Median selling price in public 
healthcare institutions in 
Singapore 
  
Average annual cost of allopurinol (daily dosage=up 
to 600mg) 66 33 132 
  
Average annual cost of probenecid (daily 
dosage=up to 2g) 132 66 265 
 
Average drug cost of acute gout flare treatment (7 
days) 22 11 92 
  Cost of doctor consultation (per visit) 46 23 123 
Public healthcare institutions in 
Singapore 
  Cost of safety program (per 3 month) 62 31 123 
Cost estimate based on similar 
programs in public healthcare 
institutions in Singapore 
  Average annual cost to manage dry eye syndrome 200 100 800 124 
QoL/Utility  
  SJS (duration=8.9 days) 0.35 0.25 0.45 
123 
  SJS-TEN overlap (duration=9.2 days) 0.3 0.2 0.4 
  TEN (duration=12.4 days) 0.25 0.15 0.35 
  Achieving SUA target * 0.7463 0.6463 0.8463 
125   Not achieving  SUA target * 0.7 0.6 0.8 
  Utility discounting factor for dry eye syndrome 0.8 0.7 0.9 126 
Treatment outcomes of ULTs (clinical response at 3 months post treatment initiation among patients with gout)  
  
Proportion of patients achieving SUA target with 
allopurinol daily dose up to 300mg/day* 0.38 0.2 0.5 127,128 
  
Proportion of patients who achieve SUA target  with 
allopurinol daily dose up to 600mg/day* 0.76 0.4 0.85 129 
  
Proportion of patients who achieve SUA target with 
probenecid daily dose up to 2g/day* 0.68 0.4 0.85 130 
  
Proportion of patients having side effects (excluding 
SJS/TEN) upon taking allopurinol  0.05 0.025 0.1 130  
 
Proportion of patients having side effects upon 
taking probenecid 0.12 0.035 0.14 131,132  
 
Annual number of flares experienced by chronic 
gout patients with uncontrolled SUA 4 2 10 Assumption 
SJS/TEN fatality and  incidence 
 
Incidence of allopurinol-induced SJS/TEN among 
patients who initiate allopurinol 0.002 0.001 0.004 43,106 
  Fatality of SJS 0.05 0.025 0.1 
123 
  Fatality of SJS-TEN overlap 0.15 0.075 0.3 
  Fatality of TEN 0.3 0.15 0.6 
  Proportion of SJS among SJS/TEN 0.7 0.65 0.75 
  Proportion of TEN among SJS/TEN 0.2 0.15 0.25 
  
Percentage of SJS/TEN patients developing dry eye 
syndrome 0.59 0.3  0.8 121 
HLA-B*5801 genotyping  
 
Proportion of HLA-B*5801 carriers in the Singapore 
population (ethnicity-weighted) 0.185 0.1 0.3 133 
  
Incidence of allopurinol-induced SJS/TEN among 
patients who initiate allopurinol for the first time 0.002 0.001 0.004 106,134  
Effectiveness of safety program 
 Percentage reduction in SJS/TEN mortality 0.3 0.1 0.8 111 
Other inputs 
  Duration modeled , years 30 10 40 Assumption 
  Annual discount rate  0.03 0.01 0.05 Assumption 
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 Predictive value of HLA-B*5801 genetic testing 
Prevalence of HLA-B*5801 carriers is 22.3%, 7.3% and 3.5% among Singaporean 
Chinese, Malays and Indians respectively, based on published allele frequencies and 
Hardy-Weinberg Equilibrium,133 resulting in an ethnicity-weighted prevalence of 18.5%. 
Among Asian populations with SJS/TEN incidence data, Taiwan has the closest ethnic 
makeup to Singapore. The incidence of allopurinol-induced SJS/TEN in Singapore was 
assumed to be the same as Taiwan, or 0.2%.134 Sensitivity and specificity of HLA-B*5801 
test were assumed to be 100% and 85% respectively with resulting PPV of 1.52% and NPV 
of 100%.134  
Safety program 
Early withdrawal of causative drugs among SJS/TEN patients is associated with 
lower risk of dying (odds ratio 0.69 per day),111 though early withdrawal may not stop 
disease progression.135 We therefore assumed that the hypothetical safety program did not 
reduce the incidence of SJS/TEN but reduced SJS/TEN mortality by 30%.  
Costs and utilization 
In first year of treatment, patients are assumed to require four doctor consultations 
for ULT initiation and dose titration. Patients achieving satisfactory response with ULTs 
were assumed to continue life-time ULT treatment with the same ULT, and maintained 
satisfactory SUA levels. As hyperuricemia is a major risk factor for flares, patients meeting 
SUA target were assumed to have no flares in maintenance period and require two routine 
doctor visits annually. Patients who failed ULTs or had side effects were assumed to receive 
no ULT in the long-term, and have four flares on average, which were treated using 
colchicine, non-steroidal anti-inflammatory drugs (cyclooxygenase-1 and 2 inhibitors),or 
glucocorticoids. In addition to four doctor consultations for acute gout treatment, these 
patients were assumed to have 3 hospital admissions every 10 years. This estimate was 
based on a study which reported average number of hospital admission for gout or gout-
related complications to be 1.5 over 10 year.136 We doubled this number to reflect the higher 
accessibility of hospital care in Singapore. Costs of doctor consultations, ULTs, medications 
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 for acute flares management, and gout-related admissions were obtained from public 
healthcare institutions in Singapore. Based on the bills of 11 gout-related admissions 
between 2012 and 2013, average cost per admission was around US$1,484 and the 
average length of stay being 3.36. All costs were displayed in US dollars with 1US$ 
equivalent to 1.27 Singapore dollars as of 2 October, 2014.137 
Cost-effectiveness analysis 
The total costs and QALYs associated with each treatment strategy were calculated 
over 30-year time horizon. QALYs is define as life years adjusted for QoL, and was 
calculated as  
 
where QoL or utility score ranges between 0 and 1, with 1 indicating perfect health and 0 
indicating death; d, annual discount rate is 3%; and t indicates years since treatment 
initiation. Incremental Cost-effectiveness Ratios (ICERs) was calculated as incremental 
cost over incremental QALYs.  
Sensitivity analysis 
To examine the robustness of results over various assumptions, one-way sensitivity 
and probabilistic sensitivity analyses were conducted. In the one-way sensitivity analyses, 
variable were varied within the sensitivity ranges, one at a time, and ICERs were generated 
(Figure 4). In the probabilistic sensitivity analysis, all variables were varied simultaneously, 
and the distribution of ICERs based on 10,000 repeated draws from assigned distributions 
were obtained. All variables were assumed to follow triangular distributions, with most likely 






Figure 4. One-way sensitivity analysis of assumptions on the incremental cost-effectiveness ratio (ICER). (A) G->ULT->SP 








 3.4 Results  
Cost-effectiveness  
 
Consistent with recommendations,138 strategies were listed according to increasing 
order of costs, and ICERs were calculated regards to the next most costly strategy (Table 
6). Standard ULT coupled to a safety program (ULT+SP) compared to standard ULT alone 
yields an ICER of US$79,140/QALY, relative to standard ULT. GULTSP had an ICER 
of US$85,630/QALY compared to ULT+SP. Three strategies were dominated (more 
expensive and less QALYs than another strategy): genetic testing to enroll test positive 
allopurinol patients in SP (GSP); genetic testing-guided ULT treatment (GULT); and no 
ULT. US$50,000 is a commonly used ICER threshold to identify cost-effective 
interventions.86 This is very similar to the National Institute of Health and Clinical Excellence 
ICER threshold of £20,000-30,000,49 which is approximately US$48,000 at the currency 
exchange rate on 2 October 2014.137 In the base case, genotyping and safety program are 
both not cost-effective, by any of the commonly used cost-effectiveness thresholds. 
 













Standard ULT 4,130 - 14.9966 - - Undominated 
ULT+SP 4,200 60 14.9974 0.0008 79,140 Undominated 
GSP 4,420 220 14.9974 0 - Dominated 
GULTSP 4,590 390 15.0020 0.0046 85,630 Undominated 
G ULT 5,160 570 14.9597 -0.0423 -13,510 Dominated 
No ULT 15,310 10,720 14.1319 -0.8701 -12,320 Dominated 
ULT, urate-lowering therapy; SP, safety program; G, HLA-B*5801 genetic testing; QALY, quality-
adjusted life years; ICER, incremental cost-effectiveness ratio. 
 
Sensitivity analyses 
One-way sensitivity analysis shows that cost of safety program, mortality reduction 
due to safety program, and the incidence of SJS/TEN were the most influential factors on 
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 ICERs, and variations in all others inputs within the defined ranges did not alter the cost-
effectiveness results (Figure 4). Probabilistic sensitivity analysis showed based on 
willingness-to-pay of US$50,000/QALY, allopurinol without genetic testing (standard ULT) 
is the preferred strategy in 40.7% of iterations, compared to 38.5% of iterations and 20.8% 



















Figure 5. Probabilistic Sensitivity Analysis. (A) Strategy Selection at Willingness-to-Pay of $50000/QALY. (B) Cost-effectiveness 
acceptability curves of six strategies. ULT, urate-lowering therapy; SP, safety program; G, HLA-B*5801 genetic testing; QALY, quality-








 3.5 Discussion  
This study compares six potential risk mitigation strategies in chronic gout 
management. Among all strategies, no ULT resulted in the lowest QALYs, and 
surprisingly the highest long-term cost. This is because high SUA levels result in more 
frequent flares, and higher costs due to flare treatments and hospitalizations. This 
suggests that forgoing ULT treatment because of the fear of SJS/TEN risk would 
results in worse outcome and higher life-time gout treatment costs.  
Genetic testing strategies  
The three strategies involving genetic testing were either dominated or not cost-
effective under the base case scenarios. Genetic testing-guided ULT treatment 
(GULT) incurs additional testing costs and higher drug costs as the alternative drugs 
for HLA-B*5801 positive patients are more expensive than allopurinol. Paradoxically, 
if allopurinol is completely avoided among test positive patients, these patients have 
lower QALYs as they are restricted to fewer alternative ULT options, and consequently, 
will have poorer SUA management outcomes. Patients who test positive of HLA-
B*5801 and fail to respond to probenecid would receive no ULT in the long term and 
have more frequent flares when they might have benefitted from allopurinol. Given the 
HLA-B*5801 prevalence in the Singapore population (18.5%) and the low PPV of the 
test (1.52%), a GULT strategy, in which genetic test results dictate the selection of 
the initial ULT, will switch 18.5% of patients away from allopurinol when only 1.52% of 
them would be expected to develop SJS/TEN.  
We also considered whether genetic testing might be a useful tool for 
prioritizing high-risk patients for an enhanced safety program upon allopurinol initiation 
(GSP) when it is operationally challenging to enroll all gout patients in safety program 
in busy clinic settings. We found that GSP is more expensive, as the current cost of 
genetic testing (US$270) is relatively high compared to that of an enhanced safety 
program (US$63). If the cost of genetic testing drops to US$23, GSP achieves the 
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 same cost as the safety program for all patients. At this cost, genotyping may be a 
useful strategy in busy clinics to screen patients and prioritize monitoring resources to 
the most at-risk patients. 
As completely avoiding allopurinol in test positive patients is not favorable from 
cost-effectiveness perspective, the alternative strategy GULTSP provides an 
option for clinicians who would like to achieve good SUA control with a lowered risk of 
SJS/TEN. This involves using probenecid first in test-positive patients, before 
embarking on allopurinol therapy with an enhanced safety program for those who do 
not respond to probenecid. This strategy has an ICER of US$85,630/QALY and is not 
cost-effective at an ICER threshold of US$50,000. However, it would become cost-
effective if the cost of the genetic test drops below US$90, which is possible.  
The main reason why genetic guided ULT selection reduced QALYs is the 
limited alternative options. Febuxostat, widely used in Europe and USA as a alternative 
drug, is not readily available in Singapore, and the current cost is 40 times higher than 
allopurinol. However, when febuxostat was modeled as third-line ULT, genetic testing-
guided ULT still yields fewer QALYs than standard ULT and at higher cost, which 
implies that using allopurinol, probenecid and febuxostat to optimize treatment for 
patients achieves higher overall response rate than using probenecid and febuxostat 
only. Moreover, hypersensitivity reactions associated with febuxostat, including 
Stevens-Johnson syndrome, have also been reported.139 
In contrast to our results, Saokaew 140 et al. concluded genetic testing is very 
cost-effective (ICER=US$5,062/QALY) in preventing allopurinol-induced SJS/TEN in 
Thai population. 140The divergent findings result from differences in 1) treatment costs, 
2) incidence of allopurinol-induced SJS/TEN in the respective populations, 3) 
population frequency of HLA-B*5801, and 4) assumptions on gout treatment outcomes. 
To the latter point, whereas Saokaew et al. didn’t distinguish responders and non-
responders to ULTs, we assigned different QoL and treatment costs to the two groups, 
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 which we believe is more realistic. This is a key difference that generated the divergent 
results. 
In addition to SJS/TEN, HLA-B*5801 is also associated with other adverse skin 
reactions such as Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).106 
Data on incidence, costs of treatment, and long-term complications of DRESS are 
scarce. As an approximation of incidence, we examined the number of DRESS cases 
in the national Singapore voluntary adverse drug reaction database. Between 1993 
and 2014, DRESS constituted 30% of all serious cutaneous adverse reactions (SCAR) 
associated with allopurinol. In the base case model, we assumed that the incidence of 
SJS/TEN alone is 0.2%; an estimate of the combined incidence of DRESS and 
SJS/TEN therefore is 0.28%. As noted above, the ICER of the GULTSP strategy 
only drops below the cost-effectiveness threshold when the incidence is higher than 
0.35%.  
Safety program 
Based on the commonly cited cost-effectiveness threshold of 
US$50,000/QALY, enrolment of all gout patients into safety program when initiating 
allopurinol is not cost-effective compared with ULT alone, under base case 
assumptions.86 However it would become cost-effective compared with standard ULT, 
if cost of safety program were reduced to below US$39 per patient, or if safety program 
resulted in over 47% reduction in SJS/TEN mortality, or 24% reduction in SJS/TEN 
incidence. In fact a 30% reduction in mortality assumed under base case may not fully 
capture the benefits of safety program, which may reduce seriousness and costs of 
treating other adverse reactions reported within the wide clinical spectrum of 
AHS.141,142  
Study limitations 
This study has several limitations. First, the study presumes the efficacy of 
ULTs in the short term continues for the long-term when metabolic changes, 
comorbidities and other medical therapies may ensue with aging. Second, long-term 
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 complications of SJS/TEN and other side effects of gout management may be 
underestimated due to lack of long-term data. However, sensitivity analysis on 
treatment costs showed the results are robust even when the costs were doubled. 
Third, the treatment outcomes modelled were based on published clinical studies. In 
practice, effectiveness of ULTs may be lower than controlled circumstances; as 
monitoring of SUA and up-titration of drug dosage may not be universally performed, 
and patients’ non-adherence to ULT is an issue.143-145 Nonetheless, as these factors 
pertain to ULT treatment in general, conclusions on genetic testing and safety program 
are not likely to be influenced. Finally, this study is likely to underestimate the benefits 
of HLA-B*5801 genetic testing in reducing the mortality and morbidities attributable to 
other serious cutaneous adverse reactions.141  
3.6 Conclusion 
Complete avoidance of ULT due to the fear of SJS/TEN in chronic gout 
management results in the worst outcome and highest long-term costs. An enhanced 
safety program for all patients initiating ULT may become cost-effective if program 
costs are low or if significant mortality reduction can be achieved. HLA-B*5801 genetic 
testing for all gout patients commencing ULT, if used to avoid allopurinol in all test-
positive patients, reduces the overall QALYs at a population level. Test positive 
patients (18.5%) would have fewer alternative treatment options, and thus worse gout 
outcomes, while SJS/TEN would be avoided in 1.5% of patients. HLA-B*5801 genetic 
testing and prescribing probenecid in test-positive patients initially, but switching non-
responders to allopurinol coupled with an enhanced safety program, although not cost 
effective currently, would become cost-effective if testing costs drop substantially. Our 
results do not preclude individuals from seeking genetic test should they choose to do 
so nor implementation of safety program for extra clinical vigilance, only that the use 




 Chapter 4 . Introduction to patients’ preference for using 
pharmacogenetic testing to reduce severe adverse drug 
reactions 
4.1 Introduction 
Severe adverse drug reactions (ADRs) have long been a medical and public 
health concern. With the advancement of genetic research, genetic testing has been 
shown promising to select drugs for safer gout treatment.106 Cost-effectiveness 
analysis (CEA) described in Chapter 3 provides information on the value of HLA-
B*5801 testing from the health system. The negative cost-effectiveness results 
suggests that implementing HLA-B*5801 testing at the system level will not bring high 
value from the public resource allocation perspective. However, this does not 
necessarily imply that individual patients and doctors should not test. In fact, cost-
effectiveness analyses are not aimed to answer the question whether patients should 
or would use the test. The adoption of genetic test is a complex issue, concerning the 
interplay between various stakeholders (patients, physicians, providers, payers, 
regulators). Patients are the consumers, and often times the payers too. Patients’ 
preferences are therefore crucial to determine the uptake of HLA-B*5801 genetic test 
and inform testing policies.  
This chapter is an introduction to patients’ preferences for using 
pharmacogenetic testing to reduce risk of severe ADRs. It motivates the empirical 
study in Chapter 5, and facilitates the formulation of research questions and 
hypotheses. This chapter starts by outlining the importance of understanding patients’ 
preferences, and then reviews the theoretical framework to analyze patients’ 
preferences, followed by the literature on patients’ attitudes towards genetic testing. I 
then review the evidence on the determinants of patients’ preferences for genetic 
testing, with a focus on the methods using which these determinants were studied. At 
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 the end of this chapter, I summarized the research question and hypotheses, which are 
studied in the next chapter.  
4.2 Why is patients’ preference important? 
4.2.1 Why may individual preferences for HLA-B*5801 testing differ 
from assessment at the health system level? 
Cost-effectiveness analysis assesses the benefit and cost of genetic testing to 
the health system, and applies a societal willingness-to-pay to determine whether a 
service is of high value from a public resource allocation perspective. However, individual 
patients may not go through the same process in their decision making, and significant 
heterogeneity can be expected. Patients’ decisions may be different from system level 
cost-effectiveness analysis for several reasons.  
First, cost-effectiveness applies a threshold (such as $50,000/QALY to define 
cost-effectiveness),86 which is meant to represent the societal willingness-to-pay for one 
quality-adjusted life year (QALY). However, there may be individual variations in the 
perceived value and benefit of pharmacogenetic test, and therefore the worthiness of 
testing. The willingness-to-pay may also correlate with individual’s ability to pay and other 
socio-demographic characteristics.  
Second, when uncertainty is involved, the decision making usually deviates from 
expected value calculation, as used in CEAs. In CEAs, expected reduction in utility due 
to SJS is calculated as the chance of SJS multiplying by the utility reduction associated 
with SJS, which is consistent with the expected utility theory.146 As the chance of SJS is 
only 0.2%, the adverse negative impact of SJS at the population level is small. Despite 
the low incidence, life-threatening adverse drug reactions, is a big safety concern among 
some patients and physicians. In prospect theory, the probabilities of outcomes 
happening are transformed into decision weights, which can be thought as the decision 




Where w(pi) is the decision weight of probability pi, and v(xi) is the valuation of outcome 
xi. For small probability events, such a life-threatening adverse drug reaction, individuals 
tend to overvalue the small probability (ie. w(𝑝𝑝𝑖𝑖) > 𝑝𝑝𝑖𝑖) Therefore, individuals may have a 
high willingness-to-pay to avoid the small chance of developing SJS.  
Third, the judgement of cost-effectiveness is relative to a comparator which is 
often the current practice. In the CEA described in the previous chapter, it is assumed 
the status quo to be allopurinol treatment for all eligible chronic gout patients, based on 
clinical guidelines. In reality, some doctors and patients are not comfortable with 
prescribing or taking allopurinol knowing the risk of SJS. The fear may results in lack of 
ULT treatment, which the cost-effectiveness analysis showed to be the most costly and 
least effective strategy. Genetic testing, in addition to reduce risk of SJS, may also 
improve gout control, due to the more confident use of allopurinol. Therefore, the actual 
benefit of genetic testing may be higher than modelled in CEA. However without data, 
these cannot be precisely quantified.  
Fourth, cost-effectiveness evaluates the benefit of testing in terms of the clinical 
utility, which is the potential of the test results to improve treatment outcome.149 
Consequently, those who have negative test results, which will not alter their treatment, 
receive no health benefit from testing. However, from patients’ perspective, there may 
be a “value of knowing”,150 which is, those who test negative derive utility from the 
assurance that they are not at risk.  
Cost-effectiveness analysis offers a convenient and standardized tool for policy 
makers to efficiently allocate scarce public resources among competing needs to achieve 
the most value or best health outcomes within budget constraints. The fact that HLA-
B*5801 is not cost-effective suggests public resources spent on reimbursing the test 
would not achieve high value for the health system compared to a cost-effective 
intervention. However question remains whether services should be made available for 
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 voluntary test, and whether clinical practice guidelines should encourage routine genetic 
testing.  
4.2.2 Why is understanding patients’ preferences important for 
medical practices and policy-making? 
Knowing the availability of the genetic test, there is an urgent demand for 
information and guidance on the use of genetic test and genetic-test guided treatment 
regimen from the physician community. However, existing evidence does not provide 
sufficient indications on the appropriate use of genetic test. To inform policy making, we 
sought to understand patients’ preferences. Patients, as the consumer of medical 
services, derive utility from the services, even though often times the treatment is not 
directly chosen by patients. Treatment effectiveness, side effects, financial burden, and 
care experiences all influence patient’s utility. Minimizing risk of severe side effect does 
not necessarily maximize patient’s utility if the treatment effectiveness is compromised, 
or if significant financial burden is incurred.  Patient’s preference information are useful 
to physicians for several reasons. Firstly, knowing the tradeoffs can enable physicians 
to communicate risk and mitigation strategies more effectively, and choose the most 
suitable treatment based on each patient’s medical profile and preference profile. 
Secondly, inaccuracy (such as false positive, false negative results) of test can lead to 
difficult medical decisions, as false results may lead to suboptimal treatment. Directly 
eliciting patients’ preferences on accuracy parameters allow the identification of the 
maximum acceptable risk, which can facilitate clinical decision making.  
Patients’ preferences are also useful for other stakeholders. From a service 
provider perspective, a forecast of uptake rate is desirable to facilitate operation 
planning, and price setting. From the regulator perspective, understanding patients’ 
preferences can inform the formulation of risk communication letters to health 
professionals, and revise drug package insert to incorporate genetic information and 
usage advice.  Knowledge on patient’s preference could also inform the design of 
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 effective vigilance and risk minimization programs. In many cases, the uptake rates for 
public health-promoting programs are below target. For instance, colorectal cancer 
screening is promoted, and reimbursed in the United States, yet around 50% of 
individuals older than 50 years have never been screened.151 This implies some 
preference or motivation factors are underlying the screening decision. Without 
understanding the decision making process, information provision and financial incentive 
may not be successful in meeting the intended uptake target. Patients’ preferences can 
also inform the research and development of genetic tests. Identifying what test features 
patients value most, and understanding patients’ willingness-to-pay for test features can 
facilitate the development of more useful tests.150 In a broader context, understanding 
patients’ preferences may help to set agenda and prioritize pharmacogenetics research.  
Recently, patients’ preferences have garnered more attention, and have been 
increasingly considered by the medical community and regulators. In clinical guidelines, 
patients’ preferences are often mentioned, especially in situations when tradeoffs 
between risk and benefit are involved.152 One area of application by regulators is to weigh 
the benefit and risk for new drugs and medical devices.153,154 For instance, some effective 
treatments may be associated with risk of life threatening side effects. The regulatory 
and clinical perspective is usually to minimize risk or weigh the benefit and risk, which 
often runs into difficulty, as it is unclear how therapeutic benefits and risk of side effects 
should be traded off. Patients may be willing to accept higher risk of severe side effects 
in exchange for better treatment outcome, especially for conditions with limited 
alternative therapeutic options. Measuring patients’ preferences is one potential solution 
to quantify the tolerable risk in exchange for better disease management. US FDA has 
published guidance on the use of patients’ reported outcome in regulatory decisions in 
2010, and released a draft guidance on patients’ preference information in 2015.60,154 
The guidance reviews the methods to measure patient’s preferences, and the use in 
premarket approval applications (PMA), Humanitarian Device Exemption (HDE), and 
de novo review processes.154 
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 4.3 Patients’ general attitudes and preferences for the use of 
pharmacogenetic testing to reduce severe ADRs 
Literature on the preference for using pharmacogenetic testing to reduce severe 
ADRs is relatively new and limited, mainly because the basic science and clinical 
evidence were only developed in the last decade, and not yet widely applied clinically. 
Nevertheless, qualitative and quantitative studies on patients’ attitudes towards 
pharmacogenetic testing revealed wide public interest. 
Qualitative studies on patients’ perceptions about pharmacogenetic testing 
identified the lack of prior knowledge on pharmacogenetic testing.155 However, when 
educated about the definition and applications of pharmacogenetic tests, the public were 
generally enthusiastic towards pharmacogenetic testing.155-157 In a phone interview with 
328 German patients with asthma or chronic obstructive pulmonary disease, 96% of 
patients appreciated the availability of pharmacogenetic tests, and claimed the 
willingness to take a test prior to receiving asthma medication.155 In this group, the ability 
of the test to avoid side effects is an important consideration, and majority of patients 
were worried about the possibility that the test could not find the suitable drug with best 
therapeutic outcome and lowest risk of side effects. Similarly, a random-digit-dial 
telephone survey of 1,139 US adults showed that 85% of respondents were willing to 
take a pharmacogenetic test to predict serious side effects.157   
A few studies have examined patients’ preferences for pharmacogenetic tests in 
specific clinical scenarios quantitatively, and also confirmed patients’ preferences for 
taking genetic test to reduce risk of adverse drug reactions. Payne et al studied patients’ 
preferences for using pharmacogenetic test to identify the side effect neutropenia 
associated with the immunosuppressant azathioprine.158 In the study, various 
dimensions of test were listed, and patients were found to pay significant attention to the 
predictive accuracy of the test (ie. the ability of the test to predict risk of side effect). 
Herbild et al. measured Danish populations’ preference for pharmacogenetic testing prior 
to depression treatment, and found that patients were willing to pay a significant amount 
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 of money to avoid change of medication due to lack of effectiveness or unacceptable 
side effect.159  
4.4 Determinants of preferences for genetic testing to reduce 
risk of severe ADR 
4.4.1 Approach 
To identify the determinants of patients’ pharmacogenetic testing decisions, three 
synergistic approaches were adopted. Firstly, I reviewed the conceptual models of health 
behaviors, the determining factors outlined in the model, and operationalized these 
factors in the context of allopurinol pharmacogenetic testing in Singapore. Secondly, the 
empirical literature on determinants of patients’ attitudes and preferences for 
pharmacogenetic testing and other screening services are reviewed. Lastly, the 
identified factors were verified via in-depth interview with diabetes patients.  
4.4.2 The health belief model 
Various models have been proposed to explain health behaviors, such as the 
acceptance of screening or preventive services. Some commonly used models are the 
Health belief model (HBM)160,161, Anderson’s health behavior model162,163, and the theory 
of planned behavior164. The Health Belief Model was used here to conceptualize 
individual patients’ genetic testing decisions.  
Health Belief Model is one of the most commonly used models to explain and 
predict individuals’ health behaviors. It was first developed in the 1950’s and 1960’s by 
Rosenstock et al. at the United States Public Health Service to explain the series of 
failures of programs to promote disease preventives or screening tests for tuberculosis 
(TB), cervical cancer, dental disease, rheumatic fever, polio and influenza, even though 
these services were provided free of charge or at very low cost for demonstration.160,161  
HBM focuses on individual-level belief and decision making, and assumes the decision 
makers to be rational.165 HBM has outlined six key variables that will determine whether 
an individual will take preventive actions.161 Four variables concerning individual’s 
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 perceptions are: 1) perceived susceptibility to disease, 2) perceived seriousness of 
disease, 3) perceived benefits of taking actions, and 4) perceived barriers to taking 
actions. Two variables to trigger the actions are 5) cues to action, and 6) self efficacy. 
Besides the six key considerations, there are also modifiable factors, which can modify 
the perceived threat, and benefit of taken the action, and subsequently influence the 
likelihood of health behaviours. Using the HBM framework, I identified the factors that 
may determine whether or not an individual will take a genetic test before initiating 
allopurinol treatment to avoid potential life-threatening adverse reaction SJS that can be 

















 4.4.3 Literature review and conceptualization of determinants of 
pharmacogenetic testing decisions in the health belief model 
(HBM) framework 
The perceived susceptibility of the perceived seriousness 
Perceived threat of disease is the main motivation to take a screening test. The 
level of threat depends on the seriousness of disease and perceived individual 
susceptibility. Haga et al. found in a phone survey that more US individuals were more 
interested in using pharmacogenetic testing to predict serious side effect than mild side 
effects (85% vs 73%).157 Hall et al. compared the preferences of the general public and 
a high risk population (the Jewish population) to test for Tay Sachs disease, and 
discovered that Jewish respondents were more likely to be tested.166  
SJS/TEN are serious conditions that have an average mortality of 10% (5%-
40%), cause severe pain during onset, and may have long-term sequelae such as dry 
eye syndrome and blindness.16,17,122 Moreover, SJS/TEN treatment is costly, mainly due 
to hospitalization and the use of antibiotics. The seriousness of the condition is the 
primary motivation for taking the genetic test to predict the risk of SJS/TEN, and select 
appropriate drug to minimize SJS/TEN.  
The susceptibility can be best quantified by the likelihood of developing SJS/TEN 
upon initiating allopurinol. Among Taiwan Han Chinese patients receiving allopurinol 
treatment, around 0.2% would develop SJS/TEN.106,167 0.2% is a small probability that 
individuals do not commonly encounter in everyday life. It’s unclear how individuals 
interpret their susceptibility. Psychology and behavioural economics evidence suggests 
that when very small risk is involved, individual may exaggerate the probability or neglect 
the probability in their decision making.147,168-170 It is therefore not clear whether or not 




 Perceived benefit of taking actions 
The major benefit of testing prior to initiate allopurinol is to reduce the risk of 
allopurinol-induced SJS/TEN. The benefit of testing can be measured by the reduction 
in the risk of SJS/TEN. The extent of risk reduction depends on the accuracy and 
predictive power of the test. Indeed, many studies on patients’ preferences on diagnostic 
tests have highlighted the importance of test accuracy in influencing patients’ testing 
behaviours using various accuracy indicators. Hall et al. studied the false negative rate 
of genetic test, defined as the chance that someone carries the risk gene when the test 
is negative, and found that higher false negative rate significantly discouraged testing.166 
Knight et al. also used the false negative rate as an indicator for accuracy for a colorectal 
screening test.171 Payne et al. varied the predictive accuracy (defined as the ability of the 
test to predict the risk of the side effect) in their study, and discovered that patients were 
willing to compromise test experiences (eg. waiting longer) for a small improvement in 
predictive accuracy of test.158 Marshall et al. examined patients’ decisions on colorectal 
cancer screening, and found the sensitivity and specificity of screening test to be crucial 
information.172  
Despite patients’ strong preferences for more information on test being 
provided,158 it has long been recognized that the framing of risk and accuracy information 
can influence patients’ perceptions and decisions.173 For instance, there are several 
ways to describe the accuracy of the HLA-B*5801 test for allopurinol-induced SJS/TEN: 
(a) the test-guided treatment can reduce the risk of SJS/TEN from 0.2% to almost 0; (b) 
the test-guided treatment can reduce the risk of SJS/TEN by more than 99%; (c) the test 
have a sensitivity of 98%, and a specificity of 95.8%; and (d) the test has a 0% false 
negative rate, but a 98% false positive rate. All statements are true, yet people may react 
differently.169 It is therefore worth considering the appropriate form of accuracy 
information communication, and the impact of framing on the responses elicited. Though 
technical terms such as sensitivity, specificity, false positive/negative rate, and 
positive/negative predictive value are often used to describe the accuracy of test, 
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 laypeople and even health care professionals may not understand the precise meaning 
of these terms. In the case of HLA-B*5801 test, the most straightforward and objective 
indicator of accuracy is the risk of SJS/TEN with and without testing (format a). When 
both probabilities are provided, respondents can easily visualize the absolute magnitude 
of risk reduction, without the need to understand technical jargons or undertake 
additional calculations. Format b can potentially be misleading as it emphasizes on the 
relative level of risk reduction (over 99%), but neglects the fact that the incidence of 
allopurinol-induced SJS/TEN is low (0.2%) even without testing. Format c and d are not 
easily comprehensible by laypeople, and the need to understand technical jargons may 
increase the cognitive burden of making testing decision. 
Other benefits of testing can result from the reduction in SJS/TEN risk, such as 
lower risk of dying, lower chance of having high medical expenditure to treat SJS. In 
addition, some literature suggests the “value of knowing” regarding the utility of testing, 
where even no treatment or preventive actions are involved after the test, knowing the 
test result has value.149,174,175  
Barriers of taking actions 
One type of barrier was cost. The HLA-B*5801 test currently costs S$375 in 
Singapore. Compared to allopurinol treatment cost of around $200 per year, test cost is 
high. Taking an expensive test for an inexpensive medicine may be a barrier to the 
uptake of genetic testing. The cost of long-term gout treatment depends on the genetic 
test results. Test positive patients require alternative drugs that do not induce SJS/TEN, 
but are significantly more expensive. Depending on the choice of second line drug, and 
the dosage, the medication cost can be twice to ten times the cost of allopurinol. Gout is 
a chronic condition, requiring long-term management. Switching to a more expensive 
medication may incur significant long-term cost.  
Empirical evidence shows patients are sensitive to price when making medical 
decisions.166,171,176 Various structural factors such as government subsidy and insurance 
reimbursement directly alter the out-of-pocket cost, which is the part of price that patients 
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 pay. A study on the actual use of colorectal cancer screening services revealed that 
those with insurance coverage were more likely to attend screening.151 Government 
subsidy and insurance coverage are therefore possible ways to remove the cost barriers 
of testing.  
In addition to cost, there are other test-process related barriers. At the moment, 
HLA-B*5801 can only be done in centralized laboratories. Therefore the logistics is 
inconvenient, and the waiting time to receive test results is relatively long. In addition, 
patients will not receive urate lowering therapy before test result is received. An 
additional clinic visit may be required for test result pickup and prescription filing.  
Ethical concerns for genetic testing has long been recognized.177-179 For those 
genetic tests used to predict future disease risks, knowing the information may have 
negative impact because patients and  family members worry about unfavorable results, 
especially for diseases without a cure or a prevention strategy.166,174 The availability of 
genetic predisposition to insurers may lead to discrimination against the insured.180,181 
However, for pharmacogenetic testing, which has more defined clinical utility (ie. to guide 
drug selection, and dosage adjustment), empirical studies find relatively low level of 
ethical concerns. A phone survey of a sample of the U.S. public found that 90% of 
respondents were extremely or somewhat comfortable to share their pharmacogenetic 
test results with other doctors involved in their care management. 70% of respondents 
felt comfortable with incorporating their pharmacogenetic test results into their personal 
record. A survey targeting German patients revealed that only 27% of respondents were 
very or slightly worried about results sharing with insurance companies.155 
Cues to action 
A decision maker not only evaluates the benefits and harms of testing, but can 
also be influenced by the information cues. Medical decisions are not made in isolation. 
Even when information on treatment options is provided, patients usually seek other 
sources of information such as doctor’s recommendation, media information, internet, or 
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 opinions of family, friends, and the other peer patients. Among these cues, the research 
on doctor’s recommendation and herd behaviour were extensively studied. 
 Doctor’s recommendation 
Studies have demonstrated the power of doctor’s recommendation in influencing 
patients stated choices as well as actual behaviors on choosing treatment options, taking 
up screening tests or vaccinations.166,182-187 Doctor’s recommendation is one of the most 
important factors in patients decision making, and an experiment that randomly assigned 
recommendations led patients to choose an option that was obviously suboptimal.188 
Though patients are encouraged to make informed decisions on their own treatments, a 
survey on patients preferred role in medial decision making revealed that even though 
nearly all respondents preferred to know the different options, half prefer to leave the 
final decision to their physician.189 The extent to which patient prefer decision making by 
physicians also vary by gender, education, and health status.189  
In fact, physicians’ preferences for pharmacogenetic testing are more extensively 
studied than patients’ preferences for its importance in shaping behaviors. In general, 
physicians have positive believes that pharmacogenetic test may improve patient care 
by personalizing treatment for patients, and anticipate increased clinical usage.155,190 
However, even some recent studies revealed the lack of genetic testing knowledge and 
training among physicians. A survey of 260 US specialist and primary care physicians in 
2010 identified that 40% to 72% of them had “no to minimal knowledge” on genetic topics, 
and were not certain how to incorporate genomic medicine into their practice.191  Another 
national survey of a sample of US primary care physicians in 2011 showed that only 13% 
of responding physicians were comfortable ordering pharmacogenetic tests.192 Therefore 
for successful implementation of test programs, physician education is crucial.  
Different forms and strength of physician recommendation may have different 
impact. Among the studies reviewed, both general recommendations (recommend a 
behavior such as screening) and specific recommendations (recommend a specific test) 
improves the test uptake.166,187 Stronger recommendations is associated with higher 
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 uptake rate. 182 186 A study to examine the relationship between strength of 
recommendation and HPV vaccination status revealed that, when the strength of doctor’s 
recommendation was rated on a 1 to 5 scale, there is a 4-fold difference in the likelihood 
of vaccination between those receiving a strong recommendation and those receiving a 
weak recommendation.182 Recommendations on the timing of test and location of test 
may also influence patients’ decision.184,186,187   
Patients consider physician recommendation important for many reasons, in a 
patient’s survey by Gurmankin et al., the most common reasons of following the doctor’s 
recommendations are: “physicians had important additional information”, “physician had 
information about my risk that went beyond the data given in the question”, “physicians 
know best” “I don’t like having the responsibility of making my own medical decisions” “I 
don’t trust myself to make the right decision”.188 Recommendation by physicians 
indicates the quality of a treatment option. Following doctor’s recommendation may 
therefore be a decision heuristics that allows easy and fast decision making.193,194 
Though deviates from the “rational” decision making pathway based on logic and 
calculation, some empirical findings and economic theories have recognized the 
presence and advantages of decision heuristics.193-195 
Herd behavior 
Herd behavior has been recognized as another decision heuristic or shortcut. 
Herd behavior describes the trend that individuals’ decisions tend to be influenced by 
what people around them are doing. Several related concepts are “following the herd” 
and “social conformity”. It was first recognized by psychologist Soloman, and then widely 
observed in psychology, economics, consumer behaviors and finance.194-199. Though 
relatively fewer studies were conducted to understand patients’ herd behavior in medical 
decisions, several studies have demonstrated the presence of herd behavior in fertility 
choices, and physician’s prescription behaviors.166,200-204. One choice experiment by Hall 
et al. attempted to quantify the effect of providing information on other people’s decision 
about genetic carrier screening on individual respondent’s decision.166 When informed 
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 that “80% of people like you have been tested”, respondents were more likely to test, all 
else equal. 
Following the herd is a simple decision heuristic, especially when health decision 
is difficult, and the optimal choice is unclear. Banerjee argues that in a sequential 
decision model, it is rational for decision makers to look at the decisions made the 
previous decision makers, as other decision makers may have information that is 
important. Moreover, he demonstrated that the optimizing strategy is to do what other 
people do, rather than using their information.195 Carlsson developed an economic model 
of environmental conformity for the consumption of eco-friendly coffee. The key 
assumption is that individuals derive utility not only from consumption, but also from 
following certain social norms. Carlsson modeled the utility from eco-friendly coffee as 
the sum of direct utility from consumption and a self-image component.205 The self-image 
of the individual can be negatively influenced by the difference between the product 
chosen by the individual and the social norm (eg: when 90% of people choose the eco-
friendly coffee, consuming eco-friendly coffee is the norm).  
Self-efficacy 
Self-efficacy refers to one’s confidence in his or her ability to take the action and 
overcome the barriers. Studies suggest that decision are useful to the extent decision 
maker have the confidence to adequately implement the behaviour.206 Self-efficacy is 
therefore important to determine the actual health behaviours.  
Modifiable factors 
In the Health Belief Model, another set of variables are the modifiable factors, 
which can influence individual’s perceived threat of disease, perceived benefit of action, 
and therefore the likelihood of action. Such factors include socio-demographic factors 
(eg: age, gender, ethnicity, employment status, income, housing type, education), and 
knowledge and experiences with gout, and genetics. Empirically, decision maker 
characteristics have been found to influence the attitudes towards genetic testing. Those 
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 with higher income and education are found more likely to attend regular colorectal 
cancer screening.151  
A summary of important variables 
In summary, various determinants of testing decisions have been identified and 
summarized in Table 7. These factors were investigated in in-depth interviews with 
Singapore patients. 
 
Table 7. Determinants of testing decisions 
Concepts/ Domains Attributes/Factors Related attributes 
Perceived threat 
Risk of SJS/TEN  
Severity of SJS/TEN  
Perceived benefit 
SJS/TEN risk reduction 
(Some related factors are : 
 
Accuracy and predictive value of 
test (sensitivity, specificity, false 
positive rate, false negative rate, 
positive predictive power, 
negative predictive power) 
Fatality reduction 
Cost saving 
Barriers of testing 
Cost of test   
Availability of insurance 
reimbursement, government 
subsidy  
Cost of long-term gout 
treatment 
 
Convenience of testing  
Patients’ privacy  
Cue to action 
Doctor’s recommendation  
Herd behavior  





Knowledge and awareness of 
test 
 




 4.5 In-depth interview to gauge patients’ opinions 
After identifying the determining factors in the literature, in-depth interviews were 
conducted with 5 patients to understand laypeople’s attitudes towards pharmacogenetic 
testing, and the decision making process. Individual interview was chosen over focused 
group, in order to understand each respondent’s independent perception and valuation 
of genetic testing while minimizing the impact of peer respondents. The in-depth 
interview was aimed to achieve 3 objectives: 1) understand respondents’ general 
perceptions and attitudes towards genetic testing; 2) verify whether respondents 
consider the pre-identified attributes to be important for their decision to adopt genetic 
testing; and 3) identify other important factors that were missing.  
A structured interview guide was designed to guide the in-depth interview. 
(Appendix A) The guide included an introduction to gout and pharmacogenetic testing, a 
section on general preferences for genetic testing, and considerations on various test 
outcome features identified in the literature review. Then respondents were then asked 
to share their thoughts on the role of doctor’s recommendation, and most common choice 
when making a testing decision. The perceptions and expectations about test service 
delivery process and use of genetics data were also elicited.  Interviewer asked the 
guiding questions, and allowed respondents to share their opinions freely. Specific 
questions on the guide that were not answered by respondent in the previous step were 
asked again as a probe. Respondents were also given the opportunity to share other 
important factors that were not raised by interviewer. 
Consistent with the literature, respondents were generally receptive to the idea 
of using a genetic test to reduce the risk of severe adverse drug reactions. Respondents 
considered the test outcome features (risk of SJS, test accuracy, cost of test, cost of 
long-term gout treatment) very important, while the service delivery process factors (test 
location, sample collection, results delivery) to be less important. Majority of respondents 
considered doctor’s recommendation to be very important. Most respondents would 
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 consider the choice of peer patients, but would not necessarily follow. No additional 
salient factors were raised by respondents. In addition, heterogeneity in preferences 
were observed across different respondents.  
Findings from the in-depth interview, combined with the literature information, 
formed a pool of attributes, the effect of which would be quantified and further 
investigated using a discrete choice experiment (DCE). 
 
4.6 Using discrete choice experiment (DCE) to study 
preferences for pharmacogenetic testing 
Discrete choice experiment is a stated-preference method to quantify 
preferences using a series of choice questions.50-52 When revealed preferences or actual 
market behaviors are not observable, such as when a market does not exist, or when a 
product is not yet available, stated preference method can provide useful insights on 
preferences by offering hypothetical choice sets. Discrete choice experiment is also 
referred to as choice-based conjoint analysis. The name “Conjoint analysis” arose from 
the key characteristics of this type of study that different features of products or services 
are “CONsidered JOINTly”.53 Each feature is referred to as an attribute. And each choice 
alternative is composed of combinations of levels of each attribute. Compared to other 
stated-preference methods, such as contingency valuation, the key advantage of DCE 
is that it is better at measuring the preferences for each attribute level (the marginal 
value), the relative importance of various attributes, and the tradeoffs between different 
attributes.54 DCE elicit preferences using choice questions, which is a more intuitive and 
realistic way of everyday decision making, compared to other methods such as rating, 
or ranking.53  
First developed in marketing, later adopted by public and environmental 
economists, conjoint analysis and DCE have been increasingly used in health care in the 
recent decade. The preference of patients and other stakeholders regarding medical 
treatments, screening and preventive services, and health service delivery have been 
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 used to inform clinical practices.53,55-59  Recently, DCE has gained popularity in informing 
regulatory decisions. US FDA has published a draft guidance on the use of patients’ 
preference information in 2015,60 with a section on the methodology of DCE and its 
applications in weighing the benefit and risk of new drugs and devices.   
Common attributes included in DCEs are health care outcome-related attributes 
(such as treatment efficacy, side effects, and survival), health care process-related 
attributes (such as waiting time, quality of care, mode of service, and type of health care 
professionals), cost attributes, and others. DCE allows the explicit quantification of 
tradeoffs individuals make between different attributes. The tradeoff between an attribute 
and the cost attribute provides estimates on the monetary value of the attribute level, or 
the willingness-to-pay (WTP). The DCE results have also been used to predict the choice 
probability or the uptake rate of a certain product or service. 
As will be described in chapter 5, a DCE was conducted to understand patients’ 
preferences for pharmacogenetic testing to reduce risk of severe adverse drug reactions 
prior to starting allopurinol in gout treatment in Singapore. Based on the literature and in-
depth interview presented in this chapter, factors important for patients’ testing decision 
making were included as attributes in the DCE. These factors include: the risk of SJS, 
the accuracy of genetic test, the test cost, the long-term treatment cost, doctor’s 
recommendation and herd behavior. The objective is to examine the relative importance 
of these attribute, and quantify the tradeoffs patients made between different attributes. 
The WTP for genetic testing, and the test uptake rate were of interest. In addition, the 
impact of potential policies or test feature changes on test uptake was simulated to inform 
clinical practice and policy making. The hypotheses are: 1) Respondents prefer lower 
risk of SJS, lower cost of genetic test and long-term gout treatment; 2) There is 
preference heterogeneity across patients, in terms of relative importance of attributes 
and willingness-to-pay; 3) Information that an alternative is recommended by doctor 
leads to higher willingness-to-pay and higher uptake rate for this alternative, compared 
to when it is not the doctor recommended; and 4) Information that an alternative is the 
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 most common choice results in higher willingness-to-pay and higher uptake rate for this 
alternative, compared to when it is not the most common choice.   
Several factors were not studied in DCE. First, self-efficacy factors were not 
considered, as DCE only elicit stated preferences, but not actual behaviors. Second, test 
process variables (such as location of test, waiting time for test results, test results 
disclosure) were not included in the study, as respondents considered these factors to 
be less important. Third, those factors that are unlikely to change (such as incidence and 
mortality of SJS) were given as background information, instead of as attributes in DCE. 
 
4.7 Conclusion 
This chapter outlined the importance of understanding patients’ preferences, 
and reviewed the theoretical and empirical literature on patients’ preferences for 
genetic testing and its determinants. These leads to the formulation of specific research 
hypotheses to be tested in the DCE.
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 Chapter 5 High-risk Asian patients’ preferences for 
pharmacogenetic testing to identify risk of severe 
adverse drug reaction in chronic gout treatment--A 
discrete choice experiment 
5.1 Abstract 
Aims 
This study aims to investigate patients’ preferences for using genetic testing to reduce 
the risk of a life-threatening adverse drug reaction named Stevens-Johnson syndrome 
(SJS). This study also explored the impact of doctor’s recommendation and herd 
behavior on patients’ decision making. 
Methods 
A discrete choice experiment was conducted in which 200 patients were asked to 
choose between 3 treatment alternatives that differed in six attributes: whether genetic 
test is involved, risk of developing SJS, cost of the test, cost of long-term gout 
treatment, doctor’s recommendation, and the most common choice. Conditional logit, 
mixed logit, and latent class models were used to analyze the choice data. Relative 
importance of attributes, willingness-to-pay for risk reduction, and test uptake rate were 
estimated. 
Results 
The latent class model identified two distinct classes of patients. Most patients are risk 
averse, and had higher preference weights for level of risk reduction than for cost of 
test. Other patients are more cost conscious, and considered cost of test and long-term 
treatment more important than the level of risk reduction. Given the current available 
genetic test, the risk-averse class had higher willingness-to-pay (S$1,215) and 
predicted test uptake rate (98.3%) at a price of S$400 compared to the cost-conscious 
class (S$0, and 8.8%). Overall, our results predicted the test uptake rate to be 65.10% 
in Singapore. The study also revealed the strong impact of doctor’s recommendation 
and moderate effect of herd behavior in shaping individuals’ test decisions.   
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 Conclusions  
There is a potentially large demand for genetic tests that could reduce the risk of life-
threatening ADRs. Physician recommendations and providing information on the 
choices of others are powerful influences on demand, even more so than moderate 




 5.2 Introduction 
Using a discrete choice experiment (DCE), this study aims to investigate 
patients’ preferences for using genetic testing to reduce the risk of a life-threatening 
adverse drug reaction named Stevens-Johnson syndrome (SJS). Based on the 
literature review and in-depth interview described in the previous chapter, various test 
features and decision context information were included as attributes in the DCE. 
Based on DCE results, the willingness-to-pay for risk reduction and test uptake rate 
were estimated for various scenarios to inform clinical practice and policies. The 
specific aims and hypotheses are: 
Aim 1: To quantify patients’ preferences for various features of pharmacogenetic 
test.  
Hypothesis 1.1: Respondents prefer lower risk of SJS, lower cost of genetic test 
and long-term gout treatment. 
Hypothesis 1.2: The test uptake rate will be higher when a test can reduce the 
risk of SJS to a lower level, or when the cost of genetic test and long-term gout 
treatment is lower. 
Hypothesis 1.3: Patients are willing to pay additional cost for a test-guided 
treatment strategy that results in lower risk of SJS. 
Hypothesis 1.4: There is preference heterogeneity across patients, in terms of 
relative importance of attributes and willingness-to-pay. Some patients may 
consider the risk of SJS as the most important factor and have high willingness-
to-pay for risk reduction, whereas others may care more about cost.  
Aim 2: To quantify the extent to which information on doctor’s recommendation 
can influence the likelihood of an alternative being chosen.  
Hypothesis 2.1: Information that an alternative is recommended by doctor leads 
to higher willingness-to-pay and higher uptake rate for this alternative, compared 
to when it is not the doctor recommended.   
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 Hypothesis2.3: Doctor’s recommendation is more influential among women, 
elderly, and those with lower educational attainment.  
Aim 3: To quantify the extent to which information on the most common choice 
can influence the likelihood of an alternative being chosen.  
Hypothesis 3.1: Information that an alternative is the most common choice 
results in higher willingness-to-pay and higher uptake rate for this alternative, 
compared to when it is not the most common choice.   
Hypothesis 3.3: Information on the most common choice is more influential 
among women, elderly, and those will lower educational attainment.  
Hypothesis 3.4: When doctor’s recommendation differs from the most common 
choice, doctor’s recommendation is more influential on the final decision.    
Aim 4: To forecast the impact of various hypothetical policies on test uptake 
rate.  
Hypothesis 4: Providing information that a test is recommended by doctor is 
more effective in improving the test uptake rate compared to a strategy that 
lowers the cost of test or long-term gout treatment.  
 
In addition to addressing the above research questions, this chapter also aims 
to provide a detailed description of the techniques and processes of conducting a DCE 
when decision context attributes are involved. Standard DCEs require attributes levels 
to vary independently in different choice alternatives within the same choice set. 
However, the presence of choice context requires the different choice alternatives to 
have correlated attribute levels, which adds to the complexity of study design. 
Alternative options are discussed to illustrate the process of evaluating and choosing 




 Conducting a DCE involves several key tasks: problem refinement and stimuli 
development, experimental design, survey instrument construction, data collection, and 
statistical analysis (Figure 7).50 Stimuli development refers to the determination of 
attributes, levels, and choice question format. Experimental design is the process of 
systematically combining attribute levels to make choice alternatives and choice sets. 
The design process and methods have been reviewed in the literature.50,51,207,208 Table 
8 lists the questions to be addressed in each step. Importantly, study design is an 
iterative process. In-depth interview, cognitive interview and pre-testing are necessary 
to obtain respondents’ feedback on the design, and suggest improvements on the 
earlier tasks. For instance, experimental design considerations and respondents 
feedback may require the modification of attribute levels. An untested design may fail 
to answer the research questions, and lead to biased preference estimates.  
In this study, three iterations were undertaken for survey instrument design. The 
first iteration involved the identification of a preliminary list of attributes based on the 
literature review and in-depth interview. In the second iteration, attribute levels and 
choice question format were selected, and tested in cognitive interviews. In a cognitive 
interview, each participant was asked to answer specially constructed DCE questions, 
and “think aloud” to describe their decision making process and rationale to the 
interviewer.176 Interviewer also directed questions to better understand the responses. 
Based on responses, attributes levels were fine-tuned, and choice format was revised 
so that respondents can understand the questions, and make trade-offs between 
various attributes and levels as intended. An experimental design and choice sets were 
generated at the end of the second iteration. The third iteration was a pre-test of the 




Figure 7. The process and key tasks of undertaking a discrete choice 
experiment. Modified from “Applied choice analysis: a primer.” By Hensher, 





 Table 8. Checklist of factors to consider in undertaking and assessing the 
quality of a discrete choice experiment.  
 
From "Conducting discrete choice experiments to inform healthcare decision 
making." By Lancsar, Emily, and Jordan Louviere. Pharmacoeconomics 26, no. 
8 (2008): 661-677.51  
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 5.3.1 Problem refinement and stimuli development 
This step involves the development of attributes, levels, and choice question 
format, the process of which is described in details in this section. The final set of 
attributes and levels are shown in Table 9. Two sample choice sets are displayed in 
Figure 8.  
 
Table 9. Final attributes and levels studied in DCE 
Attributes Levels 
The chance of getting the severe 
side effect 
 
1 out of one million patients 
1 out of 5,000 patients                       
1 out of 1,000 patients  
1 out of 600 patients 
Cost of one-time genetic test 
 




Cost of gout medicines (over 
two years)  
 
S$250 if test positive (2 in 10 chance), S$200 if test 
negative (8 in 10 chance)                              
S$400 if test positive (2 in 10 chance), S$200 if test 
negative (8 in 10 chance)                              
S$1,500 if test positive (2 in 10 chance), S$200 if test 
negative (8 in 10 chance)                              
S$4,000 if test positive (2 in 10 chance), S$200 if test 
negative (8 in 10 chance)                              
Your doctor’s recommendation 
 
No information on doctor’s recommendation 
An alternative is the doctor recommended alternative 
An alternative is not the doctor recommended 
alternative 
Most common choice 
 
No information on the most common choice 
An alternative is the most common choice 











 5.3.1.1 Attributes development based on literature and in-depth interview  
The determinants of genetic testing decisions identified based on the Health 
Belief Model and supported by empirical literature and in-depth interview in the 
previous chapter formed the initial pool of attributes: 
Test feature attributes: 
• Risk of developing SJS (with test-guided treatment) 
• Cost of test 
• Cost of long-term gout treatment 
Choice context attributes: 
• Doctor’s recommendation 
• Most common choice 
5.3.1.2 Attribute level development and testing through cognitive interview 
Determine Attribute levels 
Once attributes were determined, the next step was to select levels for each 
attribute. Levels were quantified or unambiguously defined to avoid confusion and 
minimize variations in interpretation. Four criteria were considered for attributes level 
selection. Firstly, the observed or most realistic levels were included, in order to make 
predictions about real life behaviors. Secondly, policy relevant levels, or levels that 
would become realistic in the future were included, to improve the predictive power of 
the study to forecast impact of policies and future changes. Thirdly, a broad range of 
levels were included to explore the switching point, at which respondents may switch 
choices. When all levels of an attribute are considered very low or very high to a 
respondent, this attribute may dominate other attributes, or may be neglected, both of 
which are inefficient in collecting preference information. Including appropriate range of 
levels ensures that respondents actively evaluate the different attribute levels, and 
made trade-offs between attributes. Fourthly, the number of levels was set at 4 for risk 
and cost attributes, and 3 for doctor recommendation and most common choice 
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 attributes. With more levels included, the more information regarding preferences for 
that attribute can be captured. However design size and cognitive burden will increase 
with number of levels.50  
The attribute level extremes identified above were systematically tested in 
cognitive interviews to 1) fine-tune the attribute levels, especially the extreme ranges, 
so that respondents feel the presented attribute levels are relevant, and may change 
their decisions based on the different levels, and 2) to explore respondents’ willingness 
to make trade-off between different attributes. In a cognitive interview, each participant 
was asked to answer specially constructed DCE questions, and “think aloud” to 
describe their decision making process and rationale to the interviewer.176 The 
interviewer also directed questions to better understand the responses. Each specially 
constructed DCE choice set includes 2 hypothetical test alternatives, where two 
attributes were varied at one time, while fixing the other attributes at the middle levels, 
in order to examine the trade-offs made between any two attributes. The best level of 
an attribute was combined with the worst level of another attribute in one of the 
profiles, and vice versa for the other profile. (See Table 10 for the design of DCE 
choice sets for cognitive interview). A no test alternative was then added to each 




 Table 10. Cognitive interview DCE choice sets template to identify extreme ranges of attributes. 
 Q1 Q2 Q3 
 Test A Test B No test Test A Test B No test Test A Test B No test 
Risk of developing SJS Best level Worst level  Best level Worst level  Middle level Middle level  
Cost of test Worst level Best level Fixed Middle level Middle level Fixed Best level Worst level Fixed 
Cost of long-term gout treatment Middle level Middle level  Worst level Best level  Worst level Best level  
Doctor’s recommendation Middle level Middle level  Middle level Middle level  Middle level Middle level  
Most common choice Middle level Middle level  Middle level Middle level  Middle level Middle level  
   
 Q4 Q5 Q6 
 Test A Test B No test Test A Test B No test Test A Test B No test 
Risk of developing SJS Best level Worst level  Best level Worst level  Middle level Middle level  
Cost of test Middle level Middle level Fixed Middle level Middle level Fixed Best level Worst level Fixed 
Cost of long-term gout treatment Middle level Middle level  Middle level Middle level  Middle level Middle level  
Doctor’s recommendation Worst level Best level  Middle level Middle level  Worst level Best level  
Most common choice Middle level Middle level  Worst level Best level  Middle level Middle level  
   
 Q7 Q8 Q9 
 Test A Test B No test Test A Test B No test Test A Test B No test 
Risk of developing SJS Middle level Middle level  Middle level Middle level  Middle level Middle level  
Cost of test Best level Worst level Fixed Middle level Middle level Fixed Middle level Middle level Fixed 
Cost of long-term gout treatment Middle level Middle level  Best level Worst level  Best level Worst level  
Doctor’s recommendation Middle level Middle level  Worst level Best level  Middle level Middle level  
Most common choice Worst level Best level  Middle level Middle level  Worst level Best level  
   
 Q10  
 Test A Test B No test 
Risk of developing SJS Middle level Middle level  
Cost of test Middle level Middle level Fixed 
Cost of long-term gout treatment Middle level Middle level  
Doctor’s recommendation Best level Worst level  
Most common choice Worst level Best level  




 A total of 50 diabetes patients were recruited from Singapore General Hospital 
(SGH) Diabetes Centre and the National University Hospital (NUH) Diabetes Clinic for 
cognitive interviews. Several rounds of cognitive interviews were conducted, with the 
attribute level extremes adjusted based on respondents’ choices in the previous round 
of cognitive interview. For instance, when no respondent chose the no test alternative, 
it suggested that the highest risk of developing SJS associated with test alternatives 
should be increased to encourage trade-offs. If respondents always chose the lower 
risk alternative, regardless of cost, the highest cost level should be increased in order 
to identify the maximum willingness-to-pay. In the last round of cognitive interviews, 
tradeoffs were observed. Among respondents, very few made their responses always 
consistent with the better available level of one attribute (dominating on an attribute), 
indicating that with the current attribute level extremes, all attributes are important so 
that they make trade-offs between different attributes instead of only considering one 
attribute.  
Determine the attribute level display format 
In the cognitive interviews, the best framing and presentation format of attribute levels 
were also explored.  
The risk of developing SJS is 0.2% without testing, and further reduced to almost 0 
with testing-guided treatment. Such small probabilities that people do not often 
encounter in daily life are difficult to make sense of by respondents. In the literature, it 
is found that people are not good at understanding probability expressions, especially 
small probabilities.169,173,209-211 Some common graphic displays tools such as grid, and 
dots do not work well for very small probabilities. We tested three possible formats of 
presenting the risk of SJS including the use of percentage, the use of frequency, and a 
graphic display with a Pailing scale (Table 11).209,210  The frequency format (1 out of 
xxx patients) was found easy to understand and quantify, and was used in the final 
survey. Respondents reported that percentage expressions were not easy to imagine, 
and some respondents considered all levels to be very low when presented in 
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 percentages. The Pailing perspective scale is a method to display the probability of an 
event relative to the probability of other events which people are more familiar with 
(such as the risk of dying off cancer, the chance of winning TOTO lottery, the chance 
of getting HIV infection from transfusion).  In cognitive interviews, this was found to be 
time-consuming, and incurring significant cognitive burden to respondents.  
 














1 out of 
500 
patients 
1 in 500 
 
 
The cost of long-term gout treatment is an attribute with an uncertainty 
component. As genetic test results can aid the selection of drugs, the long-term gout 
treatment cost depends on the test results. We therefore displayed the gout treatment 
costs associated with positive and negative test results, as well the chance of testing 
positive. The gout treatment cost associated with negative test results (S$200 over 2 
years) and the chance of test positive (20%) are fixed across different levels, and only 
the cost associated with positive test results was varied (S$250, S$400, S$1,500,and 
S$4,000). In the pre-testing, respondents could understand that gout treatment cost 
was uncertain at the time of making testing decisions, and the actual cost would 
depend on test results. We provided the cost of gout treatment in 2 years, as gout is a 
chronic condition with one episode of treatment lasting for over 2 years. 
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 The display of doctor’s recommendation was explored in the cognitive 
interviews. In real life scenarios, doctors often recommend one treatment from the 
available alternatives. In other cases, doctors may provide information on the treatment 
alternatives but make no clear recommendation, and encourage patients to make a 
decision based on his/her own preference. We therefore imposed the restriction that 
only one alternative can be recommended by doctor in each choice set, or no 
information on doctor’s recommendation is provided. The doctor’s recommendation 
attribute was framed as the information on doctor’s recommendation. It differs from a 
real recommendation delivered by a doctor personally during a face-to-face 
consultation. The physical presence of doctor and the interactive nature of the 
recommendation will make an actual recommendation more salient and effective than 
providing information on doctor’s recommendation in a survey questionnaire. To 
improve the saliency of the doctor’s recommendation attribute, a flag shape label was 
used to indicate doctor’s recommendation (Figure 8). A graphic display not only 
attracts respondents’ attention, but also makes it easier to understand the 
recommendation. 
To test for the presence of herd behavior, the choice of the herd can be 
described in quantitative or qualitative ways. Showing the percentage of respondents 
choosing each alternative gives precise information, however multiple levels may be 
required in the design to identify the percentage at which respondents will follow the 
herd. In addition, as several alternatives were offered in each choice set, respondents 
may undertake calculations with percentages, and confusion may arise if all 
percentages do not sum up to 100%. To simplify this attribute and avoid confusion, the 
levels were described qualitatively. An alternative can be “the most common choice” or 
“not the most common choice”. In some choice sets, this attribute has the level “no 
information”. A visual display was used, with the most common choice indicated by a 
tick mark (Figure 8).  
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 Given the above considerations and findings, the final set of attributes and 
levels are shown in Table 9. The initial set of attributes and levels formulated without 
testing or revision are shown in Table 12.  Comparing the two sets, significant changes 
in attribute framing and attribute levels were made to improve the survey.  
 
Table 12. Initial set of attributes and levels before cognitive interview 
Attributes  Levels 




Your chance of 
developing SJS 
0 (no chance) 
1 SJS case in 50,000 users of allopurinol 
1 SJS case in 5,000 users of allopurinol 
Gout treatment costs  2 every 10 people will test positive. If you are one of these people, you 
will have to take a drug that will cost you SGD500 a year. If you do not 
test positive, you can safely use allopurinol   
2 every 10 people will test positive. If you are one of these people, you 
will have to take a drug that will cost you SGD1,000 a year. If you do 
not test positive, you can safely use allopurinol     
2 every 10 people will test positive. If you are one of these people, you 
will have to take a drug that will cost you SGD2,000 a year. If you do 
not test positive, you can safely use allopurinol                                                                                  
Your doctor’s 
recommendation 
You receive a doctor’s recommendation on the genetic test 
You receive no recommendation on the genetic test 
Herd behaviour 10% of people in your situation take the genetic test 
90% of people in your situation take the genetic test 
 
5.3.1.1 Determine DCE question format and test via cognitive interview  
Besides fine-tuning the attributes and levels, there are several other objectives 
of cognitive interviews: 1) to explore the ability of respondents to understand the 
attributes and DCE questions, and determine the appropriate format of DCE question, 
2) to understand the cognitive burden and difficulty level of the survey in the study 
population, and 3) to test and improve the wording of survey instrument.  
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 Inclusion of an opt-out option in the choice set 
DCE question aims to elicit a response on the preferred alternative within each 
choice set. However, it is possible that none of the test alternatives is preferred, even 
though one test is perceived better than the others. It is important to capture this type 
of non-demander preference when trying to make predictions about real life 
behaviors.212 This is particularly relevant for this study as we sort to understand 
whether or not individual patients are willing to take a genetic test, in addition to 
estimating the preferences for test features. Without an opt-out option, the test uptake 
rate may be overestimated.213 Three types of modifications can accommodate the non-
demander behaviors: 1) having a no test alternative with all features displayed, 2) 
including  “none” as an option in the response, or 3) adding a follow-up question after 
the preference question to verify whether the preferred option will be implemented 
when offered. After testing in cognitive interviews, the no test alternative was chosen. 
Display of all attributes levels for the no test alternative allows respondents to compare 
the cost and consequences of testing and no testing, and minimizes the discrepancies 
in individual beliefs about no test. To make the questions realistic, we constructed the 
no test alternative using the realistic attribute levels, and kept the risk and cost 
attributes of this alternative fixed in all DCE choice sets.  
Number of alternatives in a choice set 
Having more profiles in a question will increase the amount of information 
obtained from each question, however may increase the complexity of questions and 
the cognitive burden to respondents. Most DCE studies in health care include 2 or 3 
alternatives in each choice set. In the cognitive interviews, both numbers were tested, 
and respondents had no difficulty in handling three alternatives. Furthermore, having 3 
alternatives (2 test alternatives + 1 no test alternative) has advantages over 2 
alternatives (1 test alternative+ 1 no test alternative) in reducing the labeling effect of 
testing. With only one test alternative and one no test alternative, respondents may 
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 take the mental shortcut to always choose test or no test based on their prior belief 
about genetic testing instead of looking at the attribute levels. 
Labeled vs. unlabeled alternatives 
In addition to the attributes and levels, the label of alternatives also significantly 
influences the responses. In an unlabeled design, the alternatives are given generic 
names such “Alternative A”, “Alternative B” or “Treatment A” and “Treatment B”. In a 
labeled design, the name of alternative confers some information about the alternative, 
such as “Genetic test A”, “Genetic test B” and “No test”. Assigning informative labels to 
the profile will make it more realistic to respondents, which is likely to improve the 
power of DCE to predict real behaviors. However, the label has been shown to 
influence individual choices and reduce the attention respondents give to the 
attributes.214 Both labeled and unlabeled designs were tested in the cognitive 
interviews.    
When the three profiles were labeled as “Genetic test A”, “Genetic test B”, and 
“No test”, respondents were less likely to indicate the no test alternative as the most 
preferred, compared to the unlabeled design, where the alternatives were labeled 
“Alternative A”, “Alternative B” and “Alternative C”. This may be reasonable as the 
genetic test label confers information, and patients may have intrinsic preferences for 
taking a genetic test to reduce risk of life-threatening ADRs, regardless of the attribute 
levels. However, a small number of respondents mistakenly understood the no test 
alternative as having no gout treatment. In order to minimize the potential 
misunderstanding, the labels were revised to be “Treatment A” “Treatment B” and 
“Treatment C” to reassure respondents that gout treatment will be given in all three 
alternatives, with the difference being the involvement or absence of genetic testing 
prior to treatment. An additional attribute was introduced to indicate whether a 
treatment involves genetic testing to capture respondents’ intrinsic preferences for the 
label of genetic test. 
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 Type of preference-eliciting questions  
The most common type of preference-eliciting question requires respondents to 
indicate the most preferred alternative. Newer DCE studies has explored different 
types of questions, such as the best-worst type, which require respondents to report 
both the most preferred (best) and least preferred (worst) alternatives.215 In a DCE 
study with 3 alternatives in each choice set, the best-worst type questions provide the 
complete preference ranking of an individual over different alternatives. The coefficient 
estimates using both the best and worst response have smaller standard errors than 
models estimated using responses on the best alternative only, demonstrating gains in 
statistical efficiency from the additional preference information gathered.215,216 However, 
the cognitive processes and certainty of responses to the best and worst question are 
different, and there are controversies on the appropriate weights assigned to the best 
and worst questions.215,217 In addition, there are concerns on the cognitive burden of 
asking 2 follow-up questions in each choice set. In pre-testing, best and worst types of 
questions were tested, and some confusion was observed, especially among those 
with lower education level. The switch between best and worst questions appeared to 
require a switch in the decision making pathway, and increased the cognitive burden. 
There is also trade-off between the number of follow-up questions in each choice set 
and the number of choice sets respondents can go through in a given amount of time. 
Therefore, respondents were only asked to choose the most preferred alternative in 
the final survey. 
Number of DCE choice sets in the survey 
In the DCE literature, a wide range of choice set numbers have been used. The 
optimal number of questions depends on the complexity of DCE questions, and the 
cognitive power of respondents.  A study that compares a design of 5, 9, and 17 choice 
sets found that respondents exposed to 17 choice sets had higher response variance, 
suggesting a large number choice sets may increase cognitive burden.218 Cognitive 
burden may leads to inattentive or inconsistent responses. Cognitive interviews reveal 
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 that respondents can answer 10 questions with reasonably good attention and 
certainty. Even though a small number of respondents started to fatigue after 4-6 
questions mainly because all DCE questions looked similar, they could re-gain focus 
with the encouragement of interviewers. 10 trade-off questions were included in the 
final survey.  
5.3.2 Experimental design 
Experimental design is the process of systematically generating a sample of 
choice sets which constitutes choice alternatives that are specific combinations of 
attributes and levels.208 Experimental design should be tailored based on the research 
objective, specifications of attributes and levels, choice question format, as well as the 
analysis requirements.208  According to the ISPOR Task Force on Conjoint Analysis, 
the good practice of experimental design requires researchers to evaluate alternative 
design approaches and justify the approach chosen.207 In order to select and evaluate 
various design approaches, four aspects were considered. Johnson et al. highlighted 
two general objectives in experimental design: model identification and efficiency.208 
Louviere et al. discussed two additional design objectives: reduce cognitive complexity 
and market realism.52 Model identification means independent and unbiased estimation 
of the desired form of effect parameters from the survey data, and is the most 
important design consideration. Efficiency refers to the statistical power of the design 
to estimate the effect parameters precisely with relatively small sample size. Reducing 
cognitive complexity requires researchers not to incur excessive cognitive burden on 
respondents, as cognitive burden may threaten the consistency and validity of 
responses. Market realism influences the power of the study to explain or predict real 
life behaviors. A perfect design may not exist. Often, the importance of the four 
objectives needs to be weighed and compromised to achieve a good balance. 
5.3.2.1 Experimental design theories and approaches—a literature review 
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 To generate an experimental design, several approaches are commonly used 
in the DCE literature.208 Different approaches have different underlying algorithms and 
properties. In general, there are two classes of designs: full factorial design and 
fractional factorial design.50,51,219 Full factorial design generates all possible 
combinations of levels from each attribute, and the main effects and interaction effects 
of all attribute levels can be estimated independently. However, full factorial design 
requires large number of questions if the study involves many attributes and levels, 
which are usually impractical. In this study, there are three attributes with four levels 
each, and two attributes with three levels each (denoted as 4332). A full factorial design 
would generate 4x4x4x3x3=576 different combinations. In contrast, fractional factorial 
designs select only a small fraction of possible combinations while ensuring the effects 
of interest can be estimated.  Different approaches are used to select a fraction of 
combinations. Designs can be obtained from catalogues, software, or generated by 
hand.51,208  The generated designs may differ in three key properties: orthogonality, 
statistical efficiency and response efficiency.  
Orthogonality is a constraint that all attributes be statistically independent of 
each other (though conceptually attributes may be related), and zero correlations 
between attributes.50 Orthogonality relates to the design objective of unbiased 
identification of parameters in statistical analysis. For example, in a study to 
understand patients’ preferences for treatment effectiveness and adverse drug 
reactions, if the treatment that is more effective always results in lower rate of adverse 
drug reactions, researchers will not be able to distinguish the independent effect of 
effectiveness and adverse drug reactions on patients’ preferences. Balance is a related 
property that requires each level of an attribute to appear equal number of times, and 
is a necessary condition for strict orthogonality. The designs that emphasize on 
orthogonality are referred to as orthogonal or near-orthogonal fractional factorial 
designs. These include orthogonal arrays (which can be obtained from manual 
catalogue), orthogonal main-effects plan (OMEP), and OMEP-based designs such as 
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 the fold-over design, and designs generated by Sawtooth software.208,220-222 These 
designs require zero or near zero correlation between attributes, and therefore 
guarantees the identification of main effects and sometimes interaction effects. 
However, small size orthogonal arrays may not be available for some number of 
attributes and levels. Moreover, orthogonal designs cannot incorporate constraints on 
dominance or implausible combinations. For instance, some random combinations 
may be implausible or dominated (where all levels of one alternative are 
unambiguously better than the levels of another alternative). This is likely to occur 
when the attribute levels are naturally ordered.208 This type of combinations does not 
reveal information on preferences as the better choice is obvious regardless of 
preference if people are rational. Imposing restrictions to avoid implausible 
combinations may improve statistical efficiency and reduce potential confusion among 
respondents.  
Statistical efficiency refers to the minimization of confidence intervals around 
parameter estimates in a choice model for a given sample size.208 A statistically less 
efficient design may be compensated by a large sample size to obtain rather small 
confidence intervals.208 However, when the intended sample size is small, statistical 
efficiency is crucial. Optimal fractional factorial designs emphasize on statistical 
efficiency at the expense of orthogonality. D-efficiency and D-optimality are commonly 
used efficiency criteria to measure, generate and compare the efficiency of designs.186 
Design approaches that focus on efficiency include the SAS macros using D-efficiency, 
Street and Burgess’ cyclic design, Sandor and Wedel’s Bayesian design, and Bliemer’s 
design.216,219,223,224  
Besides statistical efficiency, there is another type of efficiency referred to as 
response efficiency, which is about the measurement errors resulting from poor quality 
response. This property relates to the objective of minimizing cognitive burden. When 
DCE questions are complex or ambiguous, or when a large number of DCE questions 
are included, respondents may fatigue and pay less attention to the questions, or even 
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 take mental shortcuts that deviate from utility maximization. The inconsistency in 
responses may result in bigger variance in estimates. Louviere et al. demonstrated that 
an increase in statistical efficiency was always associated with a decrease in response 
consistency.225 
A good design requires a balance of orthogonality, statistical efficiency and 
response efficiency. In practice, there are trade-offs that researchers have to make 
between these three considerations. Statistical efficiency can be increased by asking a 
large number of difficult trade-off questions with no implausible combinations, and no 
level overlaps. However these will violate strict orthogonality by imposing correlations, 
and incur significant cognitive burden which will threaten response efficiency. 
Empirically some design properties such as D-efficiency, correlation, balance, and 
overlap can be indicators of orthogonality and efficiency, and should be checked after 
design is generated. 
5.3.2.2 Generate experimental design using D-efficiency criteria in SAS 
In this study, the D-efficiency measure was used to generate a fractional 
factorial design. D-efficiency minimizes the joint confidence sphere around the 
complete set of estimated model parameters, that is, maximizes the statistical 
efficiency.208 The advantage of D-efficiency approach is the flexibility to incorporate 
restrictions while maximizing statistical efficiency. D-efficiency design was generated in 
SAS software based on the algorithm described by Kuhfeld.219 After the design was 
generated, properties including orthogonality, balance and overlap were checked to 
ensure sufficient identification of parameters. Pre-testing was conducted to ensure 









Figure 9. Process of experimental design in SAS 
 
 
Determine minimal degree of freedom required  
The first step of design is to determine the minimum design size or the degree 
of freedom required based on the analysis plan. We want to estimate the main effect of 
each attribute. Cost of test will be estimated as a linear variable, and the linearity of 
utility in this attribute was tested. All other variables will be treated as categorical and 
the effect of each level will be estimated separately. The presence of no test option 
requires one more degree of freedom to estimate the alternative-specific constant for 
no test. In addition, two more degrees of freedom are required to differentiate the effect 
of doctor recommendation and herd information on test alternative and no test 
alternative. In total, 14 parameters need to be estimated, which implies that the most 
parsimonious design needs to contain 14 DCE choice sets to ensure model 
identification (Table 13).  
  
Examine design properties
Split design into smaller blocks
Generate candidate design
Generate candidate profiles
Identify optimal design size
Set specific design restrictions
Determine minimum degree of freedom based on analysis requirement
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 Table 13. Minimum degree of freedom required for analysis 
Attribute Number of levels 
Parameters to be 
estimated/degree of 
freedom required 
Cost of test 4 1 
Risk of SJS 4 3 
Cost of gout treatment 4 3 
Alternative specific constant for no test 1 1 
Doctor’s recommendation (main effect+ 
interaction with no test) 
3 2+1=3 
Most common choice (main effect+ 
interaction with no test) 
3 2+1=3 
 Total  14 
 
 
Special design considerations for doctor’s recommendation and the most common 
choice 
To make the choice questions realistic, correlations between alternatives were 
imposed on doctor’s recommendation and most common choice attributes, so that 
within any choice set, at most one alternative can be labeled “doctor recommended” or 
“most common choice”.  That means, when one of the three alternatives is the doctor 
recommended, the other two were not recommended by definition. As a result, doctor’s 
recommendation and most common choice attributes do not vary freely across 
alternatives within the same choice set, and are specific to each choice set to form a 
choice context.  Standard DCE designs do not easily accommodate the within-choice 
set correlations in attribute levels.  
 Three possible design solutions were considered. The first solution is to 
include only one test alternative in a choice set, and treat choice context attribute as a 
normal attribute. However, it will reduce the amount of information obtained from each 
question, and may require a larger number of questions. The second solution is to 
have multiple versions of questionnaires that contain the same set of DCE questions 
that only differ in the choice  context.226 This again requires larger sample sizes. We 
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 adopted a third solution, in which we designed the level of doctor’s recommendation 
and most common choice attributes for the two test alternatives and allow the levels to 
vary independently across alternatives. The level for the no test alternative was 
inferred and displayed based on the correlation. See Figure 10 for an illustration of the 
design output and level modifications. In brief, when there are 2 levels of doctor’s 
recommendation (doctor recommended, not the recommended), there are 4 possible 
scenarios in a 2-alternative choice set: 1) A is recommended, 2) B is recommended, 3) 
A and B are both recommended, and 4) neither A nor B is recommended. For scenario 
1, 2 and 4, the level for the no test alternative can be easily imputed based on the 
restriction that at only one alternative can be recommended. For scenario 3, it violates 
our restriction, and the levels can be replaced by “no information” in all alternatives. 
SAS algorithm minimizes level overlap, which is the chance of the two alternatives 
sharing the same level (scenario 3, and 4) is low. To ensure the four scenarios occur in 
equal frequencies, the two levels were duplicated, and 4 levels (doctor recommended, 
not the recommended, doctor recommended, not the recommended) were used in 
design. The most common choice attribute was designed in the same way. Notably, 
modifying the levels after the generation of design may alter the design properties. So 
some important properties (such as efficiency, orthogonality, balance, and overlap) of 





Figure 10. Possible design scenarios and level modifications 
 
 
5.3.2.3 Generate experimental design in SAS  
The above design considerations require a design for 5 attributes with 4 levels 
each. Interaction term was specified between the doctor’s recommendation and most 
common choice attributes.  Among the design sizes suggested by SAS, 32 was 
chosen as the final design size. All attributes have 4 levels, and the interaction term 
has 16 levels. 32 is dividable by both 4 and 16, and therefore are likely to results in 
good level balance, which is necessary for orthogonality and efficiency. The design 
was generated using the %mktex, %choiceff, and %mktblock autocall SAS macros. In 
brief, 20,000 alternatives were constructed using the attribute levels. 32 choice sets 
with 2 alternatives in each choice set were then generated using the 20,000 
alternatives based on D-efficiency criteria, with restrictions to exclude dominant-pair 
choice sets where one alternative unambiguously dominate the other. The 32 choice 
sets were partitioned into 4 blocks of 8 questions, so that each respondent does not 
need to answer all questions. The levels for doctor’s recommendation and most 
common choice attributes were manipulated as described previously to form the final 
design. Final design was included in Appendix B. 
Design Manipulate the levels 
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 5.3.2.4 Examine design properties 
The final design was examined in terms of correlations (orthogonality), level 
balance, cross-level balance, and overlap, all of which are important for parameter 
identification and design efficiency. In brief, no serious correlations between different 
attributes and attribute levels were detected. Attribute levels were roughly balanced, 
that is, different levels of the same attribute appeared roughly equal number of times. 
The frequency of level combinations between any 2 levels of different attributes were 
roughly balanced (cross-level balance). The frequency of overlap where two 
alternatives within the same choice set share the same level for a certain attribute was 
low.  
5.3.2.5 Survey validity test 
To assess the reliability of responses, we incorporated two internal validity 
questions to examine respondents’ attention and understanding.(see Figure 11) Based 
on cognitive interview feedback, some respondents had difficulty quantifying the small 
probabilities in the risk attribute. Therefore the first validity test was placed before DCE 
questions, and required respondents to identify the scenario indicating higher risk. 
Respondents who failed to identify the higher risk scenario was given additional 
explanations on probability expressions before moving on to DCE choice questions. 
The second test was a “dominant-pair” test in DCE format, in which the two test 
alternatives share the same level for all attributes, except for the risk attribute where 
one alternative results in lower risk than the other. In this test, utility maximizers should 
always prefer the lower risk alternative, regardless of preferences. Respondents who 










 5.3.3 Survey design 
The survey questionnaire can be found in Appendix C. Questionnaire starts with 
two screener questions to verify the eligibility of respondents. An introduction section 
then briefly educates respondents on gout, side effect of gout treatment and genetic 
testing, so that respondents have the essential knowledge to answer choice questions, 
even if they do not have prior knowledge on the topic. The third section defines the 
attributes and possible levels that respondents will see in the DCE questions. Before 
introducing the cost attributes, a budget reminder is included to remind respondents to 
think about the impact of a certain amount of money on their daily life. There is a 
literature on the hypothetical bias of the DCE approach, which is mainly due to the fact 
that respondents only state their preference, without actually paying to receive the 
preferred service or product. The willingness-to-pay estimated from DCE may be 
higher than that in real life. A budget reminder in cheap-talk format may encourage 
respondents to think about cost carefully, which will improve the predictive power of 
DCE.176 After introducing each attribute, one to two warm-up questions are included to 
understand respondents’ perceptions and attitude towards the attribute levels and to 
encourage active thinking. Another purpose of the warm-up question is to provide a 
check point and attract respondents’ attention to each attribute, as it was observed in 
cognitive interviews that respondents had the tendency to focus on questions and skip 
trunks of reading. The DCE section then starts with short instructions and precautions 
on common mistakes that respondents should avoid. An example DCE question is 
provided with explanations on how respondents should interpret the question. Nine 
DCE questions follows, with the first one being validity test question, and 8 questions 
from the experimental design. The survey questionnaire ends with questions on 




 The survey was pre-tested (n=10) to ensure that respondents have no difficulty 
answering questions, and the questionnaire doesn’t incur too much cognitive burden. 
Based on pre-testing the survey was revised and simplified. For instance, some 
technical jargons such as “HLA-B*5801 testing”, “adverse drug reactions”, which 
respondents have difficulty understanding are replaced with simple language such as 
“genetic testing”, and “side effects of medicines”. 
A proportion of Singaporean do not speak or read English, the majority of which 
can speak and read Mandarin. To also gauge the preference of this group, the survey 
questionnaire and informed consent were translated into Mandarin, and accuracy was 
verified via a back translation by a different researcher. 
5.3.4 Sample size calculation 
Orme’s rule of thumb was used to determine the minimum acceptable sample 




where n is the minimum sample size, t is the number of DCE tasks, a is the number of 
choice alternatives per task, and c is the maximum number of attribute levels. In our 
study, t=8, a=3, c=4. The minimum sample size required is therefore 84. The actual 
sample size was set at 200, which allows accurate estimation of all attribute levels, and 
additional analyses.  
5.3.5 Sampling and survey fielding 
Gout and diabetes are recognized features of metabolic syndrome.227,228 Gout 
is a risk factor for diabetes,229 and diabetes patients have higher risk for gout.230 
Diabetes patients therefore have higher chance of requiring chronic gout treatment 
with allopurinol, and facing the genetic testing decision in the future. We surveyed a 
convenient sample of 200 diabetes patients from the Singapore General Hospital 
(SGH) Diabetes Centre and the National University Hospital (NUH) Diabetes Clinic, 
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 which are the specialist diabetes clinics in two of the largest government’s restructured 
general hospitals in Singapore. The inclusion criteria include being a Singapore citizen 
or permanent resident, having a diagnosis of diabetes, between the ages of 21 and 80 
years. Those who have a diagnosis of gout and have been treated with urate-lowering 
therapy, and those with limited mental capacity were excluded from study.  
We sampled diabetes patients instead of gout patients for two reasons. Firstly, 
the genetic testing decision is only relevant for those patients who require chronic gout 
treatment with allopurinol, but have not initiated allopurinol. Based on current 
knowledge patients who have taken allopurinol but did not develop SJS within the first 
two months are unlikely to develop SJS in the future, and do not require genetic 
testing.120 Therefore, a significant proportion of chronic gout patients are not eligible for 
our study. Secondly, most gout patients are managed in the primary care setting by 
general practitioners (GPs) and family physicians in the government’s polyclinics and 
private clinics. GPs usually initiate allopurinol for gout patients and manage the 
symptoms, and only refer complex cases such as non-response and severe adverse 
reactions to rheumatologists in the specialist clinics in hospitals. There are eighteen 
government’s polyclinics, and over 2,000 GPs in private clinics. Gout patients therefore 
seek care in diverse locations. The number of gout patients treated by each doctor and 
clinic is small, making it operationally challenging to sample.  
To recruit respondents, trained interviewers approached patients in the waiting 
room of the diabetes clinic, verified their eligibility using the inclusion and exclusion 
criteria, and asked for their willingness to proceed with the survey after reading the 
information sheet. Informed consent was obtained from each respondent. The study 
received ethical approval from the National Healthcare Group’s Domain Specific 
Review Board (DSRB), and Singhealth Centralised Institutional Review Board (CIRB).  
Each respondent was asked to complete a paper version of the survey 
instrument, with the help an interviewer to explain the information on the survey 
instrument and clarify doubts. There were four equivalent versions of survey 
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 instruments each contain one of the four blocks of DCE questions. To minimize version 
effect and ensure balanced number of each version, we used a block randomization 
method to randomly assign a survey version to each respondent. Respondents were 
allocated to blocks of 8, and within each block, two copies of each version of 
questionnaires were answered. Five interviewers conducted the survey interviews. 
Interviewers were trained to facilitate the interview and clarify doubts based on a 
standardized script. Interviewers were also instructed to be neutral and not to express 
their own opinions on the topic. The presence of potential interviewer effect was tested 
in data analysis. In addition to respondents’ responses to questions, comments from 
respondents were also documented by interviewers.  
5.3.6 Data analysis 
5.3.6.1 Analysis of dominance preferences 
In discrete choice experiments, respondents are encouraged to make trade-offs 
between attributes. However, respondents may be unwilling to trade (non-
compensatory decision making) and have strong preferences that deviate from this 
assumption. Lancaster defined a scenario “dominance” as “A characteristic is dominant 
within some group of characteristics, in some set of situations, if the consumer always 
prefers a collection with more of the dominant characteristic, whatever the amounts of 
the other characteristics.”231 Empirically, if a respondent chose the alternative with the 
best available level of an attribute in all choice sets, the respondent was considered to 
have a dominant preference for that attribute.232 Dominant preferences for each 
attribute including the test label were analyzed. The proportion of respondents with 
dominance preferences was calculated. Socio-demographic predictors of dominant 
preference for each specific attribute were also analyzed using logistic regressions. 
DCE analysis models  
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 Random utility model framework 
The theoretical framework of analyzing choices is McFadden’s random utility 
model (RUM).233,234 Each respondent faces a choice among j alternatives, repeated 
under s scenarios or choice situations. The utility that individual n derives from 
alternative j in scenario s can be decomposed into a systematic component 𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛 and a 
stochastic component 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛 : 
𝑈𝑈𝑛𝑛𝑛𝑛𝑛𝑛 = 𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛 + 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛       (1) 
The analyst do not observe 𝑈𝑈𝑛𝑛𝑛𝑛𝑛𝑛, but may observe some characteristics of the 
alternatives 𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛 and characteristics of decision maker Zn, which determine the 
representative utility 𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛: 
𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛=𝑉𝑉(𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛,𝑍𝑍𝑛𝑛)      (2) 
Analyst assumes decision makers to be utility maximizers, and only chooses 
alternative i when 𝑈𝑈𝑛𝑛𝑛𝑛𝑖𝑖 > 𝑈𝑈𝑛𝑛𝑛𝑛𝑛𝑛  ∀𝑗𝑗 ≠ 𝑖𝑖. After assigning a joint density of the random 
component 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛, the choice probability that decision maker n chooses alternative i in 
scenario s can be expressed as: 
𝑃𝑃𝑛𝑛𝑛𝑛𝑖𝑖 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃�𝑈𝑈𝑛𝑛𝑛𝑛𝑖𝑖 > 𝑈𝑈𝑛𝑛𝑛𝑛𝑛𝑛  ∀𝑗𝑗 ≠ 𝑖𝑖�                                   = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃�𝑉𝑉𝑛𝑛𝑛𝑛𝑖𝑖 + 𝜀𝜀𝑛𝑛𝑛𝑛𝑖𝑖 > 𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛 + 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛  ∀𝑗𝑗 ≠ 𝑖𝑖� = 𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃�𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛 − 𝜀𝜀𝑛𝑛𝑛𝑛𝑖𝑖 <  𝑉𝑉𝑛𝑛𝑛𝑛𝑖𝑖 −  𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛 ∀𝑗𝑗 ≠ 𝑖𝑖�       (3) 
Depending on the specification of the density of 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛, equation (3) may or may 
not have a closed form. A logistic specification will give closed form solutions. Several 
commonly used logistic model include conditional logit model (CLM), mixed logit (MXL) 




 Conditional logit model (CLM)1  
𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛 can be specified as the following: 
𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛=𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛′ 𝛽𝛽 + 𝑍𝑍𝑛𝑛′ 𝛾𝛾         (4) 
𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛 is a matrix of alternative characteristics, 𝑍𝑍𝑛𝑛is a vector of decision maker 
characteristics, and  𝛽𝛽 and 𝛾𝛾 are vectors of coefficients. 
Assuming 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛to be identically and independently distributed (IID) as extreme 
value, this results in the conditional logit specification.237 The choice probability is the 
integral of 𝑃𝑃𝑛𝑛𝑛𝑛𝑛𝑛|𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛 over all values of 𝜀𝜀𝑛𝑛𝑛𝑛𝑛𝑛. The solution to this integral is the probability 
of individual i choosing alternative j in scenario s: 
𝑃𝑃𝑛𝑛𝑛𝑛𝑛𝑛 = exp (𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛′ 𝛽𝛽+𝑍𝑍𝑛𝑛′ 𝛾𝛾)∑ exp (𝑋𝑋𝑛𝑛𝑛𝑛ℎ′ 𝛽𝛽+𝑍𝑍𝑛𝑛′ 𝛾𝛾)Jj=1     (5) 
This model is easy to estimate using maximum likelihood method.237 However, 
one limitation of this model is that it cannot account for preference heterogeneity 
among different individuals.  
Mixed logit model (MXL)2  
Heterogeneity among individuals is usually expected due to differences in 
tastes and decision making processes. Therefore different individuals may value and 
weight attributes and levels differently. Mixed logit model is a more general 
specification that allows the coefficients to differ across individuals.  
𝑉𝑉𝑛𝑛𝑛𝑛𝑛𝑛=𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛′ 𝛽𝛽𝑛𝑛 + 𝑍𝑍𝑛𝑛′ 𝛾𝛾         (6) 
𝛽𝛽𝑛𝑛 is a Kx1 vector of coefficients for attribute levels for individual n, and 𝛽𝛽𝑛𝑛~𝑁𝑁𝐾𝐾(?̅?𝛽, V) 
ie. 𝛽𝛽𝑛𝑛1,𝛽𝛽𝑛𝑛2,…,𝛽𝛽𝑛𝑛𝐾𝐾, follow a multivariate normal distribution. Now each coefficient 𝛽𝛽𝑛𝑛𝑛𝑛 
1 Conditional logit model for discrete choice analysis is also referred to as multinomial logit (MNL) model, 
or mix conditional logit model in the literature.  
2 Mixed logit model is also referred to as random parameter logit model or random effect logit model. 
Mixed logit model are abbreviated as MXL or MLM. 
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 follows a distribution, with the mean ?̅?𝛽𝑛𝑛 representing the mean parameter for the 
population. 
The mixed logit choice probability is given by: 
𝑃𝑃𝑛𝑛𝑛𝑛𝑛𝑛 = ∫ exp (𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛′ 𝛽𝛽+𝑍𝑍𝑛𝑛′ 𝛾𝛾)∑ exp (𝑋𝑋𝑛𝑛𝑛𝑛ℎ′ 𝛽𝛽+𝑍𝑍𝑛𝑛′ 𝛾𝛾)Jj=1  f(β|θ)dβ   (7) Where f(β|θ) is the density function of β. 
Mixed logit model can be estimated using maximum simulated likelihood (MSL) 
method.238,239  
Latent class logit model (LCM) 
In the mixed logit model, the distributions of coefficients are continuous. A 
discrete distribution of coefficients will lead to a latent class model. Latent class model 
assumes that individual behaviors depend on observable attributes and latent 
heterogeneity which are unobservable. In latent class models, individuals are implicitly 
sorted into different classes, however analyst does not know which class a particular 
individual belongs to.236  A latent class model estimates a different set of coefficients 
for each class. The probability of individual n, whose is a member of class q, choosing 
alternative j in choice set s is given by: 
𝑃𝑃𝑛𝑛𝑛𝑛𝑛𝑛|𝑞𝑞 = exp (𝑋𝑋𝑛𝑛𝑛𝑛𝑛𝑛′ 𝛽𝛽𝑞𝑞)∑ exp (𝑋𝑋𝑛𝑛𝑛𝑛ℎ′ 𝛽𝛽𝑞𝑞)Jj=1       (8) 
𝛽𝛽𝑞𝑞 is a vector of coefficient for class q. The probability of individual n being in 
class q can be specified as: 
𝐻𝐻𝑛𝑛𝑞𝑞 = exp (𝑍𝑍𝑛𝑛′ 𝛾𝛾𝑞𝑞)∑ exp (𝑍𝑍𝑛𝑛′ 𝛾𝛾𝑞𝑞)Qq=1               (9) 
where 𝛾𝛾𝑞𝑞 is a vector of coefficient for class q.  
Latent class model can be estimated using maximum likelihood method, and 
the optimal number of classes can be selected based on AIC, BIC criteria.236 
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 A summary of the three models 
Under the framework of random utility model, various logit models are 
commonly used to analyze DCE data. The choice of model depends on the data 
characteristics. CLM which is the most basic model for DCE analysis was used to 
analyze the data, and the observed characteristics that influence choice probabilities 
were also identified. However, unobserved heterogeneity was not accounted for in 
CLM.  To account for unobserved heterogeneity or other sources of unobserved 
variability, MXL and LCM were used to obtain more accurate estimates, and make 
predictions. The difference in MXL and LCM lies in the assumption of underlying 
distribution. In MXL model, respondents were assumed to come from the same 
underlying distribution, whereas in LCM, there were distinct distributions of 
preferences, and preferences for each class were estimated.  
5.3.6.2 Variable specification and coding 
The commonly used coding approaches for attribute levels in DCE are linear, 
dummy, and effect codes. For attribute levels that are categorical, dummy and effect 
codes both allows the estimation for each attribute level separately. While dummy 
coding uses only 0 and 1, effect coding uses 0, 1, and -1. See Table 14 for the effect 
coding template. The advantage of effect coding is that none of the levels has a coding 
of all 0’s, as a result, none of the levels will be confounded with the grand mean (ie. the 




















Level 1  1    
Level 2 -1    
     
Level 1 1 0   
Level 2 0 1   
Level 3 -1 -1   
     
Level 1 1 0 0  
Level 2 0 1 0  
Level 3 0 0 1  
Level 4 -1 -1 -1  
     
Level 1 1 0 0 0 
Level 2 0 1 0 0 
Level 3 0 0 1 0 
Level 4 0 0 0 1 
Level 5 -1 -1 -1 -1 
 
 
Variable specification and coding used in analysis are shown in Table 15. Cost 
of test variable was assumed to be linear in utility function, for simplicity in willingness-
to-pay estimates. It was also treated as categorical variable and effect coded to 
explore the linearity of this cost variable. Risk of developing SJS and cost of gout 
treatment were effect coded, as they were not expected to be linear. Doctor’s 
recommendation was coded using two dummy variables, one indicating whether 
information on doctor’s recommendation was available in a choice set, the other 
indicating whether an alternative was recommended by doctor. Most common choice 
was coded in a similar way using two dummy variables. All socio-demographic 
variables were coded using dummy variables. For categorical socio-demographic 
variables with more than two categories, some categories were combined, and 




 Table 15. Variable specification and coding type 











Alternative specific attributes (Specific to each test alternative) 
Cost of test 0                                   





Risk of adverse side effect 0                                        
1 in 50,000                        
1 in 5,000  

















General/Context attributes (Specific to both test alternatives in a choice set) 
Doctor’s recommendation No information on doctor’s 
recommendation 
Doctor recommended 








Herd behavior No information on herd behavior 
Most common choice 








Table 16. Decision maker characteristics and coding 
Continuous variables 
Age=age in years 
Income, linear=Monthly household income (in $1,000)a 
Dummy variables 
Gender, female=1 if female 
Ethnicity, minority=1 if non-Chinese 
Gout, hadgout=1 if had a diagnosis of gout 
Hypertension, hypertension=1 if had hypertension 
Self-reported health, healthy=1 if health status is quite good or very good 
Housing type, housingbig=1 if HDB 5 room or private housing 
Education level, eduhigh=1 if JC/Poly or above  
Working status, working=1 if full-time/part-time/self-employed 
a Household income was measured as categorical, and linearized assuming the average income of each 





 5.3.6.3 Utility function 
There are four types of explanatory variables in the utility function: 1) 
alternative specific constant that accounts for the type of alternative (test involved vs. 
no test involved); 2) test feature attributes (cost of test, risk, cost of gout treatment) that 
vary across test alternatives; 3) context attributes (doctor’s recommendation, and 
information on the most common choice), which vary across different choice sets; and 
4) socio-demographic variables that may influence individual taste, and decision 
making process. The specification of these four types of variables in the utility function 
is as following. 
The test alternative and no test alternative each gives some intrinsic utility 
associated with these two types of alternatives. As only the difference in utility from 
various alternatives matters for a decision, the intrinsic utility associated with test 
alternatives is normalized to 0, and the intrinsic utility associated with no test 
alternative is represented by an alternative specific constant (𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴). Three attributes 
(cost of test, risk and cost of gout treatment) always have fixed levels in the no test 
alternative throughout the survey, and the effect of them will be accounted for by 𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴. 
There are several related assumptions. 1) The utility associated with the risk and costs 
of the no test option do not vary across choice sets, even though the contrast of risk 
and cost levels between testing options and no test option vary across choice sets. 
This is likely to hold, and is a common practice when including a fixed comparator 
(such as none option or status quo) in the choices sets. 2) Decision maker 
characteristics influence the testing decision by influencing the intrinsic utility 
associated with no test alternative, and therefore the tendency of an individual to 
choose no test alternative. The effect of socio-demographic variables is estimated as 
an interaction term with the dummy variable for no test alternative.  




 𝑈𝑈𝑛𝑛𝑃𝑃 𝑛𝑛𝑡𝑡𝑡𝑡𝑛𝑛 = 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴+𝑑𝑑𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽1 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ 𝑑𝑑𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽2 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ 𝑛𝑛𝑃𝑃𝑖𝑖𝑛𝑛𝑛𝑛𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽3 +
ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽4 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽5 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ 𝑛𝑛𝑃𝑃𝑖𝑖𝑛𝑛𝑛𝑛𝑃𝑃ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽6 + (𝑍𝑍 ∗ 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡)′𝛾𝛾 + 𝜀𝜀                (10) 
 
where 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 is a dummy variable for no test alternative, 𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴 being the alternative 
specific constant for no test, 𝑑𝑑𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐 is a dummy for being the doctor recommended 
alternative, and 𝑛𝑛𝑃𝑃𝑖𝑖𝑛𝑛𝑛𝑛𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐  is the dummy for having no information on doctor’s 
recommendation. herd is a dummy for being the most common choice, and noinforherd 
is a dummy if there is no information on the most common choice. Z represents 
decision maker characteristics. 𝛽𝛽1  𝑛𝑛𝑃𝑃 𝛽𝛽6 are the utility weights of corresponding 
attribute levels, and 𝛾𝛾 reflects the impact of decision maker characteristics on utility. 𝜀𝜀 
is the random error term. 
Utility of a test alternative 
Utility of a test alternative is specified as the following: 
𝑈𝑈𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 = 𝑐𝑐𝑃𝑃𝑡𝑡𝑛𝑛𝛽𝛽1 + 𝑃𝑃𝑖𝑖𝑡𝑡𝑟𝑟1𝛽𝛽2 + 𝑃𝑃𝑖𝑖𝑡𝑡𝑟𝑟2𝛽𝛽3 + 𝑃𝑃𝑖𝑖𝑡𝑡𝑟𝑟3𝛽𝛽4 + 𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑1𝛽𝛽5 + 𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑2𝛽𝛽6 +
𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑3𝛽𝛽7 + 𝑑𝑑𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽8 + ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽9 + 𝜀𝜀                (11) 
where cost, risk1, risk2, risk3, drug1, drug2, drug3, drrec, herd describe test 
characteristics as specified in Table 15, and 𝜀𝜀 is the random error term. 
Utility of any alternative is: 
Based on equation (10) (11), the general utility function used in estimation can 
be written as: 
𝑈𝑈 = 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡𝛽𝛽𝐴𝐴𝐴𝐴𝐴𝐴 + 𝑐𝑐𝑃𝑃𝑡𝑡𝑛𝑛𝛽𝛽1 + 𝑃𝑃𝑖𝑖𝑡𝑡𝑟𝑟1𝛽𝛽2 + 𝑃𝑃𝑖𝑖𝑡𝑡𝑟𝑟2𝛽𝛽3 + 𝑃𝑃𝑖𝑖𝑡𝑡𝑟𝑟3𝛽𝛽4 + 𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑1𝛽𝛽5 +
𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑2𝛽𝛽6 + 𝑑𝑑𝑃𝑃𝑑𝑑𝑑𝑑3𝛽𝛽7 + 𝑑𝑑𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽8 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ 𝑑𝑑𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽9 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ 𝑛𝑛𝑃𝑃𝑖𝑖𝑛𝑛𝑛𝑛𝑃𝑃𝑃𝑃𝑡𝑡𝑐𝑐𝛽𝛽10 +
ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽11 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽12 + 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡 ∗ 𝑛𝑛𝑃𝑃𝑖𝑖𝑛𝑛𝑛𝑛𝑃𝑃ℎ𝑡𝑡𝑃𝑃𝑑𝑑𝛽𝛽13 + (𝑍𝑍 ∗ 𝐷𝐷𝑛𝑛𝑛𝑛 𝑡𝑡𝑡𝑡𝑛𝑛𝑡𝑡)′𝛾𝛾 + 𝜀𝜀                (12)  
5.3.6.4 Model estimation  
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 Five models were used in the analyses: 
1) CLM1: Conditional logistic regression without control variables 
2) CLM2: Conditional logistic regression with control variables 
3) MXL1: Mixed logistic regression without control variables, and all 
attributes except test cost were set random 
4) MXL2: Mixed logistic regression with control variables, all attributes 
except test cost were set random 
5) LCM1: latent class model 
Conditional logit model, mixed logit model and latent class models were 
conducted using Stata version MP11, with and without controlling for decision maker 
characteristics.   
Conditional logit model was estimated using the clogit function. The user written 
mixlogit function was used to estimate the mixed logit model, with all attributes except 
cost of test specified as random. Cost of test is assumed to be fixed a priori, as is the 
common practice in mixed logit estimates 240,241. Specifying prices to be random will 
give rise to problems in willingness-to-pay estimation due to scale heterogeneity. 
mixlogit fits the model based on maximum simulated likelihood.242 Latent class model 
was fitted using the user-written commands lclogit and lclogitml. lclogit uses an 
expectation-maximization algorithm for estimation.243,244 Two latent classes were 
specified, and control variables that were significant in the conditional logit model were 
included in the fractional multinomial logit model of class membership. The optimal 
number of latent classes were determined based on the best model fit. The model with 
2 latent classes was found superior to the simpler one-class model according to the 
AIC and BIC goodness-of-fit statistics. Models with more than 2 latent classes failed to 
converge due to the high number of parameters to estimate relative to the sample size. 
5.3.6.5 Preference weights and attribute importance  
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 Coefficients of categorical variables from three regression models were plotted 
to illustrate the relative importance of attributes and attribute levels, or preference 
weights of each attribute level. Attribute levels with larger preference weights were 
preferred to those with smaller preference weights. A greater distance between the 
best and worst level of an attribute indicates higher importance of the attribute.  
5.3.6.6 WTP estimates 
As the primary motivation to take genetic test is to reduce the risk of developing 
SJS, an indicator of interest is the willingness-to-pay for various levels of risk reduction. 
Assuming the cost of test to be linear, willingness-to-pay for risk reduction (K2 to K1) 
can be calculated using the following formula: 
𝑊𝑊𝑊𝑊𝑃𝑃 = − (𝛽𝛽𝐾𝐾1 − 𝛽𝛽𝐾𝐾2)
𝛽𝛽𝑐𝑐𝑛𝑛𝑛𝑛𝑡𝑡
 
where 𝛽𝛽𝑐𝑐𝑛𝑛𝑛𝑛𝑡𝑡 is the coefficient of test cost attribute, 𝛽𝛽𝐾𝐾1 and 𝛽𝛽𝐾𝐾2 are the coefficient of risk 
level K1 and K2.  
The marginal willingness-to-pay for an alternative when it is doctor 
recommended was calculated as: 
 




Where 𝛽𝛽𝐾𝐾 is the coefficient of the attribute level “doctor recommended”. 
Similarly, the marginal willingness-to-pay for an alternative when it is the most 
common choice was calculated.  
5.3.6.7 Uptake rate prediction 
At the system level, uptake rate can help to visualize the effect of policies or 
changes in test features. Hypothetical choice sets with one test alternative and one no 
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 test alternative was constructed, and the uptake rate of the test was predicted for 
different scenarios.  
Using utility weights estimated from the models, utility scores associated with 
different alternatives can be calculated from the utility function, which can be used to 
predict the uptake probability for any hypothetical test and scenarios. For instance, in a 
hypothetical choice set with a test alternative (T) and a no test alternative (N), the 
uptake probability of the test alternative is  
𝑃𝑃(𝑊𝑊) = exp (𝑉𝑉(𝑊𝑊))exp�𝑉𝑉(𝑊𝑊)� + exp (𝑉𝑉(𝑁𝑁)) 
5.4 Results 
5.4.1 Sample characteristics 
A total of 205 Singaporean diabetes patients were recruited, among whom 199 
completed the survey questionnaire. 10 respondents were excluded from analysis due 
to prior long-term gout treatment with allopurinol. 189 respondents were included in the 
final analysis. Respondents’ characteristics are summarized in Table 17. The average 
age was 57.1 years (95% CI: 55.3 to 59.0). Respondent were mostly male (65.6%), 
Chinese (61.4%), and currently working (55%). 35.4% had completed Junior College 
(JC)/diploma or university education, and 51.9% stayed in HDB 5 room or private 
properties. A small percentage (5.8%) of respondents had gout or hyperuricemia, but 
did not receive urate-lowering therapy.  A significant percentage of respondents had 




 Table 17. Characteristics of 189 respondents 
Variables N (%) 
Age 57  
Male 124 (66%) 
Had Gout or hyperuricemia 11 (6%) 
Ethnicity  
 Chinese 116 (61%) 
 Malay 19 (10%) 
 Indian 50 (27) 
 Other 4 (2%) 
Hypertension 111 (59%) 
Highest education attained  
 No formal education 3 (2%) 
 Primary 22 (12%) 
 Secondary 97 (51%) 
 JC/polytechnic/diploma 36 (19%) 
 University and above 31 (16%) 
Housing type  
 HDB (1-2 room) 19 (10%) 
 HDB (3 room) 23 (12%) 
 HDB (4 room) 48 (25%) 
 HDB (5 room and above) 58 (31%) 
 Condominium/Private flat 20 (11%) 
 Bungalow/semi-detached/terrace house 20 (11%) 
Self-rated health status  
 Very good 6 (3%) 
 Quite good 75 (30%) 
 Neither good nor poor 77 (41%) 
 Quite poor 29 (15%) 
 Very poor 2 (1%) 
Experiences of severe adverse drug reaction  26 (14%) 
Employment status  
 Full-time employed 91 (48%) 
 Part-time employed 13 (7%) 
 Self-employed 12 (6%) 
 Homemaker 7 (4%) 
 Retired 55 (29%) 
 Unemployed 11 (6%) 
Household income  
 S$0-1,500 34 (18%) 
 S$1,500-3,000 50 (27%) 
 S$3,000-5,000 30 (16%) 
 S$5,000-8,000 25 (14%) 
 S$8,000-10,000 18 (10%) 




 5.4.2 Analysis of warm-up questions 
Attitudes towards SJS risk, cost of test, and cost of long-term gout treatment 
When the risk of developing severe adverse drug reaction was fixed at 1 in 500 
(0.2%), 55% of respondents felt at risk, and the rest were not worried about it. If a 
hypothetical test could reduce risk of SJS, but cost S$400, 52% of respondents 
expressed willingness to take the test (definitely would or probably would). When told 
that the long-term gout treatment cost for positive test result (2 in 10 chance) was 
S$2,000 in two years, 57% of respondents expressed willingness to take the test and 
receive test-guided treatment (definitely would or probably would). 
Attitudes towards doctor’s recommendation and most common choice 
Most respondents reported doctor’s recommendation to be influential on their 
decision making. 51 % of respondents definitely would consider doctor’s 
recommendation, and 33% probably would consider. On the other hand, 15% of 
respondents probably or definitely would not consider doctor’s recommendation, and 
preferred to make independent decisions. 49 % of respondents considered information 
on the most common choice to be influential on their decision, whereas 51% of 
respondents would not consider this piece of information. 
5.4.3 Validity test  
In the first validity test, 89.4% of respondent managed to identify that “1 out 500 
patients gets the severe side effect” indicated higher risk than “1 out of 1,000 patients 
gets the severe side effect” at the first attempt, and another 6.9% answered it correctly 
in the second attempt, both of which were considered to have good understanding of 
probabilities. In the second validity test, which was a “dominant-pair” test DCE 
question, 13.2% preferred the higher risk test alternative in the first attempt, but 
corrected the answer in the second attempt. Another 2.1% of respondents indicated 
preference for the higher risk test alternative more than once, indicating confusion or 
lack of understanding of the probability or the DCE question.  
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 Failure of validity tests was defined as giving the wrong answer more than once 
in both validity test questions, and 0.5% of respondents failed the validity tests. These 
respondents were not excluded from final analysis because 1) excluding these 
respondents did not significantly change the regression results; and 2) respondents 
who failed initially may understand questions correctly in later parts of DCE, as they 
learned more about the survey questions. 
5.4.4 Non-demanders for genetic testing 
Non-demanders refer to those respondents who prefer not to receive test 
services when offered, regardless of attribute levels.213 Among 189 respondents, 16 
(9%) chose the no test alternative in all choice sets, referred to as non-demanders. 
Note that no test always resulted in lowest costs; therefore these non-demanders may 
have strong preferences for low cost, or for the no test label. 91 (48%) respondents 
chose no test in at least one choice sets. Out of 1,512 choice observations (8 from 
each respondent), no test was preferred in 317 (21%) observations, On the other hand, 
98 (52%) never preferred the no test alternative.  
Logistic regression analyses showed that respondents of older age were more 
likely to always prefer no test, whereas being non-Chinese ethnicity, with JC/poly or 
above education, currently working were less likely to be non-demanders for genetic 
test (p<0.05 for all factors mentioned above). 
5.4.5 Dominant Preferences 
22 (12%) respondents were dominant on the risk of developing SJS, and 
always preferred the alternative with lower risk of SJS, regardless of costs, doctor’s 
recommendation or most common choice. Those experienced serious adverse drug 
reactions, with JC/poly or above education, were more likely to dominant on the risk of 
getting SJS (p<0.1 for all factors mentioned above). Dominance on costs is not 
discussed here, as it cannot be disentangled from the preference for no test label.  
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 21 (11%) of respondents were dominant on doctor’s recommendation, and 
always chose the doctor recommended alternative when information was available.  
Malay or Indian ethnicity was a predictor of this dominance preference (p<0.05). In 
contrast, only 3 (2%) of respondents were dominant on most common choice, and 
always chose the alternative that was labeled the most common choice.  
Both non-demanders and dominant preferences deviate from standard 
assumption that individual make tradeoffs between different attributes in discrete 
choice experiments. The non-tradeoff may confound the estimated preference weights 
estimates. However, the percentage of non-demanders and dominant preferences was 
relatively low in the sample (34% in total), and was therefore not a major concern. 
5.4.6 Results from logit models 
5.4.6.1 Model fits 
Table 18 compares the goodness-of-fit of different logit models. MXL and LCM 
models which allow for unobserved preference heterogeneity, significantly improved 
the fit compared to CLM, as indicated by the increase in log-likelihood, and decrease in 
AIC and BIC. Controlling for decision maker characteristics in both CLM and MXL 
improved the fit of models, even though more parameters need to be estimated.  
However these metrics cannot be used to compare MXL and LCM, as the models were 





Table 18. Goodness-of-fit of models 
 CLM1 CLM2 MXL1 MXL2 LCM 
Model Type 





- Controlled - Controlled Controlled 
Log-likelihood -1391 -1307 -1035 -1002 -1144 
Pseudo R2  a 0.16 0.21 - - - 
AICb 2811 2662 2124 2073 2360 
BICc 2901 2816 2297 2291 2592 
aPseudo R2 is defined as 1-LL/LL0, where LL is the simulated log-likelihood function evaluated at the 
estimated parameters, while LL0 is the value of a log-likelihood function for a base model that only contains 
a non-random alternative-specific constant. 
bAIC=-2(LL-M) where M is the number of parameters 




5.4.6.2 Model estimates from CLM and MXL models 
Estimates from CLM, MXL, and LCM are shown in Table 19. Note that the 
estimates from different models are not directly comparable due to scale 
differences52.166,236 In MXL, the estimates are normalized relative to the extreme value 
part of the error term, which is the net of the error components introduced by the 
random coefficients. In CLM, the error term captures both sources of error, and 
therefore it will have a larger variance. Therefore estimates from CLM are expected to 
be smaller than those in MXL, which is consistent with our observation that in Table 19, 
coefficients from MXL are larger in magnitude than CLM coefficients. Nevertheless, 






 Table 19. Estimates from CLM and MXL models 
 
Conditional logit  Mixed logit, all coefficients random except cost of test 
  CLM1  CLM2  MXL1  MXL2 
  Mean  Mean  Mean SD  Mean SD 
ALSnotest -0.70**   0.50   -2.77** 4.88**   -0.75 4.79** 
                    
Cost of test (in $1,000) -0.46**   -0.49**   -0.83**     -0.90**   
                    
Risk of SJS: 1 in one million 0.45**   0.47**   0.77** 1.19**   0.87** 1.24** 
Risk of SJS: 1 in 5,000 0.23**   0.23**   0.35** 0.19   0.31** 0.13 
Risk of SJS: 1 in 1,000 -0.15*   -0.16*   -0.22* 0.12   -0.21** 0.12 
Risk of SJS: 1 in 600 -0.54**   -0.55**   -0.90** 1.26**   -0.97** 1.26** 
                   
Cost of treatment: $250 0.37**   0.38**   0.68** 0.72**   0.75** 0.69** 
Cost of treatment: $400 0.41**   0.43**   0.65** 0.58**   0.55** 0.82** 
Cost of treatment: $1,500 -0.03   -0.04   -0.11 0.07   -0.08 0.04 
Cost of treatment: $4,000 -0.75**   -0.76**   -1.22** 1.23**   -1.22** 1.47** 
                   
Doctor recommended 0.80**   0.81**   1.23** 1.6**   1.3** 1.53** 
Doctor recommended*notest -0.04   0.12   0.99* 1.22*   1.37** 1.83** 
No recommendation available  0.09   0.09**   0.22 0.18   0.39 0.14 
                    
Most common choice 0.31**   0.30**   0.52** 0.56**   0.50** 0.74** 
Most common choice * notest -0.16   -0.09   0.45 0.36   0.70 0.38 
No Most common choice info 
available 0.14   0.14   -0.09 0.04   -0.06 0.12 
                    
Control variables * no test                    
Female gender     0.07             
Age     0.00             
Ethnic minority     -0.82**         -0.46   
Big housing     -0.50**         -3.59**   
High education level     -0.66**         -0.67   
Household income (in 
$1,000)     0.04*         0.23**   
Currently working     -1.32**         -3.98**   
Had diagnosis of gout     0.62*         1.24   
Had severe ADRs     -0.76**         -1.24*   
Self-reported to be healthy     0.02             










 Intrinsic preferences for no test 
The negative alternative-specific intercept ALSnotest in Model CLM1 and MXL1 implies 
that no test resulted in disutility, and patients had intrinsic preferences for taking a test to 
reduce risk of severe adverse drug reactions. However, there is considerable heterogeneity 
in the preference for no test in the sample, evidenced by the significance and big magnitude 
of standard deviation estimate in mixed logit model MXL1. ALSnotest from model CLM2 and 
MXL2 cannot be interpreted alone, as all decision maker characteristics were estimated as 
interaction terms with no test alternative, and assumed to influence the utility individuals 
derived from the no test alternative. Model MXL2 shows that respondents staying in big or 
private housing, currently working, or had experienced severe ADRs had higher disutility 
from no test, and therefore are more likely to take the genetic test. Unexpectedly, 
respondents with higher household income were more likely to choose no test. Yet this 
finding could be confounded by housing type and working status. 
Preferences towards test features 
Consistent with hypotheses, respondents were more likely to test when the test cost 
was lower, when the test-guided treatment results in lower risk of developing SJS, and when 
long-term gout treatment cost was lower. SD estimates from MXL models revealed 
significant diversity in the way people value these attribute levels.  
The effect of information on doctor’s recommendation and most common choice 
Doctor’s recommendation on a test alternative significantly improved the likelihood of 
that alternative being chosen. Interestingly, the interaction term of doctor’s recommendation 
with no test alternative was significant and had a positive sign, suggesting that when the no 
test alternative was recommended by doctor, the increase in likelihood of it being chosen 
was even more than when a test alternative was recommended. The significance of 
standard deviation estimates suggested considerable individual differences in the valuing of 
doctor’s recommendation in the sample. On the other hand, as expected, when no 
recommendation was available, there was no impact on respondents’ choices.  
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 Information on the most common choice also had positive impact on the likelihood of 
an alternative being chosen, even though the effect was much smaller than that of doctor’s 
recommendation. The effect did not seem to be different for test and no test alternatives. 
Significant individual heterogeneity was evidenced by the big standard deviation estimates. 
5.4.6.3 Attribute importance based on MXL model 
The relative importance of various attributes can be inferred from the estimated 
coefficients. For dummy attributes, larger magnitude of the coefficient indicates the 
importance of the attribute. ALSnotest was largest in magnitude among all coefficients, 
suggesting respondents had very strong preferences to avoid no test alternative in general. 
Doctor’s recommendation also had big coefficient, suggesting it was very influential on 
respondents’ preferences. On the other hand, information on most common choice was less 
influential. For effect-coded attributes, a greater difference between coefficients of the best 
and worst level of attribute indicates a greater significance of that attribute in influencing 
decisions, within the range provided in this study. To compare the relative importance of 
three test feature attributes, another mixed logit model (referred to as MXL1c) which is a 
modification of model MXL1 in which the cost of test was also specified as categorical. The 
preference weights of three test feature attributes were plotted in Figure 12 to better 
compare the relative importance of these attributes. From Figure 12, long-term gout 
treatment cost and the risk of developing SJS in test-guided treatment were more important 
than the cost of test. Respondents were not sensitive about the cost of test within the range 
of $200 to $400. Similarly, respondents were not sensitive to the drug cost for test positive 
individuals as long as it was lower than $400. However when the cost was increased to 
$4,000 in two years, it significantly discouraged testing. The four risk levels are well 
segregated, and resulted in a wide range of preference weights, indicating respondents were 
risk-conscious. A 1 in 1 million chance of developing SJS in test-guided treatment (ie. a very 
accurate test) results in the highest probability of test uptake, increase in risk (due to 





Figure 12. Preference weights of various test feature attributes. Error bars 
indicate 95% confidence intervals. 
 
The linearity of test cost attribute was also explored using estimates from mixed logit 
model MXL1c. As shown in Figure 13, preference weights were roughly linear in test cost, 
though not perfect.  
 
 





























Cost of test (S$)
Figure 13. Preference weights for cost of test. 
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 Latent class model with 2 classes are shown in Table 20. The optimal number of 
classes was selected based on AIC BIC criteria. The 3-class model failed to converge, likely 
because the sample size did not have sufficient power for 3 classes.  
 
Table 20. Estimates from CLM and MXL models 
 Latent class 1  Latent class 2 
(cost conscious) 
37% 
 (risk averse) 
63% 
ALSnotest 1.04**  -4.95** 
     
Cost of test (in $1,000) -1.26**  -0.37** 
     
Risk of SJS: 1 in one million -0.29  0.75** 
Risk of SJS: 1 in 5,000 0.09  0.24** 
Risk of SJS: 1 in 1,000 0.03  -0.22** 
Risk of SJS: 1 in 600 0.17  -0.77** 
    
Cost of treatment: $250 0.26  0.44** 
Cost of treatment: $400 0.67**  0.46** 
Cost of treatment: $1,500 -0.13  -0.10 
Cost of treatment: $4,000 -0.79**  -0.80** 
     
Doctor recommended 1.30**  0.69** 
Doctor recommended*notest 0.07  1.01 
No recommendation available 0.18  0.50 
     
Most common choice 0.81**  0.28** 
Most common choice * notest -1.02*  2.21** 
No Most common choice info available -0.47  0.18 
** p<0.01, *p<0.05 
 
The two classes generated from the latent class model are named as “risk averse” 
class, and “cost conscious” class based on their preference weights for different attributes 
(Figure 14 and Table 20). 37% of respondents fall in the “cost conscious” class, whereas the 
rest 63% belong to the “risk averse” class. The “risk averse” class has a big negative 
ALSnotest, indicating the disutility results from not testing. The range of preference weights for 
risk of SJS is wider than that of test cost, implying that this group is more concerned about 
the risk of developing SJS, and cost has relatively small impact. On the contrary, the “cost 
conscious” class had a wide range of preference weights for cost of test, implying their 
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 decision is sensitive to test cost. Though no test gave disutility, the magnitude of disutility is 
moderate. In this class, none of the risk levels turned out to be significant, implying that this 
class was more averse to high cost than risk of developing SJS. Both groups considered 
cost of long-term gout treatment important, and high treatment cost reduces the probability 
of test in both classes. Doctor’s recommendation and most common choice affect both 
classes of respondents. 
 
 
Figure 14. Preference weights in latent class model 
 
The association of class membership and individual characteristics are shown in 
Table 21. Most factors did not appear to determine class membership, except that 
























Table 21. Class membership and individual characteristics 
 Coefficient P value 
Stay in big housing -0.36 0.30 
Ethnic minority -0.28 0.43 
Severe ADR -0.36 0.46 
Currently working -0.65 0.06 
High education level -0.55 0.16 
Monthly household income 0.02 0.66 
Had diagnosis of gout 0.74 0.26 
 
5.4.6.5 WTP estimates from MXL and LCM models 
Though coefficients from different models are not directly comparable, the 
willingness-to-pay estimates are.  The willingness-to-pay for various attribute level 
improvements is listed in Table 22.  
The current HLA-B*5801 test can reduce the risk of developing SJS from 1 out of 500 
to below 1 out of 1 million. MXL model predicts that on average, respondents were willing to 
pay close to $2,000 more to do this genetic test compared to a test that can only reduce the 
risk to 1 in 600. The presence of information on doctor’s recommendation and most common 
choice influenced individual’s willingness-to-pay for genetic test. When a test was 
recommended by the doctor, on average respondents were willing to pay S$1,474 more for 
the test (95% CI: 817, 2,131), compared to when the test was not the doctor recommended 
option. Similarly, when a test was labeled the most common choice, respondents were 
willing to pay S$623 more for the test (95% CI: 249, 997), compare to when it was not the 
most common choice.  
 Estimates from LCM shows distinct preferences across the two classes. In class 1 
(cost-conscious class), the WTP for risk reduction was negative and statistically not 
significant (from zero). In class 2 (risk-averse class), on average, respondents would be 
willing to pay S$1,215 to reduce the risk of developing SJS to 1 out of a million from 1 out of 
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 500. Both classes had high WTP for testing when test was recommended by doctor 
(S$1,032 and S$548 for class 1 and class 2), or if it is the most common choice (S$647 and 
S$219 for class 1 and class 2).  Class1 had higher WTP than class 2, indicating the 
information was more influential among class1 members. WTP estimates from LCM are 
lower than in MXL, especially in the cost-conscious class. Considering the non-demanders 












Table 22. Willingness-to-pay for attribute improvements (in S$) 
 WTP (95%CI) 
MXL1 CLM- cost conscious 
class 
CLM- risk averse 
class 
Risk reduction 1 out of 600  1 out of 1,000 818 (351, 1284) -109 (-491,274)NS 438 (161, 716) 
1 out of 600  1 out of 5,000 1,504 (835, 2173) -62 (-406, 280)NS 809 (415, 1,202) 






Not the recommendedDoctor 
recommended 
1,474 (817, 2,131) 1,032 (535, 1,530) 548 (265, 830) 
Not the most common 
choicemost common choice 
623 (249, 997) 647 (211, 1,081) 219 (34, 405) 











 5.4.6.1 Test uptake rate estimates from MXL and LCM models 
The uptake rate was forecasted for eight clinically relevant or policy relevant 
scenarios. This provides insights on the impact of various policies or clinical practices on 
uptake rate. When only one test alternative and one no test alternative was offered, the 
predicted uptake rates were shown in Table 23.  
The uptake rate predicted from mixed logit model are high in all scenarios, and the 
change in uptake rate across different scenarios were small.  The overall uptake rate 
predicted by latent class model are lower than that predicted by mixed logit model in all 
scenarios. Given the non-demander behaviors observed, the uptake rate predicted by latent 
class model may be more realistic. The uptake rate in class 2 were above 95% in all 
scenarios, and the changes in uptake were small when test features or information changed; 
whereas in class 1, uptake rate differed significantly across scenarios. When the long-term 
cost of gout treatment was reduced from $4,000 to $400, uptake rate was significantly 
increased in class 1 (29.4% vs 8.8%, p=0.0001), suggesting that the use of cheaper generic 
drugs for those who test positive can significantly increase the uptake of the test. On the 
other hand, when the cost of test was subsidized by 75%, the uptake rate improved, but the 
effect was small (12.3% vs 8.8%, p=0.0162). For patients who are more cost-conscious, one 
alternative may be a less accurate but cheaper test. When available, the cheaper alternative 
is more preferred by class 1 (16.2% vs 8.8%,p=0.0409). Compared to the small effect of cost 
strategies on test uptake, information strategies had bigger impacts on the uptake rate in 
class 1. When the current test is recommended by doctor, the predicted uptake rate 
increases to 29.7% from 8.8% (p<0.0001). When the current test is the most common 
choice, the uptake rate was predicted to increase by 3%. When the test was recommended 
by doctor and was the most common choice, the uptake rate was 37.3%, suggesting a 
synergistic effect of the information. When the test is recommended by the doctor, but the 
most common choice is not to test, the uptake is still higher than without information (24.5% 
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 vs 8.8%, p=0.0157), suggesting the impact of doctor’s recommendation is much bigger than 















Table 23. Test uptake rate in various hypothetical scenarios 
Hypothetical scenarios 































test is doctor 
recommended 





test, but test is not 




Chance of getting 
the severe side 
effect (with test-
guided treatment) 
1 out of 1 
million 
patients 
1 out of 1 
million 
patients 
1 out of 1 
million 
patients 
1 out of 
1,000 
patients 
1 out of 1 
million patients 
1 out of 1 
million 
patients 
1 out of 1 million 
patients 
1 out of 1 million 
patients 
Cost of one-test 
genetic test S$400 S$400 S$100 S$100 S$400 S$400 S$400 S$400 
Cost of gout 
medicines (over 2 
years) 


























Test uptake rate 
(MXL estimates) 86.4% 97.6% 89.1% 75.3% 96.4% 90.7% 97.7% 90.4% 
Test uptake rate 
(LCM overall 
estimates)a 
65.10% 73.49% 66.52% 66.46% 73.60% 66.62% 76.55% 68.84% 
Test uptake rate 
(LCM class 1 
estimates) 
8.8% 29.4% 12.3% 16.2% 29.7% 11.9% 37.3% 24.5% 
Test uptake rate 
(LCM class 2 
estimates) 
98.3% 99.5% 98.5% 96.1% 99.5% 98.9% 99.7% 95.0% 
aOverall test uptake rate was calculated as uptake in class1 * class 1 share+ uptake in class2 * class 2 share 
 
 
 5.5 Discussions 
5.5.1 Patients’ attitude towards pharmacogenetic testing to reduce 
risk of severe ADR 
This is the first study to use a discrete choice experiment to quantify patients’ 
preferences for using pharmacogenetic testing to reduce severe ADRs. Our study 
revealed that the majority of patients were willing to adopt risk-mitigation strategies 
such as genetic testing. Our uptake rate prediction shows that given the current 
available test and treatment (test cost=S$400, SJS risk=1 out of 1 million, gout 
treatment cost=S$4,000 in two years, no information on doctor’s recommendation and 
most common choice), 65% of the eligible patients were willing to test and receive test-
guided treatment (Table 16). When attribute levels were varied to form hypothetical 
tests, 92% of respondents preferred test to no test in at least one of the 8 scenarios 
offered. 52% always preferred testing to no testing in all 8 scenarios.  
In the research and development of diagnostic tools, test sensitivity, specificity, 
false negative, false positive are the most important features researchers consider. 
Clinicians and researchers are usually concerned about high false negative or false 
positive rates, as these false results may lead to inadequate or redundant treatment, 
both may have adverse consequences. The current available HLA-B*5801 test can 
reduces risk to below one in one million, however, it has high false positive rate, 
specifically, 20% of patients may test positive and require more expensive gout 
treatment, when in fact over 95% of test positive patients would not develop SJS even 
if taking allopurinol. Cost-effectiveness analysis showed that the extra cost due to the 
high false negative rate of test compromised the test to be non-cost-effective at the 
population level. However, we showed here, 65% of all respondents are willing to take 
the test to reduce risk of severe ADR, even though high cost may be incurred.  
In fact, qualitative remarks from patients showed that the genetic test might 
have positive “value of information”, regardless of test results. A positive test results 
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 may help to reduce the risk of SJS, whereas a negative result gives the confidence and 
assurance that the patient will not develop SJS. Patients may take the test for the 
peace of mind, and derive utility from both positive and negative test results. The same 
may be true for physicians. Allopurinol ADR has led some physicians to reduce 
allopurinol prescription and switch to the safer but more expensive new drug 
febuxostat. Genetic testing may lead to more confident use of allopurinol, which may 
result in cost-saving for the health system. 
5.5.2 Tradeoffs between test features and heterogeneity in 
preferences 
     Advancement of technologies may alter test characteristics in the near 
future. For instance, advancement in genetic testing technology may improve the 
accuracy and predictive power of testing, while reducing the testing cost. Low cost 
alternative risk mitigation strategies may be developed. The cost of long-term gout 
treatment may be lower when the drug patent expires. It is useful to understand how 
potential changes influence patients’ testing decisions. We investigated the tradeoffs 
patients made between various test features (cost of test, cost of long-term gout 
treatment, and the SJS risk associated with test-guided treatment), estimated the 
willingness-to-pay for risk reduction, and predicted the stated uptake rate.  
Latent class analyses revealed two distinct classes of decision makers that 
assign different preference weights to various features. One class considered cost of 
test and long-term treatment more important than the level of risk, so this class was 
described as the cost-conscious class. The other class had high preference weights for 
risk level, and relatively small weights for the cost of test. This class was named the 
risk-averse class. Consistently, the risk averse class derived disutility from no test, and 
therefore more likely to test, whereas the cost-conscious class derive positive utility 
from no test, likely due to the fact that no test incurs the lowest costs in the short term 
and in the long term. As expected, the risk averse class has higher uptake rate than 
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 the cost-conscious class, when offered the same test (98% vs 65%, p<0.01). The 
uptake rate and willingness to pay among risk averse patients depends heavily on risk 
level. Contrarily, no significance was detected for the cost-conscious group. These 
implies that the risk averse class are willing to take a more expensive test that is more 
accurate, and the cost conscious class may be willing to adopt a cheaper and less 
accurate risk mitigation strategy. A feasible alternative strategy to genetic testing is a 
safety monitoring program that aims to identify early signs of SJS and reduce the 
severity and mortality associated with SJS. This cheaper alternative strategy is more 
preferred to testing among the cost conscious group. Interestingly, the class 
membership was not significantly correlated with socio-demographic factors, 
suggesting the belief may not be determined by their ability to pay. 
    The long-term treatment cost attribute has an uncertainty component as 
treatment is selected based on test results. To shed some lights on individual’s 
interpretation about this attribute, the estimated willingness-to-pay was compared to 
the expected value of treatment cost. When the treatment cost for test positive 
individuals was reduced from S$4,000 to S$400, the expected payment decreased 
from by $720 (from $960 to $240). However, WTP analysis shows that in both classes, 
the WTP in one-time test cost increased more than the decrease in expected value 
($1,166, and $3,380 respectively for the two classes). This implies respondents do not 
do expected value calculation. Rather, they were willing to pay extra to avoid the risk of 
extremely high cost. Even though each individual has a small chance (20%) of 
requiring the expensive treatment, a high long-term treatment cost significantly 
discourages testing.  
5.5.3 Impact of doctor and herd  
Genetic testing decision in real clinical settings not only depends on the 
features of testing. The choice context in which the test options are offered, and the 
way testing information is delivered also matters. We found physician recommendation 
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 to be very important in decision making. 8% of respondents always preferred the 
doctor recommended option, even when the recommended option had high risk, or 
was expensive. This is consistent with other studies that found strong impact of 
doctor’s recommendation on patient choices.166,182-187 Random information on doctor’s 
recommendation appears to be influential in both cost-conscious class and risk-averse 
class. When a test was recommended by doctor, respondents were willing to pay more 
for the test compared to when the test was not recommended. This suggests 
respondents infer about the quality and value of test based on doctor’s 
recommendation. The uptake rate prediction showed consistent results. Doctor’s 
recommendation appeared to be more influential on ethnic minorities. Compare to 
doctor’s recommendation, herd behavior had smaller impact on patients’ testing 
decisions. Our findings confirmed the presence of herd behavior in patients’ genetic 
testing decisions, even though small in magnitude. Our findings are consistent with the 
limited literature in medical decision making. In an online survey on women’s breast 
cancer treatment choices, when information on social norm suggested chemotherapy 
to be popular, women showed higher interest in chemotherapy.245  Hall et al. found 
small but significant impact of information that “80% of people like you have been 
tested for Tay Sachs Disease (TSD)” on the stated uptake of TSD screening test.166 
Yang et al. studied prescription of antipsychotic drugs by physicians, and found that 
the prescription could be influenced by their colleagues in the same hospital. Though 
the peer effect was small, it was more influential on the prescription of new drugs.204 
To many patients, recommendation by physicians or being the most common 
choice indicates the quality of a treatment option.195 Following doctor’s 
recommendation or the most common choice may therefore be a decision heuristics 
that allows easy and fast decision making.193,194 Some decision making theories 
suggests the objective of decision making is not to maximize utility, but to simplify 
decision making.169,246 Though these decision heuristics may deviate from the “rational” 
decision making pathway based on logic and calculation, some empirical findings and 
139 
 
 economic theories have recognized the ecological rationality and advantage of 
decision heuristics.193-195 For instance, Banerjee argues that in a sequential decision 
model, it is rational for decision makers to look at the decisions made by the previous 
decision makers, as other decision makers may have information that is important. 
Furthermore, he demonstrated that the optimizing strategy is to do what other people 
do, rather than using their information.195 
5.5.4 Implication on genetic testing practices and policies in 
Singapore 
This study provides timely information for various stakeholders such as test 
providers, physicians, and regulators. We observed a demand for routine screening in 
primary care and hospital settings. Alternative risk-mitigation tools that are cheaper but 
less accurate (such as a less accurate test or a safety monitoring program) may also 
be desirable to some patients. Our study also highlighted three important aspects of 
physician practices regarding genetic testing. First, information on ADR risk and 
genetic tests is perceived important by patients, so it’s desirable for doctors to educate 
and effectively communicate with patients on ADR risk, potential risk-mitigation 
strategies, as well as cost and long-term consequences of genetic testing. Secondly, 
doctor’s opinion and recommendation play a very important role in shaping patient’s 
decision. So it is important for doctors to consider patient preferences, and recognize 
the heterogeneity in patients preferences when making recommendations, in addition 
to professional judgment of the risk and benefit profile. Third, some patients had 
preferences for cheaper long-term gout treatment, and are willing to bear with higher 
risk of SJS for lower treatment cost, which implies bypassing allopurinol and switching 
to febuxostat for risk considerations may not be desirable. From the regulator 
perspective, the value of genetic test was recognized by patients, however, a mandate 
is not justifiable as a significant proportion of patients prefer not to test, and the test 
cost is currently paid out of pocket. Subsidizing may be a feasible way to improve 
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 uptake, however a group of price elastic individuals should be targeted, instead of the 
whole population. Cost-effectiveness and equity are also important considerations 
when determining subsidies.  
5.5.5 Implication on health promotion strategies in Singapore 
Various types of policy tools are commonly used for health promotion, including 
education campaigns and information provision, making guidelines and mandates, and 
financial incentives. Evaluating policy impact in real life settings require considerable 
effort and resources, and may be subject to confounding. A comparison of various 
policy tools in the same setting is even more difficult. Moreover, it is desirable to have 
information on the policy effects ex ante. This study demonstrates a feasible and less 
resource demanding way to evaluate and compare various policy effects. Moreover, 
the latent class analysis suggests there may not be a one size fits all policy strategy. 
Different subgroups may require different policy solutions to achieve the most impact. It 
is therefore important to understand heterogeneity in target population behaviors and 
preferences before designing and implementing a health promotion policy. 
Providing detailed information on the benefits and costs of genetic testing in 
comparison to no test result in significant rate of stated test uptake compared to no 
detailed information. This suggests that for services individuals are not familiar with, 
information provision may increase uptake.  
Based on stated preferences in this study, providing information on physician’s 
recommendation is likely to be an effective and low-cost health promotion strategy. 
Efforts to alter physician behaviors such as recommendation by regulators or clinical 
practice guideline may achieve even stronger effects, as the physical presence of 
physician to deliver the recommendation achieves extra persuasive power than 
information on physician’s recommendation. Providing information on the most 
common practice may nudge individuals towards following the herd. Even though less 
effective than physician’s recommendation, it is a low-cost information strategy. Both 
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 types of information strategies appeared to influence most individuals. In our study, 
providing information on doctor’s recommendation and herd behavior increased the 
stated uptake rate more than a 75% price subsidy, suggesting behavior economics 
strategies may be more effective and less costly than financial strategies, and deserve 
more consideration in health promotion policies.  
In contrast, financial incentives may not have intended effectiveness, especially 
among price-inelastic individuals. In our study, 62.9% of respondents are classified as 
risk averse, among which the test uptake rate was over 95% even without financial 
incentives. Additional subsidies in test cost did not significantly increase the uptake. On 
the other hand, 37.1% of respondents were cost-conscious, and a 75% subsidy on test 
cost would increase the uptake from 8.8% to 12.3%, whereas a 90% decrease in long-
term gout treatment cost would improve uptake to 29.4%. Comparing the magnitude of 
effects, financial incentives were not as effective as physician’s recommendation.  
5.5.6 Comparing econometric models for DCE data 
When comparing econometric models for choice analysis, different domains 
need to be considered. Statistical measures of model fit, such as likelihood ratio, 
pseudo R2 are useful, but these values cannot be used to compare MXL and LCM 
models if the two models are not nested.236 The estimates from different models are 
not directly comparable due to scale differences, but behavioral outputs such as WTP 
estimates and choice probability prediction (stated uptake rate) are useful indicators of 
model appropriateness, as some information or prior knowledge on behaviors are 
available.  
All evidence suggests heterogeneity in preferences for genetic testing services. 
In analysis of non-demanders, 8.5% of respondents always preferred not to test. On 
the contrary, 51.85% always preferred to test. These groups were making different 
tradeoffs. MXL model shows the estimates had big standard deviation, suggestion 
large variations across individuals. A latent class analysis identified two classes with 
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 distinct choice patterns and preferences weights. Based on the findings, among the 
three models used, those account for heterogeneity are more appropriate than CLM.  
Mixed logit models allow parameters to be random and follow a continuous 
distribution, and provide information on the population average parameter. Latent class 
models accounts for heterogeneity by allowing parameters to follow discrete 
distributions.  Both models provide insights on preferences heterogeneity. When 
predicting the uptake rate, LCM appeared to give more reasonable predictions than 
MXL. MXL predicts higher uptake rates (ranges from 75.3% to 97.7%) than LCM 
(ranges from 65.1% to 73.6%) for all scenarios. Analysis of non-demanders showed 
that 8.5% of respondents always preferred not to test in all DCE questions, regardless 
of attribute levels. Analyses of warm-up questions also revealed the proportion of 
respondent willing to consider genetic testing was between 50% to 60%, when each 
attribute was considered separately. Even though various preference-eliciting methods 
may yield different responses, LCM predictions were more consistent with other 
findings. The inflated prediction from MXL could arise for two reasons: 1) The 
coefficient estimates were population averages, and extreme preferences were not 
well accounted for; and 2) for those who dominated on a certain attribute, no tradeoffs 
were made between different attributes, which may confound the model estimates.  
5.5.7 Strengths of study 
The study has many strengths. First, we included context variables in the DCE, 
which is closer to the real clinical setting, and the predictive value of model is better. 
Secondly, a no test option was included to allow for opting out, which is more realistic. 
In addition, the features of no test alternative were displayed. The precise definition of 
no test minimized the prior individual beliefs or knowledge about the no test. Thirdly, 
we used mixed logit and latent class models in analyses, which allow the analysis of 
heterogeneity in preferences. Fourthly, simulation of policy effects was conducted, 
which provide forecasts on the possible policy impact. Fifthly, we used a budget 
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 reminder to minimize hypothetical bias. Choosing a test does not require respondents 
to pay, and it is possible that decision may change when individuals need to make real 
payment. The fact that the DCE is hypothetical scenarios and choices can potentially 
lead to bias, such as over estimation of willingness to pay. To minimize hypothetical 
bias, a budget reminder was incorporated to remind respondents to think carefully 
about the opportunity of the test cost and the impact of test cost on their budget. 
Sixthly, various validity tests were included to test respondents’ attention and 
understanding of DCE questions.  
 
5.5.8 Limitations of study 
The study has several limitations. Firstly, DCE as a stated preference method 
has intrinsic limitations that people’s stated preferences may differ from actual 
behaviors. However, several studies evaluating the external validity of DCE has found 
consistency in DCE results and actual behavior.247,248 The DCE questions have been 
made as realistic as possible in this study by including choice context variables and 
budget reminder. More research are required to further examine the external validity of 
DCE, in relation to actual behavior, and other stated preference methods. Secondly, 
due to practical considerations, the study was conducted among diabetes patients who 
were at higher risk of gout than the general public. Patients’ preferences may change 
with time and disease experiences. However, as comprehensive background 
information provided, and the socio-demographic features were similar, we do not 
expect differences in preferences between diabetes and gout patients. Thirdly, 
willingness-to-pay for risk reduction may be related to the ability to pay, or wealth. 
However, wealth is difficult to measure. We used controlled for household income and 
housing type as proxies for wealth in the analysis to account for potential effect of 
ability to pay on preferences. Fourthly, respondents were recruited using a 
convenience sampling method, and may be subject to selection bias. For instance, 
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 patients with no interest in ADRs or genetic testing, and those with low cognitive 
capacity may refuse to participate in the study. Nonetheless, we compared the sample 
characteristics with the population demographics, and did not detect significant 
differences that will threaten the generalizability of our study.  
 
5.6 Conclusions 
Using a discrete choice experiment, this study quantified patients’ preferences 
for using pharmacogenetic testing to reduce severe ADRs. The study identified 
substantial heterogeneity across individuals. Most patients are risk averse, and had 
higher preference weights for level of risk reduction than for cost of test. This group of 
patients have higher willingness-to-pay for genetic testing. Other patients are more 
cost conscious, and considered cost of test and long-term treatment more important 
than the level of risk reduction.   Overall, our results predicted the test uptake rate to be 
65% in Singapore.  The study also revealed the strong impact of doctor’s 
recommendation and moderate effect of herd behavior in shaping individuals’ test 




 Chapter 6 Conclusions and future directions 
6.1 Conclusions 
In this thesis, I introduced the challenges in the adoption of pharmacogenetic 
testing in clinical practice to reduce risk of life-threatening adverse drug reaction, and 
described two economic evaluation methods that can inform the decision making at 
health system level and individual level on whether genetic testing should be done. 
In chapter 2, I presented a cost-effectiveness analysis of HLA-B*1502 genetic 
testing prior to carbamazepine treatment in epilepsy treatment. Results suggest that 
in a life time, testing is highly cost-effective for Singaporean Chinese, Malays, but not 
for the Indians. As there are several effective alternative anti-epileptic drugs, avoiding 
carbamazepine in HLA-B*1502 patients can reduce risk of SJS and associated 
mortality and morbidities, but will not worsen seizure control. In addition, our model 
implies that HLA-B*1502 testing is more likely to be cost-effective in populations with 
high HLA-B*1502 frequency and high incidence of CBZ/PHT-induced SJS/TEN, such 
as various southern eastern Asian countries. From a policy perspective, our results 
imply that HLA-B*1502 is a high value service in Singapore. Following this study, 
genetic testing for HLA-B*1502 prior to carbamazepine treatment has been 
recommended in Singapore, and testing services were made available in several 
tertiary hospitals. The reduction in SJS case reports has demonstrated the 
effectiveness of HLA-B*1502 testing.  
In chapter 3, I described a cost-effectiveness analysis of HLA-B*5801 genetic 
testing prior to allopurinol treatment in chronic gout management. When evaluated 
over a life time, genetic testing and avoiding allopurinol in testing positive patients is 
not cost-effective. In fact, it reduced the total QALYs, while incurring higher cost. This 
is because test positive patients (18.5%) would have fewer alternative treatment 
options, and thus worse gout outcomes, while SJS/TEN would be avoided in only 
1.5% of patients. This shows that genetic testing does not necessarily improve 
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 QALYs at population level, though risk of SJS is lowered, especially when the choice 
of alternative drugs are limited. Instead, a strategy that combines genetic testing and 
safety monitoring may become cost-effective under certain circumstances, and 
achieves a balance between risk mitigation and gout management outcomes. From a 
policy perspective, mandating HLA-B*5801 testing is not desirable.  
In chapter 4, I reviewed the factors determining patients’ preferences for 
taking genetic test to reduce risk of life-threatening adverse drug reactions. 
Determinants of patients’ testing decision include test features (including cost of test, 
risk of SJS, and cost of long-term gout treatment) and decision context information 
(including information on doctor’s recommendation, and the most common choice 
made by others). The impact of these factors were systematically tested and 
quantified in a discrete choice experiment descried in Chapter 5. Though HLA-
B*5801 genetic testing is not cost-effective as shown in chapter 3, my results from 
discrete choice experiment shows that a significant proportion of patients are willing 
to test to reduce the risk of SJS. This group of patients are less sensitive to test cost 
and treatment costs, and have high willingness-to-pay for risk reduction. On the 
contrary, the other patients are more cost-conscious and only willing to test when the 
test can significantly reduce risk of SJS, or when the treatment cost is low. Given the 
current available test, the predicted test uptake rate is 65.1% among Singaporean 
patients. The effect of choice context factors on patient’s decision making was also 
explored. Doctor’s recommendation is the single most effective factor in improving 
test uptake rate (by 8.5%). On the other hand, labelling test as the most common 
choice slightly increased the uptake rate of test, suggesting herd behaviour is not as 
strong as doctor’s recommendation. From a service provision perspective, the study 
results suggest there is a strong demand for genetic testing. From a policy 
perspective, mandating testing is likely to induce a welfare loss among those who 
prefer not to test. From a health promotion perspective, the study identified doctor’s 
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 recommendation and information on other people’s choice to be effective and low-
cost strategies to encourage healthy behaviours. 
In conclusion, the thesis has demonstrated how economic evaluations can 
inform the decision on genetic testing adoption at the health system level and 
individual patient level. Understanding the economic value of health services, and 
patient’s preferences may improve the cost-effectiveness and efficiency of health 
service delivery. 
 
6.2 Future directions 
6.2.1 Cost-effectiveness analysis 
Cost-effectiveness models are static, and analyze the most likely scenario at 
the time of study. Cost-effectiveness results will change when input parameters are 
altered, such as the discovery of a new drug, the changes in drug prices related to 
patent or demand factors. It is worthwhile to re-evaluate the cost-effectiveness 
results when the context significantly changes.   
Genetic testing technology is rapidly evolving. In the near future, it may 
become possible to conveniently test thousands of genes or the whole genome at 
relatively low costs. If true, genes that can predict individual’s drug responses may be 
tested all together at birth, or at the first time a drug with known genetic risk factor is 
prescribed. The genetic profiles could even be incorporated into individual’s 
electronic medical records. These will completely change the marginal cost and 
marginal benefit of genetic testing. Future studies could explore the costs and 
effectiveness of a combined testing of all the genes known to associate with adverse 
drug reactions, or all drug-related genes.  
6.2.2 Discrete choice experiments 
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 Discrete choice experiments as a useful tool to quantify patients’ preferences, 
has increasing been used in health care. However, the external validity of DCEs in 
health care are rarely tested. Often times, it is empirically unclear how well the 
predicted behaviors are consistent with real behaviors. In fact, for most DCEs, a 
market to test the external validity does not exist at the time of study. It is important to 
find opportunities to compare the DCE with actual choices. For instance, when HLA-
B*5801 becomes available in Singapore in the future, individual patients choices and 
the overall test uptake rate could be compared with the predictions. Nevertheless, 
any discrepancies should be interpreted with caution, as the context of DCE may be 
different from real life in many ways.  
Our study suggests providing information on doctor’s recommendation and 
herd behavior may be as effective as or more effective than traditional policy 
intervention strategies, such as cost subsidies. Further studies should be conducted 
to systematically evaluate the impact of various forms and strengths of doctor’s 
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 Appendix A. In-depth interview guide  
In-depth Interview Guide 
Key questions to be asked during the interview 
Understand the awareness 
 
Section Topic Time 
(minutes) 
1 Introduction 10 
2 Preferences for genetic testing 15 
3 Role of doctor’s recommendation 10 
4 Role of majority choice 10 
5 Service delivery 5 
6 Interview experience and suggestions 5 
   
Total time  55 
 
Part 1: Introduction 
Duration Discussion 
5 mins Approach potential participant 
Self introduction (Hi, My name is Dong Di, I am a PhD student at the 
National University of Singapore, Graduate Medical School [show student 
card]. As part of my PhD research, I am conducting a survey to understand 
Singaporean’s preferences for genetic testing; hoping that doctors and 
policy makers better understand the preferences of the general public, and 
hope future medical services and policies can be consistent with people’s 
preferences. I wonder whether you can spare 10-20 minutes time to 
answer some questions and share your view on genetic testing with me? 
We will have 20 dollar NTUC voucher as token of appreciation)  
[eg of questions: Whether people know it, do they think it beneficial, why 
and why not take it? how much people are willing to pay?] 
[If participant do not know genetic testing: It’s ok, actually a lot of people 
do not know it, some heard of it but do not know the details, I will 
introduce the details] 
[If participant no time for today: Do you think another time works for you? 
If so, I can schedule an appointment in my school] 
 
1 mins Ask for permission to record (Do you think it ok if I audio record our 
conversation, so I won’t miss the points we discussed. Information is 
confidential, I will not release to someone outside our study team. There is 
no right or wrong answers, be open minded.) 
*If environment crowded and noisy, do not record, just take note. 
Find a place if necessary  
 Moderator to greet and welcome participant (Thanks for agreeing to do 
this interview) 
2 mins Introduce genetic testing 
(Before we get start, I’d like to ask you whether you have heard of/done 
genetic testing. 





Introduce the type of genetic testing in this study (There are many uses of 
genetic testing, for instance prenatal genetic screen for genetic 
abnormalities, cancer marker screening, genetic screening to optimize drug 
dosing. The one we will focus on today is to use genetic testing to prevent 





Gout (痛风) is a common chronic rheumatic disease in Singapore that 
affects 4% of elderly people in Singapore. Patients have severe pain on 
their hot and swollen toes and joints. It’s painful that patients can’t stand. 
 
ASK Do you know someone who got this? 
 
Patients with recurrent gout are usually treated with a medicine called 
allopurinol, which they take every day. However, a small number of people 
will have life-threatening drug allergy ith allopurinol.  
 
Ask Do you know drug allergy? 
 
Stevens Johnson Syndrome (SJS) is a life-threatening drug allergy. Patients 
with SJS will have severe rash all over the body, the skin may detach. Eyes 
and mucosa may get severe inflammation. It’s extremely painful, 
comparable to a severe burn. It costs $5000 to $20000 to treat, and 20% 
patients may die.  
 
Genetic test (HLA-B*5801) can identify those people with high risk for 
allopurinol allergy, and doctor can prescribe another medicine without risk, 
but more expensive.  
 
Ask What do you think of this genetic test? 
 
Part 2: Preferences for genetic testing  
Duration Discussion 
15mins Topic: How do you decide whether or not to do a genetic test before 
initiating allopurinol if you need allopurinol? 
Hypothetical scenario: Suppose you are in the clinic where your doctor 
says you need to take allopurinol to manage your chronic gout. The doctor 
tells you that this drug is generally well tolerated, and effective. However 
there is a small chance of life-threatening adverse drug reaction. There is a 
genetic test that can tell you whether you are at risk of this adverse 
reaction, though the test is not 100% accurate.  You need to pay some 
amount for the test, and you may need to take more expensive medicines 
if the test says you are at risk. Now you need to make a decision on 
whether or not you want to do the test. 
1. What do you think of the genetic test? 
Worth doing? Why? 
2.  What factors will you consider when you make this decision? 
Probe question: Is cost/likelihood of adverse 




 3.  What other information would you like to know besides the 
information given above? 
4.  What do you think is the most important factor? 
5. How much are you willing to pay for such a test (without 
considering whether it’s feasible)? 
6. What’s the highest amount you can accept? 
7. What’s the maximum risk level that you can tolerate? 
8. Will changes in test features increase your likelihood of taking the 
test? 
 
Part 3: Role of doctor’s recommendation 
Duration Discussion 
10mins Topic: How is doctor recommendation influencing your decision? 
9. Is doctor’s recommendation important for testing decision? 
10. Suppose a doctor gives you information on the test features, and 
his recommendation, are you going to follow his recommendation 
straight away or consider the test features and the 
recommendation at the same time? 
11. If a doctor’s recommendation is different from your judgments, 
what are you going to do? 
12. Why or why not do you follow the doctor’s recommendation? 
13. Does a specialist or a GP matter? Does public or private hospital 
matter? 
14. What if a doctor recommend against a test? 
 
Part 4: Role of majority choice 
Duration Discussion 
10mins Topic: How is majority choice influencing your decision? 
1. Is what other people do important for your testing decision? 
2. Suppose you receive some information that 70% of people in your 
situation choose to do the test, are you going to follow them 
straight away or balance the test features and other people’s 
choice? 
3. If the majority choice is different from your judgments, what are 
you going to do? 
4. Why or why not do you follow the majority choice? 
5. What if the doctor recommendation is against the majority choice?  
6. Now, considering all test features, doctor recommendation and 
information on what other people do, what is the most important 
factor in your decision? 
 




 5mins Topic: How do you prefer genetic testing services to be offered in 
Singapore? 
1. Do you prefer the above genetic test for allopurinol to be available 
in Singapore? 
2. Do you want it to be offered in hospitals or clinics? 
3. What’s the most acceptable way of collecting your sample? 
4. Do you want the test results to be included in your medical record 
so that other doctors can see it in the future? 
5. What do you think of genotyping for many diseases related genes 
at the same time and include in your medical record?  
6. Are you concerned about genetic test? 
 
Part 6: Interview experience and suggestions 
Duration Discussion 
5mins Topic: How do you think of the interview experience, and how can it be 
improved? 
1. Do you have problem understanding the information given at the 
beginning of the interview? 
2. Can you make sense of the probabilities given? 
3. Will the following make it easier to understand probability? 
Graphic representation 
Example of real life probabilities 
4. Do you have difficulties calculating the cost presented above? 
5. Do you have other comments or suggestions regarding the 






 Appendix B. Final experimental design 
Block 
Choice 










1 2 1 1 in 600 400 250 No no info 
1 2 2 1 in 5,000 20 1,500 Yes no info 
1 2 3 1 in 500 0 200 No no info 
1 3 1 1 in 1 million 20 4,000 No No 
1 3 2 1 in 600 400 1,500 No Yes 
1 3 3 1 in 500 0 200 Yes No 
1 4 1 1 in 5,000 20 400 no info Yes 
1 4 2 1 in 1,000 1,000 250 no info No 
1 4 3 1 in 500 0 200 no info No 
1 5 1 1 in 1,000 20 250 Yes Yes 
1 5 2 1 in 5,000 400 4,000 No No 
1 5 3 1 in 500 0 200 No No 
1 6 1 1 in 600 1,000 400 no info No 
1 6 2 1 in 1,000 200 4,000 no info No 
1 6 3 1 in 500 0 200 no info Yes 
1 7 1 1 in 1 million 200 250 No no info 
1 7 2 1 in 600 20 4,000 No no info 
1 7 3 1 in 500 0 200 Yes no info 
1 8 1 1 in 1,000 1,000 250 No No 
1 8 2 1 in 1 million 400 400 Yes Yes 
1 8 3 1 in 500 0 200 No No 
1 9 1 1 in 5,000 200 400 No Yes 
1 9 2 1 in 600 20 1,500 Yes No 
1 9 3 1 in 500 0 200 No No 
2 2 1 1 in 1,000 200 4,000 No Yes 
2 2 2 1 in 1 million 1,000 400 Yes No 
2 2 3 1 in 500 0 200 No No 
2 3 1 1 in 1,000 400 400 No No 
2 3 2 1 in 600 200 250 No No 
2 3 3 1 in 500 0 200 Yes Yes 
2 4 1 1 in 1 million 1,000 1,500 No Yes 
2 4 2 1 in 1,000 200 250 Yes No 
2 4 3 1 in 500 0 200 No No 
2 5 1 1 in 5,000 400 250 Yes no info 
2 5 2 1 in 1,000 20 400 No no info 
2 5 3 1 in 500 0 200 No no info 
2 6 1 1 in 1 million 1,000 250 no info No 
2 6 2 1 in 600 400 1,500 no info Yes 
2 6 3 1 in 500 0 200 no info No 
2 7 1 1 in 600 20 4,000 No Yes 
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 2 7 2 1 in 5,000 200 1,500 Yes No 
2 7 3 1 in 500 0 200 No No 
2 8 1 1 in 600 1,000 250 no info Yes 
2 8 2 1 in 5,000 20 400 no info No 
2 8 3 1 in 500 0 200 no info No 
2 9 1 1 in 5,000 20 400 No No 
2 9 2 1 in 1 million 400 4,000 Yes Yes 
2 9 3 1 in 500 0 200 No No 
3 2 1 1 in 1,000 1,000 4,000 Yes Yes 
3 2 2 1 in 600 20 1,500 No No 
3 2 3 1 in 500 0 200 No No 
3 3 1 1 in 1 million 400 250 No Yes 
3 3 2 1 in 600 200 1,500 Yes No 
3 3 3 1 in 500 0 200 No No 
3 4 1 1 in 600 20 4,000 Yes No 
3 4 2 1 in 5,000 400 1,500 No No 
3 4 3 1 in 500 0 200 No Yes 
3 5 1 1 in 5,000 1,000 4,000 No Yes 
3 5 2 1 in 600 400 1,500 Yes No 
3 5 3 1 in 500 0 200 No No 
3 6 1 1 in 1 million 200 400 No no info 
3 6 2 1 in 5,000 20 250 Yes no info 
3 6 3 1 in 500 0 200 No no info 
3 7 1 1 in 1 million 200 1,500 No No 
3 7 2 1 in 1,000 1,000 400 No No 
3 7 3 1 in 500 0 200 Yes Yes 
3 8 1 1 in 600 200 1,500 No Yes 
3 8 2 1 in 1 million 400 250 No No 
3 8 3 1 in 500 0 200 Yes No 
3 9 1 1 in 5,000 1,000 4,000 no info No 
3 9 2 1 in 1,000 200 400 no info Yes 
3 9 3 1 in 500 0 200 no info No 
4 2 1 1 in 600 20 250 No no info 
4 2 2 1 in 1,000 1,000 1,500 No no info 
4 2 3 1 in 500 0 200 Yes no info 
4 3 1 1 in 5,000 1,000 250 No Yes 
4 3 2 1 in 1,000 400 4,000 No No 
4 3 3 1 in 500 0 200 Yes No 
4 4 1 1 in 1 million 200 4,000 Yes Yes 
4 4 2 1 in 1,000 400 250 No No 
4 4 3 1 in 500 0 200 No No 
4 5 1 1 in 5,000 200 4,000 No no info 
4 5 2 1 in 1 million 1,000 400 Yes no info 
4 5 3 1 in 500 0 200 No no info 
4 6 1 1 in 1 million 20 1,500 No No 
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 4 6 2 1 in 600 1,000 400 Yes No 
4 6 3 1 in 500 0 200 No Yes 
4 7 1 1 in 5,000 400 4,000 Yes Yes 
4 7 2 1 in 1 million 1,000 1,500 No No 
4 7 3 1 in 500 0 200 No No 
4 8 1 1 in 1 million 200 4,000 No No 
4 8 2 1 in 5,000 20 250 Yes Yes 
4 8 3 1 in 500 0 200 No No 
4 9 1 1 in 1,000 20 1,500 no info Yes 
4 9 2 1 in 600 200 400 no info No 
4 9 3 1 in 500 0 200 no info No 
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 A survey on the preferences for genetic testing to prevent severe 
side effects of medicines 
 
 
For interviewer use only: 
Fill in the spaces that you can at the beginning of the interview, and then 
enter Time Ended and Total Interview Time after completing the survey. 
INTERVIEWER NAME: _________ 
CASE NO.: _________ 
DATE OF SURVEY (DD/MM/YYYY): _______/_______/2014 
VENUE OF INTERVIEW: 
Hospital:      SGH                            NUH 
 
Location:      Waiting room               Private room/office________ 
TIME STARTED:_______________ 
TIME ENDED:_______________ 
TOTAL INTERVIEW TIME:_________MINUTES 
VERSION: V19_block1 
 




Hello！I am a Doctoral student from the National University of Singapore (NUS). 
We are conducting a survey to look at patient’s preferences for taking a genetic test to 
minimize severe side effects of some commonly used medicines. I would appreciate if you 
could spare 15 to 20 minutes to help answer some questions.  A $5 NTUC voucher will be 
given to you at the end as a token of appreciation.  
 
Please feel free to call the study coordinator Di Dong, at Tel: 8298 5633 if you need 
any clarification on this survey. 
 




 SECTION S: SCREENING QUESTIONS   
Question S1       
 
Are you a Singaporean or PR?     
     YES [PROCEED TO SURVEY]                    
      NO [THANKS & TERMINATE]    
Question S2       
 
Have you been diagnosed with diabetes?        
     YES [PROCEED TO SURVEY]                    




































 SECTION A: BACKGROUND INFORMATION ON GOUT TREATMENT 
Life-threatening side effect of gout medicines 
• Gout is a common form of arthritis that can cause severe pain and swelling in the joints (see 





• For chronic gout patients, the standard treatment uses a medicine called allopurinol. It is very 
effective to treat chronic gout, but can in rare cases cause a severe side effect called Stevens-







Different gout treatments (with and without genetic testing) 
• This life-threatening side effect is related to the genetics of individuals. A genetic test can be 
done via a blood test to identify whether or not an individual is more likely to have the side 
effect. 
 Test positive means you may have the severe side effect if you take the 
standard medicine. 
 Test negative means you will not have the severe side effect with the 
standard medicine. 
 
• Now, we have different treatments for gout:  
-Genetic-testing guided treatment  
-Standard allopurinol treatment without testing  
• Note that the test is not 100% accurate, so genetic test-guided treatment can not completely 
prevent the risk of severe side effect. It only reduces the risk. 
 
• 10% chance of death 
• Extreme pain for 2 weeks 
• High medical cost (S$5,000-S$20,000) 
• May have long-term complications 
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 SECTION B: FEATURES OF GOUT TREATMENTS 
 
[Hypothetical scenario] Suppose you developed gout and had to decide which treatment to 
choose. Some factors one might consider in making this decision are listed below.  
 
 
Factor 1: Whether genetic testing is involved 
There are two possibilities: 
• Test   (genetic test-guided treatment) 
• No  test   (no genetic test involved) 
 
 
Factor 2: The chance of getting the severe side effect 
 
These different treatments are equally effective in treating gout, but differ in the chance of 
getting the severe side effect. Remember that genetic-test guided treatments also have risk of the 
severe side effect. 
 
The chance of getting the severe side effect may be: 
• 1 out of 500 patients 
• 1 out of 600 patients 
• 1 out of 1,000 patients 
• 1 out of 5,000 patients 








Question B1 Among 500 patients who take a medicine, 1 will have a severe side effect.  
How would you feel about this risk?  
 I would feel at risk. 
 I would not worry about it. 
Question B2 Comparing the two scenarios below, which indicates higher risk? 
  1 out of 500 patients get the severe side effect 





 Factor 3: Cost of the test 
 
Assume the test must be paid out of pocket. You cannot use health insurance or 
Medisave. Please think carefully about how the cost of the genetic test would influence your 






Question B3 If a genetic test costs S$400, would you consider taking the test to reduce 
the chance of the severe side effect?    
 Definitely would 
 Probably would  
 Probably would not  



















 Factor 4: Cost of gout medicines  (over 2 years)  
 
As gout medicines should be taken daily for at least 2 years, costs over 2 years are shown here. 
Assume all treatment costs must be paid out of pocket. You cannot use Medisave or insurance. 
 
If you choose standard allopurinol treatment without genetic testing, the cost is:  
• S$200 over two years 
 
If you choose genetic test-guided treatment, treatment cost will depend on your test results. 
Those who test positive (assumed to be 20% of individuals or 2 in every 10 who take the test) need to 
take a more expensive alternative medicine, whereas individuals who test negative (8 in 10) can take 
the standard medicine allopurinol at a cost of $200 over two years. . The four possible costs of the 
genetic test-guided treatment for those who test positive are: 
• S$250    if test positive (2 in 10 chance)  
• S$400    if test positive (2 in 10 chance)  
• S$1,500 if test positive (2 in 10 chance)  
• S$4,000 if test positive (2 in 10 chance)  
 
 
Question B4 If the alternative gout medicine costs S$2,000 over two years, and you need 
to take this medicine if you have test positive (2 in 10 chance) would you 
consider choosing the genetic test-guided treatment?    
 Definitely would 
 Probably would  
 Probably would not  












 Factor 5: Your doctor’s recommendation 
 
When you make a decision, you may or may not receive advice from your doctor.  
Question B5 Would your doctor’s recommendation influence your decision? 
 Definitely would  
 Probably would    
 Probably would not 










Factor 6: Most common choice 
 
When given several options to choose from, some people are interested to know how other people 
choose in the same situation. The most common choice here is defined as the option chosen by 80% of 
people in the same situation.   
Question B6 Would knowing what the most common choice is influence your decision? 
 Definitely would  
 Probably would    
 Probably would not 




 SECTION C: TRADE-OFF QUESTIONS 
 
• Suppose you developed gout and were asked to choose your preferred treatment option 
among several different scenarios.  
 
• Please answer the 10 questions I am going to show you. They may look similar but all 
differ. In each question, you need to think about the pros and cons of each option.  
 
• When making decisions we ask what you would prefer for yourself, not what you think would be 
best for your friends or other people. 
 
• Remember, assume that costs must be paid out of pocket; you cannot use Medisave or 
health insurance.  
 
 

















 Example Question: If you had to choose one of the treatment strategies below, which 








Whether genetic testing 
is involved  
 
Test  Test  No Test 
The chance of getting 
the  severe side effect 
 1 out of one million 
patients  
1 out of 600 
patients   
1 out of 500 
patients  
Cost of the one-time 
genetic test 
 
S$200  S$20  $0 
Cost of gout medicines 
(over two years) 
 
 
S$1,500 if test positive 
(2 in 10 chance);  
 
S$200 if test negative 
(8 in 10 chance) 
 
 
S$400 if test positive 
(2 in 10 chance); 
 
S$200 if test 
negative   (8 in 10 
chance) 
 

















Question: If these were the 
only 3 options available, 
which ONE would you 













Explanation of the above scenario: 
• If you chose treatment A, you take a genetic test, which costs S$200. Your chance of 
getting severe side effect is 1 in one million. If you test positive (2 in 10 chance), you pay S$1,500 
over two years for the more expensive gout medicine. If you test negative, you pay $200 over two 
years for the standard gout medicine.  
• If you chose treatment B, you take a genetic test, which costs S$20. Your chance of 
getting severe side effect is 1 in 600. If you test positive (2 in 10 chance), you will need to pay 
S$400 over two years for the more expensive gout medicine. If you test negative, you pay $200 
over two years for the standard gout medicine.  
• If you choose treatment C, you don’t need to test, but your chance of getting severe side 
effect is 1 in 500. The gout medicine costs you S$200 over 2 years.  
• In this scenario, treatment B is the doctor recommended option, and you have no 


































The chance of getting 
the  severe side effect 
 
1 out of one million 
patients  
 
1 out of 600 
patients 
 
1 out of 500 
patients  








Cost of gout 




S$400 if test positive  
(2 in 10 chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$400 if test positive  
(2 in 10 chance);  
S$200 if test negative 








No information  No information  No information 
Most common choice 
 
No information  No information  No information 
 
Question: If these were the 
only 3 options available, 
which ONE would you 



















































The chance of getting 
the  severe side effect 
 
1 out of 600  
patients  
 
1 out of 5,000 
patients  
 
1 out of 500 
patients  








Cost of gout 
medicines (over two 
years) 
 
 S$250 if test positive  
(2 in 10 chance);   
S$200 if test negative 
(8 in 10 chance) 
 
 
S$1,500 if test 
positive (2 in 10 
chance);  
S$200 if test negative 









   
 








Question: If these were the 
only 3 options available, 
which ONE would you 



















































The chance of getting 
the  severe side effect 
 1 out of one million 
patients  
 1 out of 600  
patients  
 1 out of 500 
patients  








Cost of gout 




S$4,000 if test 
positive (2 in 10 
chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$1,500 if test positive 
(2 in 10 chance);  
S$200 if test negative 






















Question: If these were the 
only 3 options available, 
which ONE would you 






















































The chance of getting 
the  severe side effect 
 1 out of 5,000  
patients  
 1 out of 1,000 
patients  
 1 out of 500 
patients  








Cost of gout 




S$400 if test positive     
(2 in 10 chance);  
S$200 if test negative   
(8 in 10 chance) 
 
 
S$250 if test positive 
(2 in 10 chance);  
S$200 if test negative 






















Question: If these were the 
only 3 options available, 
which ONE would you 





















































The chance of getting 
the  severe side effect 
 1 out of 1,000  
patients  
 1 out of 5,000 
patients  
 1 out of 500 
patients  








Cost of gout 




S$250 if test positive  
(2 in 10 chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$4,000 if test 
positive (2 in 10 
chance);  
S$200 if test negative 




over two years 
Your doctor’s 
recommendation 













Question: If these were the 
only 3 options available, 
which ONE would you 





















































The chance of getting 
the  severe side effect 
 1 out of 600  
patients  
 1 out of 1,000 
patients  
 1 out of 500 
patients  








Cost of gout 




S$400 if test positive  
(2 in 10 chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$4,000 if test positive 
(2 in 10 chance);  
S$200 if test negative 






















Question: If these were the 
only 3 options available, 
which ONE would you 





















































The chance of getting 
the  severe side effect 
 
1 out of one million 
patients  
 
1 out of 600  
patients  
 
1 out of 500 
patients  








Cost of gout 




S$250 if test positive  
(2 in 10 chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$4,000 if test positive 
(2 in 10 chance);  
S$200 if test negative 




















Question: If these were the 
only 3 options available, 
which ONE would you 























































The chance of getting 
the  severe side effect 
 
1 out of 1,000 
patients  
 
1 out of one million 
patients  
 
1 out of 500 
patients  








Cost of gout 




S$250 if test positive  
(2 in 10 chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$400 if test positive  
(2 in 10 chance);  
S$200 if test negative 









   
 









Question: If these were the 
only 3 options available, 
which ONE would you 





















































The chance of getting 
the  severe side effect 
 
1 out of 5,000 
patients  
 
1 out of 600  
patients  
 
1 out of 500 
patients  








Cost of gout 




S$400 if test positive  
(2 in 10 chance);  
S$200 if test negative 
(8 in 10 chance) 
 
 
S$1,500 if test positive  
(2 in 10 chance);  
S$200 if test negative 









   
 









Question: If these were the 
only 3 options available, 
which ONE would you 
























 SECTION D: BACKGROUND QUESTIONS 
Question D1 In which year were you born?_____________ 
Question D2 




If YES, have you ever taken long-term gout treatment (ie. take medicine daily even when 
you don’t feel the pain)? 
 Yes 
 No 
Question D3 Have you ever been diagnosed with hypertension (high blood pressure)? 
 Yes 
 No 
Question D4 How would you rate your general health status? 
 Very good  
 Quite good 
 Neither good nor poor 
 Quite poor 
 Very poor 
Question D5 Have you ever had severe side effects from medicines (such as serious drug allergy)? 
 Yes 
 No 
Question D6 Record the gender 
 Male 
 Female 




 Other (Please specify:________________) 
Question D8 What type of housing do you live in? 
 HDB flat (1-2 room) 
 HDB flat (3 room) 
 HDB flat (4 room) 
 HDB flat (5 room and above/HUDC/EC) 
 Condominium/Private flat 




How many people are there in your household?_______________________ 
Question D10 What is the total monthly income of your household (from all sources includes drawing 









 Above 10,000 
Question D11 What is your highest educational level completed? 
 No formal education 
 Primary 
 Secondary  
 Junior college/ Polytechnic/ Diploma 
 University and above  
Question D12 What is your current employment status? 
 Full-time employment 









------------------------------------------------------Thank you very much!---------------------------------------------------- 
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